|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions increases expression |
ISO |
[Ribose co-treated with Glucose] results in increased expression of AGER protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]] Ribose results in increased expression of AGER protein |
CTD |
PMID:30101366 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
B2m |
beta-2 microglobulin |
increases glycation |
ISO |
Ribose results in increased glycation of B2M protein |
CTD |
PMID:21864514 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
[Creatine co-treated with Ribose] results in decreased activity of CASP3 protein |
CTD |
PMID:21220914 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
increases phosphorylation |
ISO |
Ribose results in increased phosphorylation of CHUK protein |
CTD |
PMID:30101366 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
increases phosphorylation |
ISO |
Ribose results in increased phosphorylation of IKBKB protein |
CTD |
PMID:30101366 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Ins1 |
insulin 1 |
increases secretion |
ISO |
Ribose results in increased secretion of INS1 protein |
CTD |
PMID:30101366 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation multiple interactions |
ISO |
Ribose results in increased phosphorylation of NFKBIA protein [Ribose co-treated with Glucose] results in increased phosphorylation of NFKBIA protein |
CTD |
PMID:30101366 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Oat |
ornithine aminotransferase |
multiple interactions |
EXP |
Ribose inhibits the reaction [Cyclic AMP results in increased activity of OAT protein] |
CTD |
PMID:2827574 |
|
NCBI chr 1:187,347,862...187,367,644
Ensembl chr 1:187,347,865...187,367,682
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases phosphorylation |
ISO |
[Ribose co-treated with Glucose] affects the localization of RELA protein; AGER protein affects the reaction [Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein]]; Ribose promotes the reaction [Glucose results in increased phosphorylation of RELA protein] Ribose results in increased phosphorylation of RELA protein |
CTD |
PMID:30101366 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein; Deoxycytidine inhibits the reaction [[9-deaza-9-(3-thienylmethyl)guanine co-treated with Deoxyguanosine] results in increased activity of CASP3 protein] |
CTD |
PMID:9297556 PMID:9403342 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
CYP1A1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP1A2 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP1A2 protein promotes the reaction [Estrone binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
CYP1B1 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
CYP3A4 protein promotes the reaction [Aflatoxin B1 binds to Deoxyguanosine]; CYP3A4 protein promotes the reaction [Estrone binds to Deoxyguanosine] |
CTD |
PMID:21907773 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases activity |
ISO |
Deoxyguanosine analog results in decreased activity of MGMT protein |
CTD |
PMID:17880193 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
|
G |
Tymp |
thymidine phosphorylase |
increases abundance |
ISO |
TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate |
CTD |
PMID:11103787 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
|
G |
Tymp |
thymidine phosphorylase |
increases abundance |
ISO |
TYMP protein results in increased abundance of 2-deoxyribose 1-phosphate |
CTD |
PMID:11103787 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
[NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of diosbulbin B] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A analog] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]]; [NADP co-treated with Uridine Diphosphate Glucuronic Acid co-treated with Phosphoadenosine Phosphosulfate] promotes the reaction [[Enzymes and Coenzymes results in increased metabolism of saikogenin A] inhibits the reaction [ABCB11 protein results in increased transport of Taurodeoxycholic Acid]] |
CTD |
PMID:35101544 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
P2ry1 |
purinergic receptor P2Y1 |
decreases activity |
ISO |
Phosphoadenosine Phosphosulfate results in decreased activity of P2RY1 protein |
CTD |
PMID:22273509 |
|
NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions increases sulfation |
ISO |
2,2',3,4,4',5',6-heptabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; 2,2',4,4'-tetrabromodiphenyl ether inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; [NQO1 protein co-treated with NADP co-treated with Phosphoadenosine Phosphosulfate co-treated with SULT1A1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Halogenated Diphenyl Ethers analog inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; pentabrominated diphenyl ether 100 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; Pentachlorophenol inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein]; tribromodiphenyl ether 28 inhibits the reaction [[Estradiol co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of SULT1A1 protein] SULT1A1 protein results in increased sulfation of Phosphoadenosine Phosphosulfate |
CTD |
PMID:11425650 PMID:16601080 PMID:20545351 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
ISO |
[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol; Celecoxib affects the reaction [[Phosphoadenosine Phosphosulfate co-treated with SULT2A1 protein] affects the sulfation of Ethinyl Estradiol]; SULT2A1 protein affects the metabolism of [Phosphoadenosine Phosphosulfate co-treated with Ethinyl Estradiol] |
CTD |
PMID:15483193 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
|
G |
Adora3 |
adenosine A3 receptor |
multiple interactions |
EXP ISO |
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]]; 2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 mRNA]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA3 protein] [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Dizocilpine Maleate; [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein] which results in decreased susceptibility to Scopolamine; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine binds to and results in increased activity of ADORA3 protein |
CTD |
PMID:12672554 PMID:15452191 PMID:19966059 |
|
NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:16116186 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression decreases response to substance |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of BIRC3 mRNA BIRC3 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine |
CTD |
PMID:16088125 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases response to substance |
ISO |
BIRC5 protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine |
CTD |
PMID:16088125 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of FOS mRNA] |
CTD |
PMID:15452191 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:16116186 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]; Pertussis Toxin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]]; Wortmannin inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:16116186 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Naip6 |
NLR family, apoptosis inhibitory protein 6 |
decreases response to substance decreases expression |
ISO |
NAIP protein results in decreased susceptibility to N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine results in decreased expression of NAIP mRNA |
CTD |
PMID:16088125 |
|
NCBI chr 2:31,507,423...31,559,098
Ensembl chr 2:31,507,424...31,570,542
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
2,3-diethyl-4,5-dipropyl-6-phenylpyridine-3-thiocarboxylate-5-carboxylate inhibits the reaction [N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]]; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA] |
CTD |
PMID:15452191 PMID:19966059 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
multiple interactions |
EXP |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of RGS2 mRNA] |
CTD |
PMID:15452191 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Slc9a1 |
solute carrier family 9 member A1 |
multiple interactions |
EXP |
N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of SLC9A1 protein] |
CTD |
PMID:15452191 |
|
NCBI chr 5:145,576,341...145,629,630
Ensembl chr 5:145,576,334...145,629,624
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
ISO |
5'-S-methyl-5'-thioadenosine decreases expression of Acta2 mRNA in Mdr2-/- mouse liver and liver myofibroblasts |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adora2b |
adenosine A2B receptor |
multiple interactions |
ISO |
5'-S-methyl-5'-thioadenosine enhances the reaction [lipopolysaccharide increases expression of Adora2b mRNA in mouse liver myofibroblasts] |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein IL7 protein inhibits the reaction [5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:31712395 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
5'-S-methyl-5'-thioadenosine decreases expression of Ccl2 mRNA in Mdr2-/- mouse liver and myofibroblasts |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
5'-S-methyl-5'-thioadenosine decreases expression of cyclin-D1 mRNA in Mdr2-/- mouse liver myofibroblasts |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression |
ISO |
5'-methylthioadenosine results in decreased expression of COL1A1 mRNA 5'-S-methyl-5'-thioadenosine decreases expression of Col1a1 mRNA in Mdr2-/- mouse liver and liver myofibroblasts |
CTD RGD |
PMID:15983038 PMID:21209952 |
RGD:153297773 |
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
ISO |
5'-methylthioadenosine results in decreased expression of COL1A2 mRNA |
CTD |
PMID:15983038 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of 5'-methylthioadenosine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ifng |
interferon gamma |
multiple interactions decreases secretion |
ISO |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IFNG mRNA] 5'-methylthioadenosine results in decreased secretion of IFNG protein |
CTD |
PMID:17080400 PMID:31712395 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ifnl1 |
interferon, lambda 1 |
multiple interactions |
ISO |
5'-methylthioadenosine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of IFNL1 mRNA] |
CTD |
PMID:37611859 |
|
NCBI chr 1:83,798,651...83,800,297
Ensembl chr 1:83,798,703...83,800,235
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL1B mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions decreases secretion |
ISO |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL2 mRNA] 5'-methylthioadenosine results in decreased secretion of IL2 protein |
CTD |
PMID:17080400 PMID:31712395 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il33 |
interleukin 33 |
multiple interactions |
ISO |
5'-methylthioadenosine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of IL33 mRNA] |
CTD |
PMID:37545493 |
|
NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
ISO |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of IL6 mRNA] 5'-S-methyl-5'-thioadenosine decreases expression of Il6 mRNA in Mdr2-/- mouse liver |
CTD RGD |
PMID:17080400 PMID:21209952 |
RGD:153297773 |
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il7 |
interleukin 7 |
multiple interactions |
ISO |
IL7 protein inhibits the reaction [5'-methylthioadenosine results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:31712395 |
|
NCBI chr 2:94,235,219...94,280,075
Ensembl chr 2:94,234,766...94,280,075
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
ISO |
5'-S-methyl-5'-thioadenosine decreases expression of JunD protein in Mdr2-/- mouse liver myofibroblasts |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Ltb |
lymphotoxin beta |
multiple interactions |
ISO |
5'-methylthioadenosine inhibits the reaction [fumonisin B1 results in increased expression of LTB mRNA] |
CTD |
PMID:17080400 |
|
NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
|
|
G |
Mdm4 |
MDM4 regulator of p53 |
multiple interactions |
ISO |
5'-methylthioadenosine affects the splicing of and affects the expression of MDM4 mRNA alternative form |
CTD |
PMID:31712395 |
|
NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
decreases expression |
ISO |
5'-S-methyl-5'-thioadenosine decreases expression of Ki-67 protein in Mdr2-/- mouse liver |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
decreases expression |
ISO |
5'-S-methyl-5'-thioadenosine decreases expression of MMP13 mRNA in Mdr2-/- mouse liver |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
5'-methylthioadenosine results in decreased phosphorylation of MTOR protein |
CTD |
PMID:31712395 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression |
ISO |
5'-S-methyl-5'-thioadenosine decreases expression of iNOS mRNA in Mdr2-/- mouse liver |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
5'-methylthioadenosine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:31712395 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression |
ISO |
5'-S-methyl-5'-thioadenosine decreases expression of Tgfb1 mRNA in Mdr2-/- mouse liver myofibroblasts |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
decreases expression |
ISO |
5'-S-methyl-5'-thioadenosine decreases expression of Tgfb2 mRNA in Mdr2-/- mouse liver and myofibroblasts |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tnc |
tenascin C |
decreases expression |
ISO |
5'-S-methyl-5'-thioadenosine decreases expression of tenascin-C mRNA in Mdr2-/- mouse liver |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
5'-S-methyl-5'-thioadenosine inhibits the reaction [lipopolysaccharide increases expression of Tnf-alpha mRNA and protein in mouse liver myofibroblasts] |
RGD |
PMID:21209952 |
RGD:153297773 |
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression |
ISO |
5'-methylthioadenosine results in increased expression of TP53 protein |
CTD |
PMID:31712395 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA] |
CTD |
PMID:22841775 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
affects expression |
ISO |
Azacitidine affects the expression of ADRB1 mRNA |
CTD |
PMID:19002953 |
|
NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects expression multiple interactions |
ISO |
Azacitidine affects the expression of ADRB2 mRNA Azacitidine inhibits the reaction [Particulate Matter results in decreased expression of ADRB2 mRNA] |
CTD |
PMID:19002953 PMID:30986742 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Afp |
alpha-fetoprotein |
increases expression |
ISO |
Azacitidine results in increased expression of AFP mRNA |
CTD |
PMID:27590069 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Aggf1 |
angiogenic factor with G patch and FHA domains 1 |
increases expression |
ISO |
Azacitidine results in increased expression of AGGF1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:26,619,336...26,646,050
Ensembl chr 2:26,619,339...26,645,952
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of AHR mRNA [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]] |
CTD |
PMID:12927368 PMID:17682057 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak5 |
adenylate kinase 5 |
increases expression |
ISO |
Azacitidine results in increased expression of AK5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:241,397,297...241,581,483
Ensembl chr 2:241,397,297...241,581,458
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:22841775 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alad |
aminolevulinate dehydratase |
decreases expression |
ISO |
Azacitidine results in decreased expression of ALAD mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 5:75,961,993...75,972,334
Ensembl chr 5:75,961,993...75,972,474
|
|
G |
Alb |
albumin |
decreases expression increases expression |
ISO |
Azacitidine results in decreased expression of ALB protein Azacitidine results in increased expression of ALB mRNA |
CTD |
PMID:27590069 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of ALDH3A1 mRNA]] |
CTD |
PMID:17682057 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Andpro |
androgen regulated protein |
increases expression |
ISO |
Azacitidine results in increased expression of CST4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:136,718,601...136,725,131
Ensembl chr 3:136,718,602...136,724,966
|
|
G |
Anxa1 |
annexin A1 |
decreases expression |
EXP |
Azacitidine results in decreased expression of ANXA1 protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
App |
amyloid beta precursor protein |
decreases methylation multiple interactions |
ISO |
Azacitidine results in decreased methylation of APP promoter Azacitidine results in increased expression of and results in increased cleavage of APP protein; Betaine inhibits the reaction [Azacitidine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [Azacitidine results in increased expression of and results in increased cleavage of APP protein] |
CTD |
PMID:19635394 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp5 |
aquaporin 5 |
decreases methylation increases expression multiple interactions |
ISO |
Azacitidine results in decreased methylation of AQP5 promoter Azacitidine results in increased expression of AQP5 protein [Azacitidine results in decreased methylation of AQP5 promoter] which results in increased expression of AQP5 mRNA; Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter] |
CTD |
PMID:17198683 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Aqp9 |
aquaporin 9 |
multiple interactions increases expression |
ISO |
[Azacitidine results in increased expression of AQP9 mRNA] which results in increased uptake of arsenic trioxide; HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA] |
CTD |
PMID:25953102 |
|
NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395
|
|
G |
Ar |
androgen receptor |
multiple interactions increases expression |
ISO |
[Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to bicalutamide; [Azacitidine analog results in increased expression of AR protein] which results in increased susceptibility to Dihydrotestosterone |
CTD |
PMID:18324645 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arhgap35 |
Rho GTPase activating protein 35 |
increases expression |
ISO |
Azacitidine results in increased expression of ARHGAP35 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:77,202,436...77,319,298
Ensembl chr 1:77,202,436...77,319,298
|
|
G |
Arhgef2 |
Rho/Rac guanine nucleotide exchange factor 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ARHGEF2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:174,061,126...174,118,355
Ensembl chr 2:174,062,976...174,118,355
|
|
G |
Art1 |
ADP-ribosyltransferase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ART1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:156,478,096...156,487,172
Ensembl chr 1:156,482,621...156,487,172
|
|
G |
Asb2 |
ankyrin repeat and SOCS box-containing 2 |
increases expression |
ISO |
Azacitidine results in increased expression of ASB2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:122,474,756...122,510,854
|
|
G |
Atp2b1 |
ATPase plasma membrane Ca2+ transporting 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ATP2B1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
increases expression |
ISO |
Azacitidine results in increased expression of ATP6V0C mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500
|
|
G |
Aurka |
aurora kinase A |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of AURKA mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390
|
|
G |
Bad |
BCL2-associated agonist of cell death |
increases expression multiple interactions |
EXP |
Azacitidine results in increased expression of BAD mRNA [Azacitidine co-treated with entinostat] results in increased expression of BAD mRNA |
CTD |
PMID:21224363 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression |
EXP |
[Azacitidine co-treated with entinostat] results in increased expression of BAK1 mRNA Azacitidine results in increased expression of BAK1 mRNA |
CTD |
PMID:21224363 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
Bleomycin inhibits the reaction [Azacitidine results in increased expression of BAX mRNA] |
CTD |
PMID:32278510 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of BCAT1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:177,964,834...178,046,573
Ensembl chr 4:177,964,834...178,046,597
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 mRNA]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of BCL2 protein] Azacitidine results in decreased expression of BCL2 mRNA; Azacitidine results in decreased expression of BCL2 protein |
CTD |
PMID:32278510 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions affects expression |
ISO |
[metacept-1 co-treated with Azacitidine] results in decreased expression of BCL2L1 [Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein |
CTD |
PMID:18443271 PMID:19148494 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l13 |
Bcl2-like 13 |
increases expression |
ISO |
Azacitidine results in increased expression of BCL2L13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:154,056,116...154,112,890
Ensembl chr 4:154,056,127...154,108,985
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression decreases methylation multiple interactions |
ISO |
Azacitidine results in increased expression of BDNF mRNA Azacitidine results in decreased methylation of BDNF promoter Tetrodotoxin inhibits the reaction [Azacitidine results in decreased methylation of BDNF promoter]; Tetrodotoxin inhibits the reaction [Azacitidine results in increased expression of BDNF mRNA] |
CTD |
PMID:18184782 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
decreases expression |
EXP |
Azacitidine results in decreased expression of BGLAP protein |
CTD |
PMID:18037191 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of BICD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:182,479,071...182,631,504
Ensembl chr 4:182,479,071...182,627,434
|
|
G |
Bik |
BCL2-interacting killer |
multiple interactions increases expression |
EXP |
[Azacitidine co-treated with entinostat] results in increased expression of BIK mRNA Azacitidine results in increased expression of BIK mRNA |
CTD |
PMID:21224363 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Bmp15 |
bone morphogenetic protein 15 |
increases expression |
ISO |
Azacitidine results in increased expression of BMP15 mRNA |
CTD |
PMID:23395740 |
|
NCBI chr X:16,169,123...16,174,187
Ensembl chr X:16,169,123...16,174,187
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Azacitidine results in increased expression of BNIP3 mRNA |
CTD |
PMID:25446377 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
multiple interactions increases expression |
EXP |
[Azacitidine co-treated with entinostat] results in increased expression of BOK mRNA Azacitidine results in increased expression of BOK mRNA |
CTD |
PMID:21224363 |
|
NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of BUB1B mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
C17h6orf62 |
similar to human chromosome 6 open reading frame 62 |
increases expression |
ISO |
Azacitidine results in increased expression of C6ORF62 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:40,256,211...40,267,851
Ensembl chr17:40,256,211...40,276,020
|
|
G |
C3ar1 |
complement C3a receptor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of C3AR1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of CALCA promoter |
CTD |
PMID:19299654 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CALD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:63,265,781...63,446,938
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Calhm2 |
calcium homeostasis modulator family member 2 |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of CALHM2 mRNA Cisplatin affects the reaction [Azacitidine results in increased expression of CALHM2 mRNA] |
CTD |
PMID:36336710 |
|
NCBI chr 1:246,022,324...246,028,050
Ensembl chr 1:246,022,324...246,028,218
|
|
G |
Casp3 |
caspase 3 |
affects expression increases activity increases expression multiple interactions |
ISO |
Azacitidine affects the expression of CASP3 protein 5-azacytidine co-treated with doxorubicin increases activity of CASP3 protein in lung cancer cells Azacitidine results in increased expression of CASP3 mRNA [metacept-1 co-treated with Azacitidine] results in increased expression of CASP3 |
CTD RGD |
PMID:18443271 PMID:19148494 PMID:23395740 PMID:24356455 |
RGD:153344603 |
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases expression |
ISO |
Azacitidine results in increased expression of CASP8 mRNA |
CTD |
PMID:18082045 PMID:23395740 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
Azacitidine results in increased expression of CASP9 mRNA |
CTD |
PMID:23395740 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccna1 |
cyclin A1 |
multiple interactions decreases expression |
ISO |
Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter]; Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter]; Azacitidine promotes the reaction [H4C16 protein modified form binds to CCNA1 promoter] Azacitidine results in decreased expression of CCNA1 mRNA |
CTD |
PMID:17698632 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions decreases expression |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CCNA2 mRNA Azacitidine results in decreased expression of CCNA2 mRNA |
CTD |
PMID:18720364 PMID:20823114 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions increases expression |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CCNB1 mRNA Azacitidine results in increased expression of CCNB1 protein |
CTD |
PMID:18720364 PMID:20607034 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
Azacitidine results in increased expression of CCND1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
affects methylation multiple interactions |
ISO |
Azacitidine affects the methylation of CCND2 promoter [Azacitidine affects the methylation of CCND2 promoter] which affects the expression of CCND2 mRNA |
CTD |
PMID:17016690 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of CCNG2 mRNA |
CTD |
PMID:21245298 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Cd274 |
CD274 molecule |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]] |
CTD |
PMID:32894642 |
|
NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cdc20 |
cell division cycle 20 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CDC20 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc42bpa |
CDC42 binding protein kinase alpha |
decreases expression |
ISO |
Azacitidine results in decreased expression of CDC42BPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:91,683,775...91,903,732
Ensembl chr13:91,684,007...91,903,732
|
|
G |
Cdh1 |
cadherin 1 |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of CDH1 promoter Azacitidine results in increased expression of CDH1 mRNA |
CTD |
PMID:17520682 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
increases expression |
EXP |
Azacitidine results in increased expression of CDH2 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions increases expression |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CDK1 mRNA Azacitidine analog results in increased expression of CDK1 protein |
CTD |
PMID:18324645 PMID:18720364 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Azacitidine analog results in decreased expression of CDK2 protein |
CTD |
PMID:18324645 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Azacitidine analog results in decreased expression of CDK4 protein |
CTD |
PMID:18324645 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
ISO EXP |
Azacitidine analog results in increased expression of CDKN1A protein; Azacitidine results in increased expression of CDKN1A mRNA [Azacitidine co-treated with entinostat] results in increased expression of CDKN1A mRNA; Azacitidine inhibits the reaction [potassium bromate results in increased expression of CDKN1A protein] [metacept-1 co-treated with Azacitidine] results in increased expression of CDKN1A |
CTD |
PMID:18324645 PMID:19148494 PMID:20823114 PMID:21224363 PMID:25015661 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
increases expression |
ISO |
Azacitidine results in increased expression of CDKN1C mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions decreases methylation affects methylation increases expression |
EXP ISO |
[Azacitidine co-treated with entinostat] results in decreased methylation of CDKN2A gene; [Azacitidine co-treated with entinostat] results in increased expression of CDKN2A mRNA Azacitidine inhibits the reaction [Particulate Matter results in increased methylation of CDKN2A promoter] Hydroxyurea inhibits the reaction [Azacitidine results in decreased methylation of CDKN2A gene] Azacitidine affects the methylation of CDKN2A gene Azacitidine results in increased expression of CDKN2A mRNA |
CTD |
PMID:17686055 PMID:18443271 PMID:21224363 PMID:22355787 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
decreases methylation multiple interactions affects response to substance |
ISO |
Azacitidine results in decreased methylation of CDKN2B promoter [metacept-1 co-treated with Azacitidine] results in increased expression of CDKN2B CDKN2B promoter modified form affects the susceptibility to Azacitidine |
CTD |
PMID:17611569 PMID:19148494 PMID:19194470 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of CEBPA promoter Azacitidine results in increased expression of CEBPA mRNA |
CTD |
PMID:19194470 PMID:27590069 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cenpa |
centromere protein A |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CENPA mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cenpf |
centromere protein F |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of CENPF mRNA |
CTD |
PMID:18720364 |
|
NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669
|
|
G |
Cenpo |
centromere protein O |
increases expression |
ISO |
Azacitidine results in increased expression of CENPO mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 6:27,203,642...27,218,394
Ensembl chr 6:27,188,537...27,218,314
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression |
ISO |
Azacitidine results in increased expression of CHAT mRNA; Azacitidine results in increased expression of CHAT protein |
CTD |
PMID:19151599 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chga |
chromogranin A |
decreases expression |
ISO |
Azacitidine results in decreased expression of CHGA protein |
CTD |
PMID:20607034 |
|
NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:121,696,051...121,707,398
|
|
G |
Chit1 |
chitinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CHIT1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:45,565,841...45,613,593
Ensembl chr13:45,593,845...45,613,592
|
|
G |
Chrm1 |
cholinergic receptor, muscarinic 1 |
affects expression |
ISO |
Azacitidine affects the expression of CHRM1 mRNA |
CTD |
PMID:19002953 |
|
NCBI chr 1:205,567,226...205,583,001
Ensembl chr 1:205,567,220...205,582,356
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
affects expression |
ISO |
Azacitidine affects the expression of CHRM2 mRNA |
CTD |
PMID:19002953 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chst14 |
carbohydrate sulfotransferase 14 |
increases expression |
EXP |
Azacitidine results in increased expression of CHST14 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 3:105,916,481...105,918,538
Ensembl chr 3:105,916,466...105,918,548
|
|
G |
Ciita |
class II, major histocompatibility complex, transactivator |
multiple interactions increases expression |
ISO |
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA] Azacitidine results in increased expression of CIITA mRNA |
CTD |
PMID:18829986 PMID:20823114 |
|
NCBI chr10:5,139,947...5,187,493
Ensembl chr10:5,140,178...5,187,440
|
|
G |
Cldn10 |
claudin 10 |
decreases expression |
ISO |
Azacitidine results in decreased expression of CLDN10 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr15:95,862,785...95,954,526
Ensembl chr15:95,862,760...95,954,526
|
|
G |
Cldn6 |
claudin 6 |
increases expression decreases methylation multiple interactions |
ISO |
Azacitidine results in increased expression of CLDN6 mRNA Azacitidine results in decreased methylation of CLDN6 promoter [trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN6 promoter |
CTD |
PMID:18661270 |
|
NCBI chr10:12,710,302...12,713,987
Ensembl chr10:12,709,960...12,715,973
|
|
G |
Cldn7 |
claudin 7 |
multiple interactions decreases expression |
ISO |
Cisplatin affects the reaction [Azacitidine results in decreased expression of CLDN7 mRNA] |
CTD |
PMID:36336710 |
|
NCBI chr10:54,689,684...54,692,177
Ensembl chr10:54,689,987...54,692,171
|
|
G |
Cldn8 |
claudin 8 |
increases expression |
ISO |
Azacitidine results in increased expression of CLDN8 mRNA |
CTD |
PMID:18661270 |
|
NCBI chr11:27,875,857...27,878,106
Ensembl chr11:27,875,692...27,878,513
|
|
G |
Cldn9 |
claudin 9 |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of CLDN9 promoter [trichostatin A co-treated with Azacitidine] results in decreased methylation of CLDN9 promoter Azacitidine results in increased expression of CLDN9 mRNA |
CTD |
PMID:18661270 |
|
NCBI chr10:12,714,137...12,715,568
|
|
G |
Cnnm2 |
cyclin and CBS domain divalent metal cation transport mediator 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of CNNM2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:245,643,682...245,769,542
Ensembl chr 1:245,643,768...245,763,286
|
|
G |
Col14a1 |
collagen type XIV alpha 1 chain |
increases expression |
ISO |
Azacitidine results in increased expression of COL14A1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein] |
CTD |
PMID:22841775 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col6a3 |
collagen type VI alpha 3 chain |
decreases expression |
ISO |
Azacitidine results in decreased expression of COL6A3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:91,361,578...91,439,434
Ensembl chr 9:91,361,583...91,439,471
|
|
G |
Col9a3 |
collagen type IX alpha 3 chain |
decreases expression |
ISO |
Azacitidine results in decreased expression of COL9A3 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr 3:167,711,776...167,734,468
Ensembl chr 3:167,711,840...167,734,465
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
increases expression |
ISO |
Azacitidine results in increased expression of COX6A2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:182,788,528...182,790,746
Ensembl chr 1:182,788,528...182,789,274
|
|
G |
Cpe |
carboxypeptidase E |
increases expression |
ISO |
Azacitidine results in increased expression of CPE mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Cplx1 |
complexin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CPLX1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:1,184,677...1,216,392
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter] |
CTD |
PMID:19155497 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Creb3l4 |
cAMP responsive element binding protein 3-like 4 |
increases expression |
EXP |
Azacitidine results in increased expression of CREB3L4 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 2:175,690,340...175,695,846
Ensembl chr 2:175,690,335...175,695,932
|
|
G |
Crem |
cAMP responsive element modulator |
decreases expression |
ISO |
Azacitidine results in decreased expression of CREM mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
|
|
G |
Cryaa |
crystallin, alpha A |
increases expression |
EXP |
Azacitidine results in increased expression of CRYAA protein |
CTD |
PMID:17105402 |
|
NCBI chr20:9,783,605...9,787,351
Ensembl chr20:9,783,605...9,787,349
|
|
G |
Cryab |
crystallin, alpha B |
increases expression |
EXP |
Azacitidine results in increased expression of CRYAB protein |
CTD |
PMID:17105402 |
|
NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
EXP |
Azacitidine results in increased expression of CSF1 mRNA |
CTD |
PMID:17156202 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csn1s1 |
casein alpha s1 |
increases expression |
ISO |
Azacitidine results in increased expression of CSN1S1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:20,343,620...20,359,614
Ensembl chr14:20,343,619...20,359,614
|
|
G |
Cst3 |
cystatin C |
increases expression |
ISO |
Azacitidine results in increased expression of CST3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of CXCL12 promoter Azacitidine results in increased expression of CXCL12 mRNA; Azacitidine results in increased expression of CXCL12 protein |
CTD |
PMID:19748759 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; [Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene promotes the reaction [AHR protein binds to CYP1A1 promoter]]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]] Azacitidine results in increased expression of CYP1A1 mRNA |
CTD |
PMID:11281733 PMID:12927368 PMID:17682057 PMID:27590069 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions increases expression |
ISO |
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A2 mRNA] Azacitidine results in increased expression of CYP1A2 mRNA |
CTD |
PMID:12927368 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
multiple interactions increases expression |
ISO |
Azacitidine promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1B1 mRNA] Azacitidine results in increased expression of CYP1B1 mRNA |
CTD |
PMID:12927368 PMID:27590069 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
Azacitidine results in increased expression of CYP3A4 mRNA |
CTD |
PMID:27590069 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyth1 |
cytohesin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of CYTH1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:103,402,727...103,485,826
Ensembl chr10:103,366,145...103,485,760
|
|
G |
Dapk1 |
death associated protein kinase 1 |
affects methylation |
ISO |
Azacitidine affects the methylation of DAPK1 promoter |
CTD |
PMID:17557868 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dcn |
decorin |
multiple interactions decreases expression |
ISO |
Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein] Azacitidine results in decreased expression of DCN mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Des |
desmin |
increases expression multiple interactions |
EXP ISO |
Azacitidine results in increased expression of DES mRNA; Azacitidine results in increased expression of DES protein [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA |
CTD |
PMID:18037191 PMID:20823114 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Dhx9 |
DExH-box helicase 9 |
decreases expression |
ISO |
Azacitidine results in decreased expression of DHX9 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:65,602,322...65,639,098
Ensembl chr13:65,602,323...65,639,069
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of DIO2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dlk1 |
delta like non-canonical Notch ligand 1 |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of DLK1 promoter |
CTD |
PMID:19194470 |
|
NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522
|
|
G |
Dlx5 |
distal-less homeobox 5 |
increases expression |
ISO |
Azacitidine results in increased expression of DLX5 mRNA |
CTD |
PMID:17085970 |
|
NCBI chr 4:34,999,139...35,003,504
Ensembl chr 4:34,999,139...35,003,407
|
|
G |
Dlx6 |
distal-less homeobox 6 |
increases expression |
ISO |
Azacitidine results in increased expression of DLX6 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:34,984,264...34,989,926
Ensembl chr 4:34,984,232...34,991,343
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
multiple interactions decreases expression |
ISO EXP |
[SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Arsenic Trioxide promotes the reaction [Azacitidine results in decreased expression of DNMT1 protein]; Azacitidine inhibits the reaction [DNMT1 protein binds to MIR497 promoter] [Azacitidine co-treated with entinostat] results in decreased expression of DNMT1 protein; [Cisplatin co-treated with Azacitidine] results in decreased expression of DNMT1 protein |
CTD |
PMID:19139132 PMID:19723570 PMID:21224363 PMID:28901456 PMID:35066776 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [DNMT3A protein binds to MIR497 promoter] |
CTD |
PMID:35066776 |
|
NCBI chr 6:26,791,517...26,902,161
Ensembl chr 6:26,822,609...26,896,687
|
|
G |
Dnmt3b |
DNA methyltransferase 3 beta |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [DNMT3B protein binds to MIR497 promoter] |
CTD |
PMID:35066776 |
|
NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
decreases methylation multiple interactions decreases response to substance |
ISO |
Azacitidine results in decreased methylation of DPYD promoter [Azacitidine results in decreased methylation of DPYD promoter] which results in increased expression of DPYD mRNA DPYD protein results in decreased susceptibility to Azacitidine |
CTD |
PMID:15501990 |
|
NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of DUSP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
increases expression |
ISO |
Azacitidine results in increased expression of DUSP6 mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] |
CTD |
PMID:19451745 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of EEF1A1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Efna3 |
ephrin A3 |
increases expression |
ISO |
Azacitidine results in increased expression of EFNA3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:174,729,192...174,738,111
Ensembl chr 2:174,729,764...174,738,736
|
|
G |
Egr2 |
early growth response 2 |
increases expression |
ISO |
Azacitidine results in increased expression of EGR2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
|
|
G |
Eno2 |
enolase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ENO2 protein |
CTD |
PMID:20607034 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Entpd1 |
ectonucleoside triphosphate diphosphohydrolase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ENTPD1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:239,425,515...239,552,323
Ensembl chr 1:239,425,430...239,552,317
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ESR1 protein |
CTD |
PMID:22558281 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions |
ISO |
Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [ETS1 protein binds to KIR2DL4 promoter] |
CTD |
PMID:18945643 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Eya1 |
EYA transcriptional coactivator and phosphatase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of EYA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:4,863,501...5,101,483
Ensembl chr 5:4,955,543...5,101,483
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of FADS2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fam8a1 |
family with sequence similarity 8, member A1 |
increases expression |
ISO |
Azacitidine results in increased expression of FAM8A1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:18,026,601...18,035,509
Ensembl chr17:18,026,601...18,035,470
|
|
G |
Faslg |
Fas ligand |
increases response to substance |
ISO |
Azacitidine results in increased susceptibility to FASLG protein |
CTD |
PMID:18829727 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbln1 |
fibulin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of FBLN1 mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 7:116,310,582...116,390,075
Ensembl chr 7:116,310,582...116,390,075
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of FEN1 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
decreases expression |
ISO |
Azacitidine results in decreased expression of FGF7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Filip1l |
filamin A interacting protein 1-like |
decreases expression |
ISO |
Azacitidine results in decreased expression of FILIP1L mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
ISO |
[Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein; [Azacitidine results in decreased methylation of FOXP3 gene] which results in increased expression of FOXP3 protein |
CTD |
PMID:18493985 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Ftl1 |
ferritin light chain 1 |
decreases expression |
EXP |
Azacitidine results in decreased expression of FTL1 protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
increases expression |
ISO |
Azacitidine results in increased expression of FYN mRNA |
CTD |
PMID:21245298 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gabrb1 |
gamma-aminobutyric acid type A receptor subunit beta1 |
increases expression |
ISO |
Azacitidine results in increased expression of GABRB1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr14:36,068,725...36,548,946
Ensembl chr14:36,080,393...36,548,948
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of GADD45A promoter [Azacitidine results in increased expression of GADD45A protein] which results in increased susceptibility to docetaxel Azacitidine results in increased expression of GADD45A mRNA; Azacitidine results in increased expression of GADD45A protein |
CTD |
PMID:19190346 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gadd45b |
growth arrest and DNA-damage-inducible, beta |
multiple interactions |
ISO |
Azacitidine promotes the reaction [Depsipeptides results in increased expression of GADD45B] |
CTD |
PMID:18225533 |
|
NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
|
|
G |
Gata4 |
GATA binding protein 4 |
increases expression |
EXP |
Azacitidine results in increased expression of GATA4 mRNA; Azacitidine results in increased expression of GATA4 protein |
CTD |
PMID:18037191 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gbp2 |
guanylate binding protein 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of GBP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
|
|
G |
Gcnt2 |
glucosaminyl (N-acetyl) transferase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of GCNT2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
|
|
G |
Gdf9 |
growth differentiation factor 9 |
increases expression |
ISO |
Azacitidine results in increased expression of GDF9 mRNA |
CTD |
PMID:23395740 |
|
NCBI chr10:37,589,200...37,599,970
Ensembl chr10:37,595,679...37,599,672
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression decreases expression |
EXP ISO |
Azacitidine results in increased expression of GJA1 protein Azacitidine results in decreased expression of GJA1 mRNA |
CTD |
PMID:18037191 PMID:20823114 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gng7 |
G protein subunit gamma 7 |
affects methylation |
ISO |
Azacitidine affects the methylation of GNG7 promoter |
CTD |
PMID:18219292 |
|
NCBI chr 7:8,697,458...8,761,239
Ensembl chr 7:8,697,521...8,761,240
|
|
G |
Gpkow |
G patch domain and KOW motifs |
increases expression |
ISO |
Azacitidine results in increased expression of GPKOW mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:14,791,601...14,806,384
Ensembl chr X:14,791,610...14,806,384
|
|
G |
Gpnmb |
glycoprotein nmb |
decreases expression |
ISO |
Azacitidine results in decreased expression of GPNMB mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpx3 |
glutathione peroxidase 3 |
increases expression |
ISO |
5-azacytidine increases expression of GPX3 mRNA in epithelial cells of stomach |
RGD |
PMID:16229808 |
RGD:151665354 |
NCBI chr10:39,028,624...39,036,695
Ensembl chr10:39,028,570...39,037,035
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of GRIN2B gene |
CTD |
PMID:18618247 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Guk1 |
guanylate kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of GUK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:43,971,514...43,988,658
Ensembl chr10:43,971,509...43,980,107
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein] |
CTD |
PMID:19394699 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H1f0 |
H1.0 linker histone |
increases expression |
ISO |
Azacitidine results in increased expression of H1-0 protein |
CTD |
PMID:16006241 |
|
NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:110,592,208...110,594,694
|
|
G |
H2ax |
H2A.X variant histone |
increases expression multiple interactions |
ISO EXP |
Azacitidine results in increased expression of H2AX protein Azacitidine inhibits the reaction [potassium bromate results in increased phosphorylation of H2AX protein] |
CTD |
PMID:17991895 PMID:25015661 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
H3f4 |
H3.4 histone, cluster member |
multiple interactions |
ISO |
Azacitidine promotes the reaction [H3-4 protein modified form binds to CCNA1 promoter] |
CTD |
PMID:17698632 |
|
NCBI chr10:43,740,702...43,741,262
|
|
G |
Hgd |
homogentisate 1, 2-dioxygenase |
increases expression |
ISO |
Azacitidine results in increased expression of HGD mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:63,086,750...63,138,325
Ensembl chr11:63,086,752...63,138,323
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression |
ISO |
Azacitidine results in increased expression of HGF mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hhex |
hematopoietically expressed homeobox |
increases expression |
ISO |
Azacitidine results in increased expression of HHEX mRNA |
CTD |
PMID:27590069 |
|
NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042
|
|
G |
Hmga1 |
high mobility group AT-hook 1 |
increases expression |
ISO |
Azacitidine results in increased expression of HMGA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of HMGA2 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases expression multiple interactions |
ISO |
Azacitidine results in decreased expression of HMGB1 mRNA Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of and results in increased secretion of HMGB1 protein]; Bleomycin inhibits the reaction [Azacitidine results in decreased expression of HMGB1 mRNA] |
CTD |
PMID:32278510 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hnf1a |
HNF1 homeobox A |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of HNF1A promoter HNF1A mutant form inhibits the reaction [Azacitidine results in increased expression of AQP9 mRNA] Azacitidine results in increased expression of HNF1A mRNA; Azacitidine results in increased expression of HNF1A protein |
CTD |
PMID:25953102 |
|
NCBI chr12:41,638,536...41,672,806
Ensembl chr12:41,645,587...41,672,104
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
increases expression |
ISO |
Azacitidine results in increased expression of HNF4A mRNA |
CTD |
PMID:27590069 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hoxa1 |
homeobox A1 |
multiple interactions increases expression |
ISO |
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA] Azacitidine results in increased expression of HOXA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:81,255,814...81,258,587
Ensembl chr 4:81,255,883...81,258,504
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of HPGD gene trichostatin A promotes the reaction [Azacitidine results in increased expression of HPGD mRNA] |
CTD |
PMID:19584167 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
affects expression |
ISO |
Azacitidine affects the expression of HSD3B1 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
decreases activity |
ISO |
Azacitidine results in decreased activity of HSF1 protein |
CTD |
PMID:34170685 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspa6l-ps1 |
heat shock protein family A (Hsp70) member 6 like, pseudogene 1 |
increases expression |
ISO |
Azacitidine results in increased expression of HSPA6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr13:83,273,176...83,274,317
|
|
G |
Id1 |
inhibitor of DNA binding 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ID1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 3:141,210,666...141,212,420
Ensembl chr 3:141,211,267...141,212,419
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
increases expression |
ISO |
Azacitidine results in increased expression of ID3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein; [Azacitidine results in decreased methylation of CIITA promoter] promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]; [Azacitidine results in increased expression of KIR2DL4 protein] which results in increased secretion of IFNG protein |
CTD |
PMID:18829986 PMID:18945643 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
multiple interactions increases expression |
ISO |
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein] Azacitidine results in increased expression of IGFBP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Igfbp4 |
insulin-like growth factor binding protein 4 |
increases expression |
ISO |
Azacitidine results in increased expression of IGFBP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
Azacitidine results in increased expression of IL12B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
increases expression multiple interactions |
EXP ISO |
Azacitidine results in increased expression of IL1B mRNA Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 mRNA]]; Azacitidine inhibits the reaction [Oleanolic Acid inhibits the reaction [IL1B protein results in increased expression of CD274 protein]] |
CTD |
PMID:17156202 PMID:32894642 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of GZMB protein]; Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein] |
CTD |
PMID:19394699 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il4 |
interleukin 4 |
affects methylation |
ISO |
Azacitidine affects the methylation of IL4 promoter |
CTD |
PMID:18158872 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
affects secretion affects methylation |
ISO |
Azacitidine affects the secretion of IL6 protein Azacitidine affects the methylation of IL6 promoter |
CTD |
PMID:18158872 PMID:18443271 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6r |
interleukin 6 receptor |
affects expression multiple interactions |
ISO |
[Azacitidine affects the expression of IL6R protein] which affects the expression of BCL2L1 protein; Azacitidine affects the expression of IL6R mRNA [Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein |
CTD |
PMID:18443271 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Isca1 |
iron-sulfur cluster assembly 1 |
increases expression |
ISO |
Azacitidine results in increased expression of ISCA1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:4,905,291...4,917,955
Ensembl chr17:4,905,287...4,917,955
|
|
G |
Itgb1 |
integrin subunit beta 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ITGB1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Itgb2 |
integrin subunit beta 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ITGB2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Itprid2 |
ITPR interacting domain containing 2 |
increases expression |
ISO |
Azacitidine results in increased expression of ITPRID2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:64,536,707...64,573,978
Ensembl chr 3:64,536,707...64,573,978
|
|
G |
Kdr |
kinase insert domain receptor |
increases expression |
EXP |
Azacitidine results in increased expression of KDR mRNA |
CTD |
PMID:18037191 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kif2c |
kinesin family member 2C |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of KIF2C mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637
|
|
G |
Kir3dl1 |
killer cell immunoglobulin like receptor, three Ig domains and long cytoplasmic tail 1 |
increases expression decreases methylation |
ISO |
Azacitidine results in increased expression of KIR3DL1 mRNA; Azacitidine results in increased expression of KIR3DL1 protein Azacitidine results in decreased methylation of KIR3DL1 promoter |
CTD |
PMID:18945643 PMID:19394699 |
|
NCBI chr 1:69,715,529...69,754,050
Ensembl chr 1:69,715,535...69,754,050
|
|
G |
Klf6 |
KLF transcription factor 6 |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of KLF6 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Klk1c10 |
kallikrein 1-related peptidase C10 |
increases expression |
ISO |
Azacitidine analog results in increased expression of KLK3 protein |
CTD |
PMID:18324645 |
|
NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052
|
|
G |
Krt19 |
keratin 19 |
increases expression |
ISO |
Azacitidine results in increased expression of KRT19 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:85,075,835...85,080,552
Ensembl chr10:85,066,802...85,171,799
|
|
G |
Krt32 |
keratin 32 |
increases expression |
ISO |
Azacitidine results in increased expression of KRT32 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:85,013,551...85,020,578
Ensembl chr10:85,013,554...85,020,534
|
|
G |
Krt8 |
keratin 8 |
multiple interactions increases expression |
ISO |
Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA] Azacitidine results in increased expression of KRT8 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Lama1 |
laminin subunit alpha 1 |
affects localization |
ISO |
Azacitidine affects the localization of LAMA1 protein |
CTD |
PMID:18033690 |
|
NCBI chr 9:107,692,770...107,816,847
Ensembl chr 9:107,692,770...107,817,478
|
|
G |
Lamb2 |
laminin subunit beta 2 |
increases expression |
ISO |
Azacitidine results in increased expression of LAMB2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549
|
|
G |
Ldhb |
lactate dehydrogenase B |
increases expression |
ISO |
Azacitidine results in increased expression of LDHB mRNA |
CTD |
PMID:23437403 |
|
NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:175,428,385...175,446,403
|
|
G |
Lims1 |
LIM zinc finger domain containing 1 |
increases expression |
ISO |
Azacitidine results in increased expression of LIMS1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
decreases expression |
ISO |
Azacitidine results in decreased expression of LITAF mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
|
|
G |
Ltb4r |
leukotriene B4 receptor |
decreases expression |
ISO |
Azacitidine results in decreased expression of LTB4R mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:29,263,199...29,265,716
|
|
G |
Lyz2 |
lysozyme 2 |
increases expression |
ISO |
Azacitidine results in increased expression of LYZ mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mad1l1 |
mitotic arrest deficient 1 like 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAD1L1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr12:14,320,892...14,630,750
Ensembl chr12:14,320,892...14,630,703
|
|
G |
Mafb |
MAF bZIP transcription factor B |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of MAFB mRNA Cisplatin affects the reaction [Azacitidine results in increased expression of MAFB mRNA] |
CTD |
PMID:36336710 |
|
NCBI chr 3:148,998,111...149,000,031
Ensembl chr 3:148,998,122...149,000,031
|
|
G |
Map1a |
microtubule-associated protein 1A |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAP1A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:108,263,217...108,283,936
Ensembl chr 3:108,263,151...108,282,899
|
|
G |
Map2k5 |
mitogen activated protein kinase kinase 5 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAP2K5 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:63,625,220...63,852,090
Ensembl chr 8:63,625,221...63,851,983
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Azacitidine results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases expression |
ISO |
5-azacytidine decreases expression of MCL1 protein in lung cancer cells |
RGD |
PMID:24356455 |
RGD:153344603 |
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mcm5 |
minichromosome maintenance complex component 5 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of MCM5 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389
|
|
G |
Mdc1 |
mediator of DNA damage checkpoint 1 |
increases expression |
ISO |
Azacitidine results in increased expression of MDC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
increases expression |
ISO |
Azacitidine results in increased expression of MDM2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mecp2 |
methyl CpG binding protein 2 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [MECP2 protein binds to CCNA1 promoter] |
CTD |
PMID:17698632 |
|
NCBI chr X:151,781,177...151,844,687
Ensembl chr X:151,789,930...151,844,689
|
|
G |
Mef2a |
myocyte enhancer factor 2a |
increases expression affects expression |
ISO |
Azacitidine results in increased expression of MEF2A Azacitidine affects the expression of MEF2A protein |
CTD |
PMID:12094073 PMID:19002953 |
|
NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948
|
|
G |
Mef2d |
myocyte enhancer factor 2D |
affects expression increases expression |
ISO |
Azacitidine affects the expression of MEF2D protein Azacitidine results in increased expression of MEF2D |
CTD |
PMID:12094073 PMID:19002953 |
|
NCBI chr 2:173,606,054...173,635,620
Ensembl chr 2:173,606,490...173,634,457
|
|
G |
Megf6 |
multiple EGF-like-domains 6 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MEGF6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 5:164,738,272...164,839,142
Ensembl chr 5:164,738,352...164,839,139
|
|
G |
Mesd |
mesoderm development LRP chaperone |
decreases expression |
EXP |
Azacitidine results in decreased expression of MESD protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:137,866,707...137,879,999
Ensembl chr 1:137,874,242...137,879,999
|
|
G |
Mfap2 |
microfibril associated protein 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MFAP2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:153,312,068...153,320,266
Ensembl chr 5:153,314,711...153,320,259
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
affects expression |
ISO |
Azacitidine affects the expression of MFGE8 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
increases expression decreases methylation |
ISO |
Azacitidine results in increased expression of MGMT mRNA Azacitidine results in decreased methylation of MGMT protein |
CTD |
PMID:7511991 PMID:12807730 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mir193a |
microRNA 193a |
increases expression |
ISO |
5-azacytidine increases expression of MIR193A in liver cells 5-azacytidine increases expression of MIR193a RNA in lung cancer cells |
RGD |
PMID:28036298 PMID:24356455 |
RGD:153344564, RGD:153344603 |
NCBI chr10:64,672,343...64,672,454
Ensembl chr10:64,672,343...64,672,454
|
|
G |
Mir23b |
microRNA 23b |
increases expression |
ISO |
5-azacytidine increases expression of MIR23B miRNA in liver cells |
RGD |
PMID:28036298 |
RGD:153344564 |
NCBI chr17:1,813,667...1,813,763
Ensembl chr17:1,813,667...1,813,763
|
|
G |
Mir497 |
microRNA 497 |
increases expression multiple interactions decreases methylation |
ISO |
Azacitidine results in increased expression of MIR497 mRNA Azacitidine inhibits the reaction [DNMT1 protein binds to MIR497 promoter]; Azacitidine inhibits the reaction [DNMT3A protein binds to MIR497 promoter]; Azacitidine inhibits the reaction [DNMT3B protein binds to MIR497 promoter] Azacitidine results in decreased methylation of MIR497 promoter |
CTD |
PMID:35066776 |
|
NCBI chr10:54,951,514...54,951,582
Ensembl chr10:54,951,505...54,951,584
|
|
G |
Mir9-3 |
microRNA 9-3 |
increases expression |
ISO |
5-azacytidine increases expression of MIR9-3 in lung cancer cells |
RGD |
PMID:24356455 |
RGD:153344603 |
NCBI chr 1:133,440,049...133,440,138
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of MKI67 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of MMP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
metacept-1 inhibits the reaction [Azacitidine results in increased expression of MMP9] |
CTD |
PMID:19148494 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Morf4l2 |
mortality factor 4 like 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of MORF4L2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:100,082,562...100,093,658
Ensembl chr X:100,082,404...100,093,728
|
|
G |
Mov10l1 |
Mov10 like RNA helicase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of MOV10L1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:120,070,171...120,135,406
Ensembl chr 7:120,070,135...120,134,765
|
|
G |
Msrb2 |
methionine sulfoxide reductase B2 |
increases expression |
ISO |
Azacitidine results in increased expression of MSRB2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:81,974,378...82,000,044
Ensembl chr17:81,974,196...82,000,043
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases expression |
ISO |
Azacitidine results in decreased expression of MTHFD2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mtrex |
Mtr4 exosome RNA helicase |
increases expression |
ISO |
Azacitidine results in increased expression of MTREX mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:44,500,326...44,560,624
Ensembl chr 2:44,461,444...44,560,627
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression multiple interactions |
ISO |
Azacitidine analog results in decreased expression of MYC mRNA MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] |
CTD |
PMID:18045574 PMID:19451745 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myf5 |
myogenic factor 5 |
increases expression |
ISO |
Azacitidine results in increased expression of MYF5 mRNA |
CTD |
PMID:18938140 |
|
NCBI chr 7:42,802,946...42,806,177
Ensembl chr 7:42,802,946...42,806,177
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases expression |
EXP |
Azacitidine results in increased expression of MYH7 mRNA; Azacitidine results in increased expression of MYH7 protein |
CTD |
PMID:17105402 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myl2 |
myosin light chain 2 |
increases expression |
EXP |
Azacitidine results in increased expression of MYL2 mRNA |
CTD |
PMID:17105402 |
|
NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983
|
|
G |
Myod1 |
myogenic differentiation 1 |
increases expression |
EXP ISO |
Azacitidine results in increased expression of MYOD1 mRNA |
CTD |
PMID:18037191 PMID:18938140 |
|
NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
|
|
G |
Myog |
myogenin |
increases expression |
ISO |
Azacitidine results in increased expression of MYOG mRNA |
CTD |
PMID:18938140 |
|
NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039
|
|
G |
Ncam1 |
neural cell adhesion molecule 1 |
increases expression |
EXP |
Azacitidine results in increased expression of NCAM1 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr 8:49,865,629...50,165,687
Ensembl chr 8:49,865,633...50,166,014
|
|
G |
Nefl |
neurofilament light chain |
increases expression |
ISO |
Azacitidine results in increased expression of NEFL mRNA |
CTD |
PMID:20823114 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
increases expression |
ISO |
Azacitidine results in increased expression of NFATC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Niban1 |
niban apoptosis regulator 1 |
increases expression multiple interactions |
ISO |
Azacitidine results in increased expression of NIBAN1 mRNA TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr13:63,674,240...63,827,748
Ensembl chr13:63,674,171...63,827,729
|
|
G |
Nkx2-5 |
NK2 homeobox 5 |
increases expression |
ISO |
Azacitidine results in increased expression of NKX2-5 mRNA |
CTD |
PMID:18557828 |
|
NCBI chr10:16,340,428...16,347,004
Ensembl chr10:16,344,159...16,346,934
|
|
G |
Nlgn3 |
neuroligin 3 |
increases expression |
ISO |
Azacitidine results in increased expression of NLGN3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:66,427,926...66,457,378
Ensembl chr X:66,429,458...66,451,876
|
|
G |
Nme2 |
NME/NM23 nucleoside diphosphate kinase 2 |
increases expression |
EXP |
Azacitidine results in increased expression of NME2 protein |
CTD |
PMID:17105402 |
|
NCBI chr10:78,898,097...78,903,514
Ensembl chr10:78,897,770...78,903,538
|
|
G |
Nmi |
N-myc (and STAT) interactor |
increases expression |
ISO |
Azacitidine results in increased expression of NMI mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:36,415,607...36,439,498
|
|
G |
Nnt |
nicotinamide nucleotide transhydrogenase |
increases expression |
ISO |
Azacitidine results in increased expression of NNT mRNA; Azacitidine results in increased expression of NNT protein |
CTD |
PMID:36336710 |
|
NCBI chr 2:51,411,413...51,505,125
Ensembl chr 2:51,411,413...51,504,823
|
|
G |
Nom1 |
nucleolar protein with MIF4G domain 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of NOM1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:5,891,220...5,910,741
Ensembl chr 4:5,892,909...5,909,709
|
|
G |
Nphp1 |
nephrocystin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of NPHP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
Azacitidine results in increased expression of NPPA |
CTD |
PMID:15005238 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
Azacitidine results in increased expression of NPPB |
CTD |
PMID:15005238 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Butyrates] inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]]; Azacitidine inhibits the reaction [Chromium inhibits the reaction [Benzo(a)pyrene results in increased expression of NQO1 mRNA]] |
CTD |
PMID:17682057 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[metacept-1 co-treated with Azacitidine] results in increased expression of NR4A1 |
CTD |
PMID:19148494 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nrip1 |
nuclear receptor interacting protein 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of NRIP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr11:14,895,843...14,979,490
Ensembl chr11:14,895,553...14,981,761
|
|
G |
Nrn1 |
neuritin 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of NRN1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr17:28,129,969...28,138,898
Ensembl chr17:28,129,977...28,138,896
|
|
G |
Nt5e |
5' nucleotidase, ecto |
increases expression |
ISO |
Azacitidine results in increased expression of NT5E mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Nts |
neurotensin |
decreases expression |
ISO |
Azacitidine results in decreased expression of NTS mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:37,564,533...37,574,423
|
|
G |
Nusap1 |
nucleolar and spindle associated protein 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of NUSAP1 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:106,603,273...106,633,428
Ensembl chr 3:106,603,289...106,633,624
|
|
G |
Nxt2 |
nuclear transport factor 2-like export factor 2 |
increases expression |
ISO |
Azacitidine results in increased expression of NXT2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:105,855,616...105,862,902
Ensembl chr X:105,855,608...105,862,899
|
|
G |
Ocln |
occludin |
increases expression |
ISO |
Azacitidine results in increased expression of OCLN mRNA |
CTD |
PMID:18661270 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Ogfrl1 |
opioid growth factor receptor-like 1 |
increases expression |
ISO |
Azacitidine results in increased expression of OGFRL1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 9:25,828,865...25,842,424
Ensembl chr 9:25,828,869...25,842,352
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
decreases expression decreases methylation |
ISO |
Azacitidine results in decreased expression of OGG1 protein Azacitidine results in decreased methylation of OGG1 promoter |
CTD |
PMID:22064374 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Or8b8 |
olfactory receptor family 8 subfamily B member 8 |
increases expression |
ISO |
Azacitidine results in increased expression of OR8B8 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:37,693,578...37,694,510
Ensembl chr 8:37,693,499...37,694,547
|
|
G |
Oxr1 |
oxidation resistance 1 |
increases expression |
ISO |
Azacitidine results in increased expression of OXR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:72,528,750...72,965,666
Ensembl chr 7:72,528,786...72,965,666
|
|
G |
Oxtr |
oxytocin receptor |
decreases expression |
ISO |
Azacitidine results in decreased expression of OXTR mRNA |
CTD |
PMID:21245298 |
|
NCBI chr 4:145,598,549...145,614,674
Ensembl chr 4:145,599,561...145,614,674
|
|
G |
P4hb |
prolyl 4-hydroxylase subunit beta |
increases expression |
EXP ISO |
Azacitidine results in increased expression of P4HB protein Azacitidine results in increased expression of P4HB mRNA |
CTD |
PMID:17105402 PMID:20823114 |
|
NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500
|
|
G |
Paep |
progestagen associated endometrial protein |
decreases expression |
ISO |
Azacitidine results in decreased expression of PAEP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:8,531,136...8,534,430
Ensembl chr 3:8,531,138...8,534,430
|
|
G |
Pak1 |
p21 (RAC1) activated kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PAK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:152,111,172...152,226,390
Ensembl chr 1:152,111,188...152,226,383
|
|
G |
Pank3 |
pantothenate kinase 3 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PANK3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:20,229,129...20,252,955
Ensembl chr10:20,229,129...20,252,955
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Azacitidine results in increased cleavage of PARP1 protein Bleomycin inhibits the reaction [Azacitidine results in increased cleavage of PARP1 protein] |
CTD |
PMID:32278510 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pax4 |
paired box 4 |
increases expression |
ISO |
Azacitidine results in increased expression of PAX4 mRNA |
CTD |
PMID:18949370 |
|
NCBI chr 4:57,058,453...57,065,995
Ensembl chr 4:57,058,462...57,063,408
|
|
G |
Pcdh18 |
protocadherin 18 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PCDH18 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:133,831,996...133,845,992
Ensembl chr 2:133,832,001...133,845,883
|
|
G |
Pcdha1 |
protocadherin alpha 1 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA1 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha10 |
protocadherin alpha 10 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA10 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha11 |
protocadherin alpha 11 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA11 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha2 |
protocadherin alpha 2 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA2 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha3 |
protocadherin alpha 3 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA3 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha4 |
protocadherin alpha 4 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA4 promoter |
CTD |
PMID:18204046 |
|
NCBI chr18:28,581,040...28,846,214
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha5 |
protocadherin alpha 5 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA5 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha6 |
protocadherin alpha 6 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA6 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha7 |
protocadherin alpha 7 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA7 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdha9 |
protocadherin alpha 9 |
affects methylation |
ISO |
Azacitidine affects the methylation of PCDHA8 promoter; Azacitidine affects the methylation of PCDHA9 promoter |
CTD |
PMID:18204046 |
|
Ensembl chr18:28,581,225...28,846,211
|
|
G |
Pcdhb20 |
protocadherin beta 20 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PCDHB14 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:29,211,878...29,215,272
Ensembl chr18:29,211,883...29,215,258
|
|
G |
Pcdhb5 |
protocadherin beta 5 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PCDHB4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr18:29,024,315...29,032,183
Ensembl chr18:29,028,382...29,053,259
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression multiple interactions |
EXP |
Azacitidine results in decreased expression of PCNA protein [Cisplatin co-treated with Azacitidine] results in decreased expression of PCNA protein |
CTD |
PMID:19723570 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PDK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression decreases methylation |
ISO |
Azacitidine results in increased expression of PDK4 protein Azacitidine results in decreased methylation of PDK4 promoter |
CTD |
PMID:28003426 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression |
EXP |
Azacitidine results in increased expression of PECAM1 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pfn1 |
profilin 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PFN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:55,365,263...55,367,968
Ensembl chr10:55,365,262...55,527,631
|
|
G |
Phactr2 |
phosphatase and actin regulator 2 |
increases expression |
ISO |
Azacitidine results in increased expression of PHACTR2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:7,591,254...7,860,431
Ensembl chr 1:7,597,927...7,860,289
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha |
decreases expression |
ISO |
Azacitidine results in decreased expression of PIP5K1A mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598
|
|
G |
Pitpnc1 |
phosphatidylinositol transfer protein, cytoplasmic 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PITPNC1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:92,163,558...92,428,971
Ensembl chr10:92,167,196...92,429,297
|
|
G |
Pitx3 |
paired-like homeodomain 3 |
increases expression |
EXP |
Azacitidine results in increased expression of PITX3 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 1:245,001,106...245,013,881
Ensembl chr 1:245,001,164...245,013,892
|
|
G |
Pja1 |
praja ring finger ubiquitin ligase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PJA1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:64,580,938...64,585,846
Ensembl chr X:64,580,849...64,585,833
|
|
G |
Pkd2l1 |
polycystin 2 like 1, transient receptor potential cation channel |
increases expression |
ISO |
Azacitidine results in increased expression of PKD2L1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:243,032,891...243,070,031
Ensembl chr 1:243,032,913...243,070,031
|
|
G |
Pkm |
pyruvate kinase M1/2 |
increases expression |
ISO |
Azacitidine results in increased expression of PKM mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Plcb1 |
phospholipase C beta 1 |
decreases methylation decreases response to substance increases response to substance increases expression |
ISO |
Azacitidine results in decreased methylation of PLCB1 promoter PLCB1 promoter modified form results in decreased susceptibility to Azacitidine PLCB1 mRNA results in increased susceptibility to Azacitidine; PLCB1 protein results in increased susceptibility to Azacitidine Azacitidine results in increased expression of PLCB1 mRNA; Azacitidine results in increased expression of PLCB1 protein |
CTD |
PMID:19805378 |
|
NCBI chr 3:122,059,988...122,772,896
Ensembl chr 3:122,060,031...122,772,869
|
|
G |
Plpp1 |
phospholipid phosphatase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of PLPP1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:44,439,002...44,500,430
Ensembl chr 2:44,438,994...44,501,268
|
|
G |
Pls3 |
plastin 3 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PLS3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:111,589,193...111,683,908
Ensembl chr X:111,589,254...111,683,891
|
|
G |
Pml |
PML nuclear body scaffold |
increases expression |
ISO |
Azacitidine results in increased expression of PML mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases methylation increases expression |
ISO |
Azacitidine results in decreased methylation of PPARG promoter Azacitidine results in increased expression of PPARG mRNA |
CTD |
PMID:19589179 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions increases expression decreases methylation |
ISO |
Azacitidine promotes the reaction [CREB1 protein modified form binds to PPP2CA promoter] Azacitidine results in increased expression of PPP2CA mRNA Azacitidine results in decreased methylation of PPP2CA promoter |
CTD |
PMID:19155497 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Prdx4 |
peroxiredoxin 4 |
decreases expression |
EXP |
Azacitidine results in decreased expression of PRDX4 protein |
CTD |
PMID:17105402 |
|
NCBI chr X:40,026,762...40,044,066
Ensembl chr X:40,026,651...40,044,066
|
|
G |
Prf1 |
perforin 1 |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [IL2 protein results in increased secretion of PRF1 protein] |
CTD |
PMID:19394699 |
|
NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein |
CTD |
PMID:20823114 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prom1 |
prominin 1 |
increases expression |
EXP |
Azacitidine results in increased expression of PROM1 mRNA |
CTD |
PMID:18037191 |
|
NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527
|
|
G |
Prss12 |
serine protease 12 |
decreases expression |
ISO |
Azacitidine results in decreased expression of PRSS12 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:211,624,134...211,684,126
Ensembl chr 2:211,624,134...211,684,126
|
|
G |
Psen1 |
presenilin 1 |
decreases methylation multiple interactions |
ISO |
Azacitidine results in decreased methylation of PSEN1 promoter Betaine inhibits the reaction [Azacitidine results in decreased methylation of PSEN1 promoter] |
CTD |
PMID:19635394 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased methylation of PTEN promoter] |
CTD |
PMID:22841775 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
decreases expression |
ISO |
Azacitidine results in decreased expression of PTHLH mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Ptpa |
protein phosphatase 2 phosphatase activator |
increases expression |
ISO |
Azacitidine results in increased expression of PTPA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:13,689,742...13,720,287
Ensembl chr 3:13,689,741...13,722,549
|
|
G |
Ptprc |
protein tyrosine phosphatase, receptor type, C |
increases expression |
ISO |
Azacitidine results in increased expression of PTPRC mRNA |
CTD |
PMID:19194470 |
|
NCBI chr13:49,596,193...49,708,283
Ensembl chr13:49,596,193...49,708,692
|
|
G |
Ptpro |
protein tyrosine phosphatase, receptor type, O |
increases expression |
EXP |
Azacitidine results in increased expression of PTPRO mRNA |
CTD |
PMID:14508512 |
|
NCBI chr 4:170,164,071...170,374,790
Ensembl chr 4:170,164,431...170,374,771
|
|
G |
Rab13 |
RAB13, member RAS oncogene family |
decreases methylation |
ISO |
Azacitidine results in decreased methylation of RAB13 promoter |
CTD |
PMID:19194470 |
|
NCBI chr 2:175,674,894...175,680,043
Ensembl chr 2:175,675,005...175,680,036
|
|
G |
Rab1b |
RAB1B, member RAS oncogene family |
increases expression |
ISO |
Azacitidine results in increased expression of RAB1B mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:202,405,759...202,413,850
Ensembl chr 1:202,405,759...202,413,868 Ensembl chr X:202,405,759...202,413,868
|
|
G |
Racgap1 |
Rac GTPase-activating protein 1 |
increases expression |
ISO |
Azacitidine results in increased expression of RACGAP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831
|
|
G |
Ranbp2 |
RAN binding protein 2 |
increases expression |
ISO |
Azacitidine results in increased expression of RANBP2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr20:26,442,156...26,493,481
Ensembl chr20:26,442,217...26,493,481
|
|
G |
Rasa3 |
RAS p21 protein activator 3 |
increases expression |
ISO |
Azacitidine results in increased expression of RASA3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:75,855,360...75,969,349
Ensembl chr16:75,855,265...75,970,804
|
|
G |
Rcn1 |
reticulocalbin 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of RCN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 3:91,841,052...91,855,295
Ensembl chr 3:91,841,052...91,855,295
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization decreases expression |
ISO |
Azacitidine affects the localization of RELA protein 5-azacytidine decreases expression of RELA protein in lung cancer cells |
CTD RGD |
PMID:18443271 PMID:24356455 |
RGD:153344603 |
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ret |
ret proto-oncogene |
decreases expression |
ISO |
Azacitidine results in decreased expression of RET mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176
|
|
G |
Rfc3 |
replication factor C subunit 3 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of RFC3 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr12:1,000,987...1,011,778
Ensembl chr12:1,000,994...1,011,778
|
|
G |
Rhob |
ras homolog family member B |
multiple interactions |
ISO |
[trichostatin A co-treated with Azacitidine] results in increased expression of RHOB protein; Azacitidine promotes the reaction [trichostatin A results in increased expression of RHOB mRNA] |
CTD |
PMID:18047684 |
|
NCBI chr 6:31,363,752...31,365,926
Ensembl chr 6:31,363,548...31,366,108
|
|
G |
Rin1 |
Ras and Rab interactor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of RIN1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:202,355,729...202,362,731
Ensembl chr 1:202,355,890...202,362,729
|
|
G |
Rpp21 |
ribonuclease P/MRP subunit p21 |
increases expression |
ISO |
Azacitidine results in increased expression of RPP21 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:2,018,170...2,020,100
Ensembl chr20:2,018,147...2,020,106
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases phosphorylation |
ISO |
Azacitidine results in decreased phosphorylation of RPS6 protein |
CTD |
PMID:21245298 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Rpsa |
ribosomal protein SA |
decreases expression |
ISO |
Azacitidine results in decreased expression of RPSA mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:119,851,225...119,855,103
Ensembl chr 8:119,851,225...119,855,247
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of RRM2 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
Azacitidine results in increased expression of RRM2B mRNA |
CTD |
PMID:19010910 |
|
NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633
|
|
G |
RT1-Da |
RT1 class II, locus Da |
multiple interactions |
ISO |
[Azacitidine promotes the reaction [IFNG protein results in increased expression of CIITA mRNA]] which results in increased expression of HLA-DRA protein |
CTD |
PMID:18829986 |
|
NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455
|
|
G |
Runx1 |
RUNX family transcription factor 1 |
multiple interactions |
ISO |
Azacitidine promotes the reaction [RUNX1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [RUNX1 protein binds to KIR2DL4 promoter] |
CTD |
PMID:18945643 |
|
NCBI chr11:31,839,880...32,074,427
Ensembl chr11:31,843,764...32,074,542
|
|
G |
Runx3 |
RUNX family transcription factor 3 |
affects methylation |
ISO |
Azacitidine affects the methylation of RUNX3 gene |
CTD |
PMID:18058463 |
|
NCBI chr 5:147,360,587...147,419,161
Ensembl chr 5:147,360,994...147,419,156
|
|
G |
S100a14 |
S100 calcium binding protein A14 |
decreases expression |
ISO |
Azacitidine results in decreased expression of S100A14 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:176,008,395...176,010,423
Ensembl chr 2:176,008,395...176,010,423
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
Azacitidine results in increased expression of S100A9 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Sall4 |
spalt-like transcription factor 4 |
affects methylation |
ISO |
Azacitidine affects the methylation of SALL4 promoter |
CTD |
PMID:17546590 |
|
NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822
|
|
G |
Scamp4 |
secretory carrier membrane protein 4 |
increases expression |
ISO |
Azacitidine results in increased expression of SCAMP4 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:9,101,504...9,113,929
Ensembl chr 7:9,101,489...9,113,967
|
|
G |
Sdcbp |
syndecan binding protein |
decreases expression |
ISO |
Azacitidine results in decreased expression of SDCBP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:19,473,499...19,517,188
Ensembl chr 5:19,489,961...19,527,572
|
|
G |
Sema3a |
semaphorin 3A |
increases expression |
ISO |
Azacitidine results in increased expression of SEMA3A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 4:21,282,398...21,754,834
Ensembl chr 4:21,287,982...21,494,432
|
|
G |
Sema6c |
semaphorin 6C |
increases expression |
ISO |
Azacitidine results in increased expression of SEMA6C mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:182,733,635...182,750,066
Ensembl chr 2:182,737,474...182,746,856
|
|
G |
Senp3 |
SUMO specific peptidase 3 |
increases expression |
ISO |
Azacitidine results in increased expression of SENP3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:54,390,698...54,399,590
Ensembl chr10:54,390,694...54,399,593
|
|
G |
Six2 |
SIX homeobox 2 |
decreases expression multiple interactions |
ISO |
Azacitidine results in decreased expression of SIX2 mRNA Cisplatin affects the reaction [Azacitidine results in decreased expression of SIX2 mRNA] |
CTD |
PMID:36336710 |
|
NCBI chr 6:8,974,859...8,981,345
Ensembl chr 6:8,967,157...8,981,193
|
|
G |
Slbp |
stem-loop histone mRNA binding protein |
multiple interactions |
ISO |
Azacitidine inhibits the reaction [sodium arsenite results in decreased expression of SLBP mRNA] |
CTD |
PMID:25266719 |
|
NCBI chr14:77,071,441...77,081,911
Ensembl chr14:77,071,632...77,081,906
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
increases response to substance multiple interactions increases uptake |
ISO |
SLC28A1 protein results in increased susceptibility to Azacitidine [SLC28A1 protein results in increased uptake of Azacitidine] which results in decreased expression of DNMT1 protein; Sodium affects the reaction [SLC28A1 protein results in increased uptake of Azacitidine] |
CTD |
PMID:19139132 |
|
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
|
|
G |
Slc29a2 |
solute carrier family 29 member 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SLC29A2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:202,327,641...202,335,185
Ensembl chr 1:202,327,354...202,335,171
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions increases expression |
ISO |
[Azacitidine co-treated with Butyrates] affects the expression of SLC5A5 mRNA Azacitidine results in increased expression of SLC5A5 mRNA |
CTD |
PMID:16954431 PMID:17164311 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Snu13 |
small nuclear ribonucleoprotein 13 |
increases expression |
ISO |
Azacitidine results in increased expression of SNU13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 7:113,565,293...113,570,887
Ensembl chr 7:113,565,295...113,570,872 Ensembl chr 1:113,565,295...113,570,872
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
affects expression |
ISO |
Azacitidine affects the expression of SOCS3 protein |
CTD |
PMID:18443271 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sox13 |
SRY-box transcription factor 13 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SOX13 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:44,831,097...44,875,522
Ensembl chr13:44,831,085...44,875,762
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
increases expression |
EXP |
Azacitidine results in increased expression of SOX2 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Sox8 |
SRY-box transcription factor 8 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SOX8 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr10:14,584,829...14,589,818
Ensembl chr10:14,584,829...14,589,818
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
affects expression |
ISO |
Azacitidine affects the expression of SOX9 mRNA |
CTD |
PMID:18033690 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions decreases expression |
ISO |
Azacitidine promotes the reaction [SP1 protein binds to KIR2DL2 promoter]; Azacitidine promotes the reaction [SP1 protein binds to KIR2DL4 promoter] Azacitidine results in decreased expression of SP1 mRNA Azacitidine promotes the reaction [SP1 protein binds to AQP5 promoter] |
CTD |
PMID:17198683 PMID:18945643 PMID:20823114 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sp7 |
Sp7 transcription factor |
increases expression |
ISO |
Azacitidine results in increased expression of SP7 mRNA |
CTD |
PMID:17085970 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spag5 |
sperm associated antigen 5 |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of SPAG5 mRNA |
CTD |
PMID:18720364 |
|
NCBI chr10:63,198,717...63,216,746
Ensembl chr10:63,198,768...63,216,745
|
|
G |
Srpx |
sushi-repeat-containing protein, X-linked |
decreases expression |
ISO |
Azacitidine results in decreased expression of SRPX mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:12,676,984...12,751,296
Ensembl chr X:12,566,645...12,747,882
|
|
G |
Srsf7 |
serine and arginine rich splicing factor 7 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SRSF7 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 6:14,811,775...14,818,968
Ensembl chr 6:14,811,808...14,818,965
|
|
G |
Ssx2ip |
SSX family member 2 interacting protein |
increases expression |
ISO |
Azacitidine results in increased expression of SSX2IP mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:235,298,012...235,330,750
Ensembl chr 2:235,298,088...235,330,745
|
|
G |
St3gal6 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 6 |
increases expression |
ISO |
Azacitidine results in increased expression of ST3GAL6 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr11:42,061,282...42,121,801
Ensembl chr11:42,077,621...42,121,776
|
|
G |
St8sia2 |
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ST8SIA2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 1:127,762,573...127,838,017
Ensembl chr 1:127,762,573...127,838,091
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Azacitidine affects the expression of IL6R protein] which affects the phosphorylation of STAT3 protein |
CTD |
PMID:18443271 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stc2 |
stanniocalcin 2 |
decreases expression |
ISO |
Azacitidine results in decreased expression of STC2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
|
|
G |
Stk38 |
serine/threonine kinase 38 |
decreases expression |
ISO |
Azacitidine results in decreased expression of STK38 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr20:7,034,245...7,067,803
Ensembl chr20:7,034,242...7,068,198
|
|
G |
Sulf1 |
sulfatase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of SULF1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:6,362,894...6,526,174
Ensembl chr 5:6,362,911...6,525,584
|
|
G |
Sult1c2a |
sulfotransferase family 1C member 2A |
increases expression |
ISO |
Azacitidine results in increased expression of SULT1C2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Tat |
tyrosine aminotransferase |
increases expression |
ISO |
Azacitidine results in increased expression of TAT mRNA |
CTD |
PMID:27590069 |
|
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
|
|
G |
Tbc1d4 |
TBC1 domain family, member 4 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TBC1D4 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265
|
|
G |
Tcea1 |
transcription elongation factor A1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TCEA1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:14,631,454...14,668,769
Ensembl chr 5:14,631,454...14,668,745 Ensembl chr15:14,631,454...14,668,745
|
|
G |
Tecpr2 |
tectonin beta-propeller repeat containing 2 |
increases expression |
ISO |
Azacitidine results in increased expression of TECPR2 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 6:129,899,541...130,001,975
Ensembl chr 6:129,899,636...130,001,974
|
|
G |
Tek |
TEK receptor tyrosine kinase |
increases expression |
EXP |
Azacitidine results in increased expression of TEK mRNA |
CTD |
PMID:18037191 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases expression multiple interactions decreases methylation decreases activity |
ISO |
Azacitidine analog results in decreased expression of TERT mRNA; Azacitidine results in decreased expression of TERT mRNA E2F1 protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; E2F1 protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA]; MYC protein affects the reaction [Azacitidine results in decreased activity of TERT protein]; MYC protein affects the reaction [Azacitidine results in decreased expression of TERT mRNA] Azacitidine results in decreased methylation of TERT promoter |
CTD |
PMID:18045574 PMID:19451745 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tfe3 |
transcription factor binding to IGHM enhancer 3 |
increases expression |
ISO |
Azacitidine results in increased expression of TFE3 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr X:14,729,547...14,742,830
Ensembl chr X:14,729,550...14,742,571
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Azacitidine co-treated with TGFB1 protein] results in increased expression of FOXP3 protein Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in decreased expression of PTEN protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Azacitidine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 protein]; Azacitidine inhibits the reaction [TGFB1 protein results in increased methylation of PTEN promoter]; Azacitidine inhibits the reaction [TGFB1 protein results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18493985 PMID:22841775 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thumpd1 |
THUMP domain containing 1 |
increases expression |
ISO |
Azacitidine results in increased expression of THUMPD1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:174,078,875...174,084,915
Ensembl chr 1:174,078,878...174,084,937
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression |
ISO |
Azacitidine results in increased expression of TIMP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tjp1 |
tight junction protein 1 |
increases expression |
ISO |
Azacitidine results in increased expression of TJP1 mRNA |
CTD |
PMID:18661270 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tmed3 |
transmembrane p24 trafficking protein 3 |
increases expression |
ISO |
Azacitidine results in increased expression of TMED3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 8:90,241,516...90,249,429
Ensembl chr 8:90,241,516...90,249,346
|
|
G |
Tmpo |
thymopoietin |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of TMPO mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727
|
|
G |
Tnc |
tenascin C |
decreases expression |
ISO |
Azacitidine results in decreased expression of TNC mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
increases expression increases response to substance |
EXP ISO |
Azacitidine results in increased expression of TNF mRNA Azacitidine results in increased susceptibility to TNF protein |
CTD |
PMID:17156202 PMID:18829727 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance |
ISO |
Azacitidine results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:18829727 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnni3 |
troponin I3, cardiac type |
increases expression |
EXP |
Azacitidine results in increased expression of TNNI3 protein |
CTD |
PMID:17105402 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
increases expression |
EXP |
Azacitidine results in increased expression of TNNT2 protein |
CTD |
PMID:22496879 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of TOP2A mRNA; [Curcumin co-treated with Azacitidine] results in decreased expression of TOP2A mRNA |
CTD |
PMID:18348204 PMID:18720364 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
affects activity |
ISO |
Azacitidine affects the activity of TP53 protein |
CTD |
PMID:35435491 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp73 |
tumor protein p73 |
multiple interactions |
ISO |
TP73 protein promotes the reaction [Azacitidine results in increased expression of HMGA2 mRNA]; TP73 protein promotes the reaction [Azacitidine results in increased expression of KLF6 mRNA]; TP73 protein promotes the reaction [Azacitidine results in increased expression of NIBAN1 mRNA] |
CTD |
PMID:21245298 |
|
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
|
|
G |
Tpd52 |
tumor protein D52 |
increases expression |
EXP |
Azacitidine results in increased expression of TPD52 mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622
|
|
G |
Tpm2 |
tropomyosin 2 |
increases expression |
ISO |
Azacitidine results in increased expression of TPM2 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:57,770,919...57,780,278
Ensembl chr 5:57,770,864...57,779,992
|
|
G |
Tpo |
thyroid peroxidase |
increases expression |
ISO |
Azacitidine results in increased expression of TPO mRNA |
CTD |
PMID:17679169 |
|
NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
|
|
G |
Tpsg1 |
tryptase gamma 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TPSG1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr10:14,386,352...14,390,258
Ensembl chr10:14,386,352...14,390,258
|
|
G |
Trh |
thyrotropin releasing hormone |
decreases expression |
ISO |
Azacitidine results in decreased expression of TRH mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 4:124,742,111...124,777,094
Ensembl chr 4:124,742,111...124,744,637
|
|
G |
Trib1 |
tribbles pseudokinase 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TRIB1 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 7:91,206,579...91,213,126
Ensembl chr 7:91,206,579...91,214,731
|
|
G |
Trim8 |
tripartite motif-containing 8 |
increases expression |
ISO |
Azacitidine results in increased expression of TRIM8 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:245,369,632...245,384,513
Ensembl chr 1:245,369,632...245,384,513
|
|
G |
Tsc1 |
TSC complex subunit 1 |
multiple interactions |
ISO |
[Azacitidine affects the methylation of TSC1 promoter] which affects the expression of TSC1 mRNA |
CTD |
PMID:18538015 |
|
NCBI chr 3:11,969,547...12,018,591
Ensembl chr 3:11,979,729...12,015,674
|
|
G |
Tsc2 |
TSC complex subunit 2 |
decreases methylation multiple interactions increases expression |
ISO |
Azacitidine results in decreased methylation of TSC2 promoter [Azacitidine affects the methylation of TSC2 promoter] which affects the expression of TSC2 mRNA Azacitidine results in increased expression of TSC2 mRNA |
CTD |
PMID:18538015 PMID:19250671 |
|
NCBI chr10:13,621,135...13,655,773
Ensembl chr10:13,621,136...13,655,951
|
|
G |
Tshr |
thyroid stimulating hormone receptor |
increases expression |
ISO |
Azacitidine results in increased expression of TSHR mRNA |
CTD |
PMID:17679169 |
|
NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538
|
|
G |
Tspan32 |
tetraspanin 32 |
decreases expression |
ISO |
Azacitidine results in decreased expression of TSPAN32 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 1:198,190,128...198,204,447
Ensembl chr 1:198,190,164...198,204,445
|
|
G |
Ttk |
Ttk protein kinase |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of TTK mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651
|
|
G |
Ube2c |
ubiquitin-conjugating enzyme E2C |
multiple interactions |
ISO |
[Azacitidine co-treated with Thalidomide] affects the expression of UBE2C mRNA |
CTD |
PMID:18720364 |
|
NCBI chr 3:153,506,636...153,509,036
Ensembl chr 3:153,506,636...153,513,339
|
|
G |
Uhmk1 |
U2AF homology motif kinase 1 |
increases expression |
ISO |
Azacitidine results in increased expression of UHMK1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:82,396,646...82,416,292
Ensembl chr13:82,401,187...82,416,292
|
|
G |
Ush2a |
usherin |
increases expression |
ISO |
Azacitidine results in increased expression of USH2A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr13:99,837,445...100,503,935
Ensembl chr13:99,837,445...100,503,922
|
|
G |
Ushbp1 |
USH1 protein network component harmonin binding protein 1 |
decreases expression |
ISO |
Azacitidine results in decreased expression of USHBP1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:18,057,321...18,067,933
Ensembl chr16:18,057,326...18,067,877
|
|
G |
Vim |
vimentin |
decreases expression increases expression multiple interactions |
EXP ISO |
Azacitidine results in decreased expression of VIM protein Azacitidine results in increased expression of VIM mRNA; Azacitidine results in increased expression of VIM protein [Azacitidine co-treated with Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of VIM protein |
CTD |
PMID:17105402 PMID:20823114 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wdr47 |
WD repeat domain 47 |
decreases expression |
ISO |
Azacitidine results in decreased expression of WDR47 mRNA |
CTD |
PMID:19194470 |
|
NCBI chr 2:196,226,757...196,287,739
Ensembl chr 2:196,205,238...196,287,739
|
|
G |
Wnt10b |
Wnt family member 10B |
increases expression |
EXP |
Azacitidine results in increased expression of WNT10B mRNA |
CTD |
PMID:27415467 |
|
NCBI chr 7:129,922,088...129,927,892
Ensembl chr 7:129,922,088...129,927,892
|
|
G |
Wnt5a |
Wnt family member 5A |
increases expression |
ISO |
Azacitidine results in increased expression of WNT5A mRNA |
CTD |
PMID:20823114 |
|
NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Wwtr1 |
WW domain containing transcription regulator 1 |
increases expression |
ISO |
Azacitidine results in increased expression of WWTR1 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968
|
|
G |
Xaf1 |
XIAP associated factor 1 |
decreases expression decreases methylation increases expression |
ISO |
Azacitidine results in decreased expression of XAF1 mRNA alternative form Azacitidine results in decreased methylation of XAF1 promoter Azacitidine results in increased expression of XAF1 mRNA; Azacitidine results in increased expression of XAF1 protein |
CTD |
PMID:19077051 PMID:19549372 |
|
NCBI chr10:56,917,378...56,929,791
Ensembl chr10:56,917,121...56,929,770
|
|
G |
Zfp189 |
zinc finger protein 189 |
decreases expression |
ISO |
Azacitidine results in decreased expression of ZNF189 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr 5:63,872,596...63,884,348
Ensembl chr 5:63,872,738...63,884,121
|
|
G |
Zfp64 |
zinc finger protein 64 |
affects methylation |
ISO |
Azacitidine affects the methylation of ZFP64 promoter |
CTD |
PMID:17546590 |
|
NCBI chr 3:157,666,819...157,695,774
Ensembl chr 3:157,633,211...157,695,809
|
|
G |
Zp3 |
zona pellucida glycoprotein 3 |
increases expression |
ISO |
Azacitidine results in increased expression of ZP3 mRNA |
CTD |
PMID:20823114 |
|
NCBI chr12:20,690,547...20,697,513
Ensembl chr12:20,690,547...20,697,513
|
|
|
G |
Hsd17b2 |
hydroxysteroid (17-beta) dehydrogenase 2 |
affects binding |
ISO |
acetoacetyl CoA binds to HSD17B2 protein |
CTD |
PMID:25526675 |
|
NCBI chr19:45,753,576...45,825,203
Ensembl chr19:45,753,574...45,825,202
|
|
|
G |
Acly |
ATP citrate lyase |
increases abundance |
ISO |
ACLY protein results in increased abundance of Acetyl Coenzyme A |
CTD |
PMID:28077572 |
|
NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
|
|
G |
App |
amyloid beta precursor protein |
affects localization increases secretion multiple interactions |
ISO |
APP protein affects the localization of Acetyl Coenzyme A Acetyl Coenzyme A results in increased secretion of APP protein modified form Acetyl Coenzyme A inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form] IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] |
CTD |
PMID:16122837 PMID:22906069 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Crat |
carnitine O-acetyltransferase |
decreases activity |
EXP |
Acetyl Coenzyme A deficiency results in decreased activity of CRAT protein |
CTD |
PMID:8075222 |
|
NCBI chr 3:13,675,684...13,689,282
Ensembl chr 3:13,675,684...13,689,255
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
decreases abundance multiple interactions |
ISO |
ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A 3-Hydroxybutyric Acid inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Acetyl Coenzyme A] |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
[Fluoxetine results in decreased expression of G6PC1 protein] which results in increased abundance of Acetyl Coenzyme A |
CTD |
PMID:33179799 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
IL1B protein affects the reaction [APP protein affects the localization of Acetyl Coenzyme A] |
CTD |
PMID:16122837 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
Acetyl Coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
G |
Metrnl |
meteorin-like, glial cell differentiation regulator |
multiple interactions |
ISO |
METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Acetyl Coenzyme A] |
CTD |
PMID:30213948 |
|
NCBI chr10:106,963,880...106,977,875
Ensembl chr10:106,963,880...106,977,869
|
|
G |
Nat1 |
N-acetyltransferase 1 |
multiple interactions affects binding |
ISO |
[NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone; Acetyl Coenzyme A inhibits the reaction [Cyanamide results in decreased activity of NAT1 protein]; Acetyl Coenzyme A inhibits the reaction [Iodoacetamide results in decreased activity of NAT1 protein] Acetyl Coenzyme A binds to NAT1 protein |
CTD |
PMID:20545351 PMID:22835378 |
|
NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[SULT1A2 protein co-treated with Phosphoadenosine Phosphosulfate] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone] |
CTD |
PMID:20545351 |
|
NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
ISO |
[NAT2 protein co-treated with Acetyl Coenzyme A] promotes the reaction [[NQO1 protein co-treated with NADP] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone]; [NQO1 protein co-treated with NADP co-treated with Acetyl Coenzyme A co-treated with NAT1 protein] results in increased activity of and results in increased reduction of 3-nitrobenzanthrone |
CTD |
PMID:20545351 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
increases abundance |
ISO |
ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
increases abundance |
ISO |
HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
|
|
|
G |
Ada |
adenosine deaminase |
decreases metabolic processing increases metabolic processing |
ISO |
ADA alternative form results in decreased metabolism of Adenosine ADA protein results in increased metabolism of Adenosine |
CTD |
PMID:16221767 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions affects binding |
ISO EXP |
Adenosine analog binds to and affects the activity of ADORA1 protein; Adenosine analog binds to and results in decreased activity of ADORA1 protein; PD 81723 affects the reaction [Adenosine analog binds to and affects the activity of ADORA1 protein]; VUF 5455 affects the reaction [Adenosine analog binds to and affects the activity of ADORA1 protein] [lead acetate results in increased expression of ADORA1 protein] which results in increased abundance of Adenosine; Adenosine analog binds to and results in increased activity of ADORA1 protein Adenosine binds to ADORA1 protein |
CTD |
PMID:10649980 PMID:11520205 PMID:18404447 PMID:20571079 PMID:20932874 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adora2a |
adenosine A2a receptor |
multiple interactions affects binding |
ISO |
Adenosine analog binds to and results in decreased activity of ADORA2A protein; Adenosine promotes the reaction [Lipopolysaccharides results in increased expression of ADORA2A mRNA] Adenosine binds to ADORA2A protein |
CTD |
PMID:18404447 PMID:20067761 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Adora2b |
adenosine A2B receptor |
affects response to substance |
ISO |
ADORA2B protein affects the susceptibility to Adenosine |
CTD |
PMID:16920807 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Adora3 |
adenosine A3 receptor |
multiple interactions increases expression affects binding |
ISO |
Adenosine analog binds to and affects the activity of ADORA3 protein; Adenosine analog binds to and results in decreased activity of ADORA3 protein; Adenosine analog binds to and results in increased activity of ADORA3 protein; PD 81723 affects the reaction [Adenosine analog binds to and affects the activity of ADORA3 protein]; VUF 5455 affects the reaction [Adenosine analog binds to and affects the activity of ADORA3 protein] Adenosine results in increased expression of ADORA3 mRNA Adenosine binds to ADORA3 protein |
CTD |
PMID:11520205 PMID:18404447 PMID:20067761 PMID:20571079 |
|
NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357
|
|
G |
Alpi |
alkaline phosphatase, intestinal |
multiple interactions |
ISO |
Adenosine inhibits the reaction [Methotrexate results in increased activity of ALPI protein] |
CTD |
PMID:16598758 |
|
NCBI chr 9:87,773,411...87,776,877
Ensembl chr 9:87,773,411...87,776,877
|
|
G |
Ampd2 |
adenosine monophosphate deaminase 2 |
multiple interactions |
ISO |
[tofacitinib results in decreased expression of AMPD2 protein] which affects the abundance of Adenosine |
CTD |
PMID:25496463 |
|
NCBI chr 2:195,707,609...195,720,454
Ensembl chr 2:195,707,610...195,720,271
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases localization multiple interactions |
ISO |
Adenosine results in increased localization of BAX protein Thymidine inhibits the reaction [Adenosine results in increased localization of BAX protein] |
CTD |
PMID:11570579 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of BCL2L1 mRNA; Adenosine results in decreased expression of BCL2L1 protein Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of BCL2L1 protein] |
CTD |
PMID:20063052 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
Adenosine results in decreased expression of BIRC2 mRNA; Adenosine results in decreased expression of BIRC2 protein |
CTD |
PMID:20063052 |
|
NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
decreases expression |
ISO |
Adenosine results in decreased expression of BIRC3 mRNA |
CTD |
PMID:20063052 |
|
NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
Adenosine results in increased expression of BMP2 mRNA |
CTD |
PMID:34070360 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
increases expression multiple interactions |
ISO |
Adenosine results in increased expression of BMP4 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]; PSB603 inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA]; ZM 241385 inhibits the reaction [Adenosine results in increased expression of BMP4 mRNA] |
CTD |
PMID:34070360 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
increases expression |
ISO |
Adenosine results in increased expression of BMPR1A mRNA |
CTD |
PMID:34070360 |
|
NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity |
ISO EXP |
Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP3 protein]; Thymidine inhibits the reaction [Adenosine results in increased activity of CASP3 protein] |
CTD |
PMID:11570579 PMID:16469385 PMID:17303086 PMID:20063052 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity multiple interactions |
ISO EXP |
Adenosine results in increased activity of CASP8 protein Dipyridamole inhibits the reaction [Adenosine results in increased activity of CASP8 protein] |
CTD |
PMID:16469385 PMID:17303086 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
Adenosine results in increased activity of CASP9 protein Thymidine inhibits the reaction [Adenosine results in increased activity of CASP9 protein] |
CTD |
PMID:11570579 PMID:16469385 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
Adenosine results in increased expression of CCND1 mRNA |
CTD |
PMID:34070360 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
Adenosine results in increased expression of CD14 mRNA |
CTD |
PMID:21538184 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of CFLAR mRNA; Adenosine results in decreased expression of CFLAR mRNA alternative form; Adenosine results in decreased expression of CFLAR protein Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA alternative form]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR mRNA]; Dipyridamole inhibits the reaction [Adenosine results in decreased expression of CFLAR protein] |
CTD |
PMID:17303086 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cftr |
CF transmembrane conductance regulator |
increases activity multiple interactions |
ISO |
Adenosine results in increased activity of CFTR protein [Isoproterenol co-treated with Adenosine] results in increased activity of CFTR protein |
CTD |
PMID:15039139 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases expression multiple interactions |
ISO |
Adenosine results in increased expression of CREB1 mRNA N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]; PSB603 inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA]; ZM 241385 inhibits the reaction [Adenosine results in increased expression of CREB1 mRNA] |
CTD |
PMID:34070360 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression |
ISO |
Adenosine results in increased expression of CTNNB1 mRNA |
CTD |
PMID:34070360 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression multiple interactions |
ISO |
Adenosine results in increased expression of DIABLO mRNA; Adenosine results in increased expression of DIABLO protein Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO mRNA]; Dipyridamole inhibits the reaction [Adenosine results in increased expression of DIABLO protein] |
CTD |
PMID:20063052 |
|
NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dkk1 |
dickkopf WNT signaling pathway inhibitor 1 |
increases expression |
ISO |
Adenosine results in increased expression of DKK1 mRNA |
CTD |
PMID:34070360 |
|
NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of DPP4 mRNA; Adenosine results in decreased expression of DPP4 protein [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 protein; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 protein |
CTD |
PMID:16611738 |
|
NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901
|
|
G |
Egf |
epidermal growth factor |
increases expression multiple interactions |
ISO |
Adenosine results in increased expression of EGF mRNA Adenosine results in increased expression of and results in increased secretion of EGF protein |
CTD |
PMID:34070360 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
Adenosine results in increased expression of ESR1 protein |
CTD |
PMID:29360751 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
increases expression |
ISO |
Adenosine results in increased expression of ESR2 protein |
CTD |
PMID:29360751 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Fadd |
Fas associated via death domain |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of FADD mRNA Dipyridamole inhibits the reaction [Adenosine results in decreased expression of FADD mRNA] |
CTD |
PMID:17303086 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Faslg |
Fas ligand |
increases expression multiple interactions |
ISO |
Adenosine results in increased expression of FASLG protein [Adenosine co-treated with Coformycin] results in decreased expression of FASL mRNA |
CTD |
PMID:11992407 PMID:16419169 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fgf6 |
fibroblast growth factor 6 |
multiple interactions |
ISO |
Adenosine results in increased expression of and results in increased secretion of FGF6 protein |
CTD |
PMID:34070360 |
|
NCBI chr 4:159,854,913...159,863,447
Ensembl chr 4:159,854,913...159,863,447
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
increases expression |
ISO |
Adenosine results in increased expression of FSHB protein |
CTD |
PMID:29360751 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Fzd3 |
frizzled class receptor 3 |
increases expression |
ISO |
Adenosine results in increased expression of FZD3 mRNA |
CTD |
PMID:34070360 |
|
NCBI chr15:39,421,366...39,488,369
Ensembl chr15:39,421,355...39,488,369
|
|
G |
Fzd5 |
frizzled class receptor 5 |
increases expression |
ISO |
Adenosine results in increased expression of FZD5 mRNA |
CTD |
PMID:34070360 |
|
NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
increases secretion |
ISO |
Adenosine results in increased secretion of GDNF protein |
CTD |
PMID:34070360 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
increases phosphorylation increases expression |
ISO |
Adenosine results in increased phosphorylation of GSK3B protein Adenosine results in increased expression of GSK3B mRNA |
CTD |
PMID:34070360 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gzmb |
granzyme B |
multiple interactions |
ISO |
[Adenosine co-treated with Coformycin] results in decreased expression of GZMB mRNA |
CTD |
PMID:11992407 |
|
NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Adenosine promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
increases expression |
ISO |
Adenosine results in increased expression of HIF1A mRNA |
CTD |
PMID:20067761 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
increases abundance multiple interactions |
ISO |
IDH2 protein mutant form results in increased abundance of Adenosine Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Adenosine co-treated with Coformycin] results in decreased expression of IFNG protein |
CTD |
PMID:11992407 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression multiple interactions |
ISO |
Adenosine affects the expression of IGF1 mRNA Adenosine results in increased expression of and results in increased secretion of IGF1 protein |
CTD |
PMID:34070360 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2 |
insulin-like growth factor 2 |
multiple interactions |
ISO |
Adenosine results in increased expression of and results in increased secretion of IGF2 protein |
CTD |
PMID:34070360 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Il10 |
interleukin 10 |
multiple interactions increases expression |
ISO |
Adenosine promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] Adenosine results in increased expression of IL10 mRNA; Adenosine results in increased expression of IL10 protein |
CTD |
PMID:11023991 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
decreases expression multiple interactions |
ISO |
Adenosine results in decreased expression of IL12B protein Adenosine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:11023991 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Adenosine inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; Adenosine inhibits the reaction [IL1B protein results in increased expression of IL1R1]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:24878381 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
EXP |
Adenosine inhibits the reaction [IL1B protein results in increased expression of IL1R1] |
CTD |
PMID:24878381 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[Adenosine co-treated with Coformycin] results in decreased expression of IL2 protein |
CTD |
PMID:11992407 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Lef1 |
lymphoid enhancer binding factor 1 |
increases expression |
ISO |
Adenosine results in increased expression of LEF1 mRNA |
CTD |
PMID:34070360 |
|
NCBI chr 2:219,666,549...219,779,815
Ensembl chr 2:219,666,592...219,779,794
|
|
G |
Ly96 |
lymphocyte antigen 96 |
increases expression |
ISO |
Adenosine results in increased expression of LY96 mRNA |
CTD |
PMID:21538184 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
increases phosphorylation |
ISO |
Adenosine results in increased phosphorylation of MAP2K1 protein |
CTD |
PMID:34070360 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
increases phosphorylation |
ISO |
Adenosine results in increased phosphorylation of MAP2K2 protein |
CTD |
PMID:34070360 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO |
[Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK1 protein] which results in decreased expression of DPP4 protein |
CTD |
PMID:16611738 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation multiple interactions |
ISO |
Adenosine results in decreased phosphorylation of MAPK3 protein [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 mRNA; [Adenosine results in decreased phosphorylation of MAPK3 protein] which results in decreased expression of DPP4 protein |
CTD |
PMID:16611738 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
affects expression |
ISO |
Adenosine affects the expression of MKI67 mRNA |
CTD |
PMID:34070360 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
ISO |
Adenosine results in increased phosphorylation of MTOR protein |
CTD |
PMID:34070360 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression increases expression multiple interactions |
ISO |
Adenosine results in decreased expression of MYC protein Adenosine results in increased expression of MYC mRNA Thymidine inhibits the reaction [Adenosine results in decreased expression of MYC protein]; Uridine inhibits the reaction [Adenosine results in decreased expression of MYC protein] |
CTD |
PMID:9808420 PMID:34070360 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] results in decreased expression of NFKBIA mRNA |
CTD |
PMID:24224954 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases stability multiple interactions |
EXP |
Adenosine results in decreased stability of NOS2 mRNA Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; Adenosine inhibits the reaction [IL1B protein results in increased expression of NOS2 protein] |
CTD |
PMID:24878381 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nt5e |
5' nucleotidase, ecto |
multiple interactions |
ISO |
[alpha,beta-methyleneadenosine 5'-diphosphate results in decreased activity of NT5E protein] inhibits the reaction [Oxygen deficiency results in increased abundance of Adenosine] |
CTD |
PMID:23437309 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
Pgf |
placental growth factor |
increases secretion |
ISO |
Adenosine results in increased secretion of PGF protein |
CTD |
PMID:34070360 |
|
NCBI chr 6:104,816,102...104,826,685
Ensembl chr 6:104,816,104...104,826,685
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Adenosine results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prf1 |
perforin 1 |
multiple interactions |
ISO |
[Adenosine co-treated with Coformycin] results in decreased expression of PRF1 mRNA |
CTD |
PMID:11992407 |
|
NCBI chr20:29,246,202...29,251,712
Ensembl chr20:29,246,202...29,251,701
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
[Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased metabolism of Adenosine; [Prostaglandin D2 results in increased activity of PTGDR protein] which results in increased secretion of Adenosine |
CTD |
PMID:11562489 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:24224954 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
decreases secretion |
EXP |
Adenosine results in decreased secretion of REN protein |
CTD |
PMID:3044993 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein |
CTD |
PMID:24224954 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation |
ISO |
Adenosine results in increased phosphorylation of RPS6KB1 protein |
CTD |
PMID:34070360 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Slc28a1 |
solute carrier family 28 member 1 |
affects transport multiple interactions |
ISO |
SLC28A1 protein affects the transport of Adenosine Adenosine inhibits the reaction [SLC28A1 protein results in increased uptake of Uridine] |
CTD |
PMID:9124315 |
|
NCBI chr 1:135,079,375...135,122,791
Ensembl chr 1:135,081,385...135,122,464
|
|
G |
Slc28a2 |
solute carrier family 28 member 2 |
increases transport |
ISO |
SLC28A2 protein results in increased transport of Adenosine |
CTD |
PMID:10087507 |
|
NCBI chr 3:109,324,815...109,387,702
Ensembl chr 3:109,366,996...109,387,702
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
multiple interactions increases uptake affects abundance |
ISO EXP |
4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; 4-nitrobenzylthioinosine inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; [4-nitrobenzylthioinosine results in decreased activity of SLC29A1 protein] inhibits the reaction [Oxygen deficiency results in increased abundance of Adenosine]; [SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine; Dipyridamole inhibits the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole promotes the reaction [[SLC29A1 co-treated with Oxygen deficiency] affects the abundance of Adenosine] SLC29A1 protein alternative form results in increased uptake of Adenosine; SLC29A1 protein results in increased uptake of Adenosine cilostazol inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Dipyridamole inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; draflazine inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Ethanol promotes the reaction [SLC29A1 protein alternative form results in increased uptake of Adenosine]; Ethanol promotes the reaction [SLC29A1 protein results in increased uptake of Adenosine]; Ticagrelor inhibits the reaction [SLC29A1 protein results in increased uptake of Adenosine] Adenosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] SLC29A1 affects the abundance of Adenosine |
CTD |
PMID:9353301 PMID:9396714 PMID:11179696 PMID:21283641 PMID:21872611 PMID:23437309 PMID:28041785 More...
|
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
G |
Slc29a2 |
solute carrier family 29 member 2 |
increases uptake |
ISO |
SLC29A2 protein results in increased uptake of Adenosine |
CTD |
PMID:9396714 |
|
NCBI chr 1:202,327,641...202,335,185
Ensembl chr 1:202,327,354...202,335,171
|
|
G |
Slc29a3 |
solute carrier family 29 member 3 |
affects transport |
ISO |
SLC29A3 protein affects the transport of Adenosine |
CTD |
PMID:19164483 |
|
NCBI chr20:28,645,265...28,685,388
Ensembl chr20:28,647,391...28,685,388
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
increases expression |
EXP |
Adenosine results in increased expression of SLC5A5 mRNA; Adenosine results in increased expression of SLC5A5 protein |
CTD |
PMID:16954431 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Tgfa |
transforming growth factor alpha |
increases secretion |
ISO |
Adenosine results in increased secretion of TGFA protein |
CTD |
PMID:34070360 |
|
NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Adenosine results in increased expression of TGFB1 mRNA; Adenosine results in increased expression of TGFB1 protein |
CTD |
PMID:34070360 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
increases expression multiple interactions |
ISO |
Adenosine results in increased expression of TGFB2 mRNA Adenosine results in increased expression of and results in increased secretion of TGFB2 protein |
CTD |
PMID:34070360 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tlr4 |
toll-like receptor 4 |
increases expression affects localization multiple interactions |
ISO |
Adenosine results in increased expression of TLR4 mRNA Adenosine affects the localization of TLR4 protein Adenosine promotes the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of TLR4 protein] |
CTD |
PMID:21538184 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO |
5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; [Adenosine co-treated with Homocysteine co-treated with TNF protein] results in increased cleavage of RIPK1 protein; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein affects the localization of RELA protein modified form]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; [Adenosine co-treated with Homocysteine] affects the reaction [TNF protein results in increased phosphorylation of RELA protein]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in increased susceptibility to TNF protein; Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF mRNA]; Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; ZM 241385 inhibits the reaction [Adenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]] Adenosine results in decreased expression of TNF protein |
CTD |
PMID:11023991 PMID:21538184 PMID:24224954 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
[Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; [Adenosine co-treated with Homocysteine] inhibits the reaction [TNF protein results in increased expression of TNFAIP3 protein]; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 mRNA; [Adenosine co-treated with Homocysteine] results in decreased expression of TNFAIP3 protein |
CTD |
PMID:24224954 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Adenosine co-treated with Coformycin] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:11992407 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Adenosine promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Upp1 |
uridine phosphorylase 1 |
increases metabolic processing |
ISO |
UPP1 protein results in increased metabolism of Adenosine |
CTD |
PMID:15772079 |
|
NCBI chr14:83,809,495...83,829,299
Ensembl chr14:83,809,960...83,829,462
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression increases secretion |
ISO |
Adenosine promotes the reaction [Dipyridamole results in increased secretion of VEGFA protein]; Adenosine results in increased expression of and results in increased secretion of VEGFA protein Adenosine results in increased expression of VEGFA mRNA Adenosine results in increased secretion of VEGFA protein |
CTD |
PMID:20067761 PMID:34070360 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
EXP |
Glutathione Disulfide affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]; Glutathione Disulfide affects the reaction [Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein]]; Polychlorinated Biphenyls analog affects the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT1A1 protein] |
CTD |
PMID:21130751 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
multiple interactions |
ISO |
[2,2',4,4'-tetrabromodiphenyl ether metabolite co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; [tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein; Estradiol inhibits the reaction [[tetrabromobisphenol A co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein]; tetrabromobisphenol A inhibits the reaction [[Estradiol co-treated with adenosine 3'-phosphate-5'-phosphate] binds to SULT1E1 protein] |
CTD |
PMID:23959441 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
affects binding multiple interactions |
ISO |
adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]; Dehydroepiandrosterone inhibits the reaction [Benzoquinones analog inhibits the reaction [adenosine 3'-phosphate-5'-phosphate binds to SULT2A1 protein]] |
CTD |
PMID:24059442 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
|
G |
Nudt11 |
nudix hydrolase 11 |
multiple interactions |
ISO |
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate |
CTD |
PMID:12121577 |
|
NCBI chr X:16,326,775...16,333,396
Ensembl chr X:16,326,598...16,333,145
|
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD80 protein |
CTD |
PMID:15944274 |
|
NCBI chr11:62,254,543...62,293,414
Ensembl chr11:62,254,624...62,292,030
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of CD86 protein |
CTD |
PMID:15944274 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Il10 |
interleukin 10 |
decreases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in decreased expression of IL10 protein |
CTD |
PMID:15944274 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL12B protein |
CTD |
PMID:15944274 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
increases expression |
ISO |
adenosine 5'-O-(3-thiotriphosphate) results in increased expression of IL1B protein |
CTD |
PMID:15944274 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
affects response to substance |
ISO |
P2RX7 protein affects the susceptibility to adenosine 5'-O-(3-thiotriphosphate) |
CTD |
PMID:12873706 |
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
adenosine 5'-O-(3-thiotriphosphate) inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity multiple interactions |
EXP |
adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein Capsaicin promotes the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein]; capsazepine inhibits the reaction [adenosine 5'-O-(3-thiotriphosphate) results in increased activity of TRPV1 protein] |
CTD |
PMID:11140687 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
ISO |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
multiple interactions |
ISO |
[4-dimethylaminocinnamaldehyde co-treated with Adenosine Monophosphate] binds to ALDH1A1 protein |
CTD |
PMID:10609638 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
increases abundance |
ISO |
ERCC6 gene mutant form results in increased abundance of Adenosine Monophosphate |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions |
ISO |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Nudt11 |
nudix hydrolase 11 |
multiple interactions |
ISO |
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate |
CTD |
PMID:12121577 |
|
NCBI chr X:16,326,775...16,333,396
Ensembl chr X:16,326,598...16,333,145
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
Adenosine Monophosphate results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Adenosine Monophosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Tp73 |
tumor protein p73 |
affects abundance |
ISO |
TP73 protein affects the abundance of Adenosine Monophosphate |
CTD |
PMID:25554796 |
|
NCBI chr 5:164,621,377...164,703,958
Ensembl chr 5:164,621,377...164,681,128
|
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects binding |
ISO |
estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein mutant form]; estradiol-17 beta-glucuronide inhibits the reaction [Adenosine Diphosphate binds to ABCC1 protein]; Vanadates promotes the reaction [Adenosine Diphosphate binds to ABCC1 protein] Adenosine Diphosphate binds to ABCC1 protein; Adenosine Diphosphate binds to ABCC1 protein mutant form |
CTD |
PMID:18336795 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Adenosine Diphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ak1 |
adenylate kinase 1 |
increases abundance |
ISO |
AK1 protein results in increased abundance of Adenosine Diphosphate |
CTD |
PMID:11390963 |
|
NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041
|
|
G |
Alb |
albumin |
decreases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in decreased secretion of ALB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of ALB protein] |
CTD |
PMID:17303692 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Axl |
Axl receptor tyrosine kinase |
decreases response to substance |
ISO |
AXL protein results in decreased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein] |
CTD |
PMID:16781456 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd40lg |
CD40 ligand |
increases expression multiple interactions |
ISO |
Adenosine Diphosphate results in increased expression of CD40LG protein clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein] |
CTD |
PMID:11297035 PMID:17043144 |
|
NCBI chr X:135,127,052...135,138,768
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and results in decreased activity of CFTR protein; P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein] |
CTD |
PMID:15684079 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Diphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein] |
CTD |
PMID:23184943 |
|
NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions |
ISO |
CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid] |
CTD |
PMID:16772608 PMID:18004210 PMID:18394438 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Dtymk |
deoxythymidylate kinase |
multiple interactions |
ISO |
DTYMK protein binds to [N1-(4-bis(pivaloyloxymethyl)phosphinylbuten-2-yl)thymine co-treated with Adenosine Diphosphate] |
CTD |
PMID:21128666 |
|
NCBI chr 9:94,315,552...94,324,386
Ensembl chr 9:94,315,552...94,324,870
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Epha4 |
Eph receptor A4 |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein Benzoic Acid analog inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of EPHA4 protein] |
CTD |
PMID:22273509 |
|
NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions decreases activity |
ISO |
Adenosine Diphosphate inhibits the reaction [ERN1 protein binds to ERN1 protein] Adenosine Diphosphate results in decreased activity of ERN1 protein |
CTD |
PMID:25164867 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
F2 |
coagulation factor II, thrombin |
increases abundance multiple interactions |
ISO |
F2 protein results in increased abundance of Adenosine Diphosphate Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate]; resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:15342215 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fga |
fibrinogen alpha chain |
multiple interactions increases secretion |
ISO |
Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGA protein] |
CTD |
PMID:17303692 |
|
NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgb |
fibrinogen beta chain |
decreases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in decreased secretion of FGB protein Aspirin inhibits the reaction [Adenosine Diphosphate results in decreased secretion of FGB protein] |
CTD |
PMID:17303692 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fgg |
fibrinogen gamma chain |
increases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in increased secretion of FGG protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of FGG protein] |
CTD |
PMID:17303692 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gas6 |
growth arrest specific 6 |
increases response to substance |
ISO |
GAS6 protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]] |
CTD |
PMID:32941855 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hras |
HRas proto-oncogene, GTPase |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of HRAS protein |
CTD |
PMID:16388579 |
|
NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of Adenosine Diphosphate] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
Adenosine Diphosphate results in increased expression of IL6 protein MRS 2211 inhibits the reaction [Adenosine Diphosphate results in increased expression of IL6 protein] |
CTD |
PMID:24849676 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO |
ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate] |
CTD |
PMID:16214444 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itga2b |
integrin subunit alpha 2b |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Itgb1bp2 |
integrin subunit beta 1 binding protein 2 |
multiple interactions |
ISO |
Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Diphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr X:66,572,537...66,577,174
Ensembl chr X:66,572,537...66,577,174
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of MAPK1 protein Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]] |
CTD |
PMID:15034929 PMID:32941855 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of MAPK3 protein Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:15034929 PMID:32941855 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:24466103 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Dicumarol inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:24466103 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mertk |
MER proto-oncogene, tyrosine kinase |
increases response to substance |
ISO |
MERTK protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 3:115,939,351...116,045,141
Ensembl chr 3:115,939,351...116,046,554
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
NOS2 protein affects the susceptibility to [Phenylephrine co-treated with Adenosine Diphosphate] |
CTD |
PMID:11498454 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nt5e |
5' nucleotidase, ecto |
decreases activity |
ISO |
Adenosine Diphosphate analog results in decreased activity of NT5E protein |
CTD |
PMID:18404487 |
|
NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
|
|
G |
P2ry12 |
purinergic receptor P2Y12 |
affects response to substance increases response to substance multiple interactions |
ISO EXP |
P2RY12 gene polymorphism affects the susceptibility to Adenosine Diphosphate; P2RY12 protein affects the susceptibility to Adenosine Diphosphate P2RY12 protein results in increased susceptibility to Adenosine Diphosphate Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate] P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein] |
CTD |
PMID:11196645 PMID:11413167 PMID:18404433 PMID:23849096 |
|
NCBI chr 2:143,481,468...143,523,340
Ensembl chr 2:143,481,430...143,523,361
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
increases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in increased secretion of PDGFB protein Aspirin promotes the reaction [Adenosine Diphosphate results in increased secretion of PDGFB protein] |
CTD |
PMID:17303692 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pf4 |
platelet factor 4 |
increases secretion multiple interactions |
ISO |
Adenosine Diphosphate results in increased secretion of PF4 protein silidianin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; Silybin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein]; silychristin inhibits the reaction [Adenosine Diphosphate results in increased secretion of PF4 protein] |
CTD |
PMID:19428933 PMID:29439388 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions |
ISO |
Adenosine Diphosphate inhibits the reaction [resveratrol results in decreased activity of PFKM protein] |
CTD |
PMID:23454376 |
|
NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases phosphorylation |
ISO |
PGP protein results in decreased phosphorylation of Adenosine Diphosphate |
CTD |
PMID:24338473 |
|
NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Ppbp |
pro-platelet basic protein |
increases secretion |
ISO |
Adenosine Diphosphate results in increased secretion of PPBP protein |
CTD |
PMID:19428933 |
|
NCBI chr14:17,302,326...17,303,130
Ensembl chr14:17,302,326...17,303,130
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
multiple interactions |
ISO |
Adenosine Diphosphate binds to and affects the folding of PPP5C protein |
CTD |
PMID:23184943 |
|
NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Ptpn1 |
protein tyrosine phosphatase, non-receptor type 1 |
increases glutathionylation multiple interactions |
EXP |
Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein CAT protein inhibits the reaction [Adenosine Diphosphate results in increased glutathionylation of PTPN1 protein] |
CTD |
PMID:16781456 |
|
NCBI chr 3:156,638,811...156,687,503
Ensembl chr 3:156,638,769...156,687,504
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; CYP2C19 gene SNP affects the reaction [Adenosine Diphosphate results in increased expression of SELP protein]; Heparin promotes the reaction [Adenosine Diphosphate affects the localization of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]]; P2RY12 protein affects the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; Quercetin inhibits the reaction [Adenosine Diphosphate results in increased expression of SELP protein] |
CTD |
PMID:9740346 PMID:18394438 PMID:18404433 PMID:23249183 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Sirt3 |
sirtuin 3 |
decreases abundance |
ISO |
SIRT3 protein results in decreased abundance of Adenosine Diphosphate |
CTD |
PMID:23166782 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Taldo1 |
transaldolase 1 |
increases abundance |
ISO |
TALDO1 gene mutant form results in increased abundance of Adenosine Diphosphate |
CTD |
PMID:19436114 |
|
NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974
|
|
G |
Thbs1 |
thrombospondin 1 |
increases secretion |
ISO |
Adenosine Diphosphate results in increased secretion of THBS1 protein |
CTD |
PMID:17303692 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; Anthraquinones analog inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Diphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Tyro3 |
TYRO3 protein tyrosine kinase |
increases response to substance |
ISO |
TYRO3 protein results in increased susceptibility to Adenosine Diphosphate |
CTD |
PMID:15733062 |
|
NCBI chr 3:106,777,686...106,797,154
Ensembl chr 3:106,777,635...106,797,142
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
increases phosphorylation multiple interactions |
ISO |
Adenosine Diphosphate results in increased phosphorylation of VASP protein N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [Adenosine Diphosphate results in increased phosphorylation of VASP protein] |
CTD |
PMID:25329809 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
|
G |
Adprh |
ADP-ribosylarginine hydrolase |
increases hydrolysis |
ISO |
ADPRH protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite |
CTD |
PMID:21498885 |
|
NCBI chr11:62,299,831...62,306,170
Ensembl chr11:62,299,793...62,306,931
|
|
G |
Adprs |
ADP-ribosylserine hydrolase |
increases hydrolysis multiple interactions |
ISO |
ADPRS protein results in increased hydrolysis of Adenosine Diphosphate Ribose metabolite Adenosine Diphosphate Ribose inhibits the reaction [ADPRS protein results in increased hydrolysis of O-Acetyl-ADP-Ribose] |
CTD |
PMID:21498885 |
|
NCBI chr 5:138,614,022...138,619,296
Ensembl chr 5:138,614,022...138,619,296
|
|
G |
Nos1 |
nitric oxide synthase 1 |
multiple interactions |
ISO |
NOS1 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased ribosylation of Adenosine Diphosphate Ribose] |
CTD |
PMID:10318960 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Trpm2 |
transient receptor potential cation channel, subfamily M, member 2 |
multiple interactions increases activity |
EXP ISO |
Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]; Clotrimazole inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]]; Flufenamic Acid inhibits the reaction [Adenosine Diphosphate Ribose promotes the reaction [TRPM2 protein results in increased transport of Calcium]] Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein 2-aminoethoxydiphenyl borate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]]; Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Copper Sulfate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Eicosapentaenoic Acid promotes the reaction [Cisplatin promotes the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]]; ferrous chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; lead nitrate inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Mercuric Chloride inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Miconazole inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; Selenium Oxides inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein] 4-amylcinnamoylanthranilic acid inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; 4-amylcinnamoylanthranilic acid inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; [Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein; Glutathione inhibits the reaction [[Buthionine Sulfoximine co-treated with Adenosine Diphosphate Ribose] results in increased activity of TRPM2 protein]; Glutathione inhibits the reaction [Adenosine Diphosphate Ribose results in increased activity of TRPM2 protein]; TRPM2 protein promotes the reaction [Adenosine Diphosphate Ribose results in increased uptake of Calcium] |
CTD |
PMID:18204483 PMID:20878536 PMID:21900507 PMID:22750002 PMID:33309544 PMID:35395232 More...
|
|
NCBI chr20:10,703,568...10,753,189
Ensembl chr20:10,707,014...10,753,181
|
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Adenylyl Imidodiphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Cftr |
CF transmembrane conductance regulator |
affects activity |
ISO |
Adenylyl Imidodiphosphate affects the activity of CFTR protein |
CTD |
PMID:15657297 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
affects binding |
ISO |
Adenylyl Imidodiphosphate binds to CSNK2A1 protein |
CTD |
PMID:34344863 |
|
NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696
|
|
G |
Ptgdr |
prostaglandin D2 receptor |
multiple interactions |
ISO |
Adenylyl Imidodiphosphate inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] |
CTD |
PMID:9579725 |
|
NCBI chr15:17,360,304...17,367,679
Ensembl chr15:17,360,304...17,367,679
|
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
multiple interactions |
ISO |
Adenosine Triphosphate affects the reaction [ABCA8 protein results in increased uptake of estradiol-17 beta-glucuronide] |
CTD |
PMID:12379217 |
|
NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO EXP |
Adenosine Triphosphate promotes the reaction [ABCB11 protein results in increased uptake of fexofenadine] |
CTD |
PMID:18245269 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions affects binding increases hydrolysis |
ISO EXP |
[Cobalt results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Magnesium results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; [Manganese results in increased activity of ABCB1 protein] which results in increased hydrolysis of Adenosine Triphosphate; ABCB1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; aurapten promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; crizotinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] Adenosine Triphosphate binds to ABCB1 protein [Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:2900677 PMID:14978246 PMID:18829547 PMID:18955043 PMID:22233293 PMID:23685082 PMID:32497533 More...
|
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions affects activity increases hydrolysis affects binding |
ISO |
[Adenosine Triphosphate affects the activity of ABCC1 protein] which results in increased transport of Acetaminophen metabolite; ABCC1 protein binds to and results in increased degradation of Adenosine Triphosphate; ABCC1 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; ABCC1 protein mutant form binds to and results in increased hydrolysis of Adenosine Triphosphate; Adenosine Triphosphate binds to and affects the folding of ABCC1 protein; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Bilirubin]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of estradiol-17 beta-glucuronide]; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; daidzein promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; nobiletin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Resveratrol promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Daunorubicin promotes the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate]; Vanadates inhibits the reaction [ABCC1 protein results in increased hydrolysis of Adenosine Triphosphate] Adenosine Triphosphate binds to ABCC1 protein |
CTD |
PMID:10856430 PMID:11278000 PMID:14978246 PMID:15245331 PMID:15355964 PMID:15459206 PMID:15737336 PMID:15838832 PMID:16156793 PMID:18336795 PMID:18955043 PMID:32472168 More...
|
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions affects activity affects metabolic processing |
EXP ISO |
Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased secretion of Fluo-3]; Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of temocaprilat] Adenosine Triphosphate affects the activity of ABCC2 protein [Adenosine Triphosphate affects the activity of ABCC2 protein] which results in increased transport of Acetaminophen metabolite; [Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide; Adenosine Triphosphate affects the reaction [ABCC2 protein results in increased transport of Mercury]; verlukast inhibits the reaction [[Adenosine Triphosphate co-treated with ABCC2 protein] results in increased uptake of estradiol-17 beta-glucuronide] ABCC2 protein affects the metabolism of Adenosine Triphosphate Adenosine Triphosphate promotes the reaction [ABCC2 protein results in increased transport of S-1,2-dichlorovinyl-N-acetylcysteine] |
CTD |
PMID:9067317 PMID:9794919 PMID:20060011 PMID:22027652 PMID:24039982 PMID:32003934 PMID:32472168 More...
|
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [ABCC3 protein affects the transport of fexofenadine] |
CTD |
PMID:18245269 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions affects activity increases hydrolysis |
ISO |
[Adenosine Triphosphate affects the activity of ABCC4 protein] which results in increased transport of Acetaminophen metabolite; ABCC4 protein binds to and results in increased hydrolysis of Adenosine Triphosphate; daidzein promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Disulfiram inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; hesperetin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; naringenin promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin affects the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Quercetin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]]; Resveratrol promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]; Silymarin inhibits the reaction [Alprostadil promotes the reaction [ABCC4 protein results in increased hydrolysis of Adenosine Triphosphate]] |
CTD |
PMID:14978246 PMID:16156793 PMID:32472168 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
affects binding |
ISO |
Adenosine Triphosphate binds to ABCC6 protein |
CTD |
PMID:11880368 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
multiple interactions |
EXP |
Adenosine Triphosphate deficiency inhibits the reaction [Estradiol inhibits the reaction [Glyburide binds to ABCC8 protein]] |
CTD |
PMID:19095654 |
|
NCBI chr 1:96,598,568...96,679,563
Ensembl chr 1:96,598,647...96,679,510
|
|
G |
Abcc9 |
ATP binding cassette subfamily C member 9 |
multiple interactions |
EXP ISO |
Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] |
CTD |
PMID:11390963 PMID:28842488 |
|
NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
increases hydrolysis multiple interactions |
ISO |
ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate; Lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate]; Sulfasalazine inhibits the reaction [[Adenosine Triphosphate co-treated with ABCG2 protein] results in increased uptake of estrone sulfate] |
CTD |
PMID:18829547 PMID:32003934 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions increases chemical synthesis |
ISO |
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] ABL1 protein mutant form results in increased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:19366808 PMID:33070465 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acsl5 |
acyl-CoA synthetase long-chain family member 5 |
multiple interactions |
ISO |
[ACSL5 protein affects the susceptibility to Palmitic Acid] which affects the abundance of Adenosine Triphosphate |
CTD |
PMID:32347412 |
|
NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of ACTA2 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of ACTA2 protein] |
CTD |
PMID:32721574 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adcyap1 |
adenylate cyclase activating polypeptide 1 |
increases secretion |
EXP |
ADCYAP1 protein results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:18563302 |
|
NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions decreases expression |
EXP |
Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein]; CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein]; Cyclosporine inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A mRNA]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in decreased expression of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
Adenosine Triphosphate affects the folding of [Tetrachlorodibenzodioxin binds to AHR protein] |
CTD |
PMID:1848756 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases activity multiple interactions |
ISO |
Adenosine Triphosphate results in decreased activity of AKT1 protein Alcohols inhibits the reaction [Adenosine Triphosphate results in decreased activity of AKT1 protein] |
CTD |
PMID:24300283 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
increases abundance |
ISO |
ALDH5A1 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:29031482 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Alk |
ALK receptor tyrosine kinase |
affects binding multiple interactions |
ISO |
ALK protein binds to Adenosine Triphosphate [ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate]] which results in decreased susceptibility to crizotinib; ALK protein mutant form promotes the reaction [ALK protein binds to Adenosine Triphosphate] |
CTD |
PMID:22072639 |
|
NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases response to substance multiple interactions |
ISO |
ALPL gene mutant form results in increased susceptibility to Adenosine Triphosphate ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] |
CTD |
PMID:27466191 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Anxa1 |
annexin A1 |
multiple interactions |
EXP |
[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein; arsenite affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Cadmium affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; chromium hexavalent ion affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein]; Lead affects the reaction [[Magnesium co-treated with Adenosine Triphosphate] affects the activity of ANXA1 protein] |
CTD |
PMID:20655937 |
|
NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions increases secretion |
ISO |
Adenosine Triphosphate inhibits the reaction [Hydrogen Peroxide results in decreased secretion of APP protein modified form]; Adenosine Triphosphate inhibits the reaction [Rotenone results in decreased secretion of APP protein modified form]; Rotenone inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased secretion of APP protein modified form] |
CTD |
PMID:22906069 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
EXP |
Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; ARRB2 protein affects the reaction [Adenosine Triphosphate results in decreased activity of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
multiple interactions |
EXP |
[Acids binds to and affects the activity of ASIC1 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541
|
|
G |
Asic2 |
acid sensing ion channel subunit 2 |
multiple interactions |
EXP |
[Acids binds to and affects the activity of ASIC2 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr10:65,870,592...66,940,577
Ensembl chr10:65,870,594...66,940,424
|
|
G |
Asic3 |
acid sensing ion channel subunit 3 |
multiple interactions |
EXP |
[Acids binds to and affects the activity of ASIC3 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr 4:10,760,509...10,764,987
Ensembl chr 4:10,760,597...10,764,643
|
|
G |
Atp7a |
ATPase copper transporting alpha |
multiple interactions |
ISO |
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7A protein |
CTD |
PMID:20964302 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atp7b |
ATPase copper transporting beta |
multiple interactions increases phosphorylation |
ISO |
[Copper co-treated with Adenosine Triphosphate] results in increased phosphorylation of ATP7B protein Adenosine Triphosphate results in increased phosphorylation of ATP7B protein |
CTD |
PMID:19405516 PMID:20964302 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
increases hydrolysis |
EXP |
ATP8B1 protein results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:11584374 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Avp |
arginine vasopressin |
multiple interactions increases secretion |
EXP |
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of AVP protein]; bisindolylmaleimide I inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; Dactinomycin inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of AVP protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of AVP protein] |
CTD |
PMID:11102496 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Adenosine Triphosphate binds to P2RY11 protein] which results in decreased expression of BCL2 protein |
CTD |
PMID:21503959 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcr |
BCR activator of RhoGEF and GTPase |
multiple interactions |
ISO |
[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19366808 |
|
NCBI chr20:13,469,325...13,596,942
Ensembl chr20:13,471,668...13,597,016
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases abundance |
ISO |
BIRC5 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:32497533 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Cabin1 |
calcineurin binding protein 1 |
multiple interactions |
EXP |
CABIN1 protein inhibits the reaction [Adenosine Triphosphate results in decreased expression of and results in decreased activity of AGTR1A protein] |
CTD |
PMID:21464294 |
|
NCBI chr20:12,893,314...13,015,357
Ensembl chr20:12,893,358...13,015,357
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases secretion multiple interactions |
EXP |
Adenosine Triphosphate results in increased secretion of CALCA protein Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]; Flurbiprofen inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]]; Suramin inhibits the reaction [Adenosine Triphosphate promotes the reaction [Protons results in increased secretion of CALCA protein]] |
CTD |
PMID:12044622 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Casp1 |
caspase 1 |
increases activity multiple interactions |
EXP ISO |
Adenosine Triphosphate results in increased activity of CASP1 mRNA; Adenosine Triphosphate results in increased activity of CASP1 protein [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; fraxinellone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of and results in increased cleavage of CASP1 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased cleavage of CASP1 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP1 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP1 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein; [Niclosamide co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of CASP1 protein; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of CASP1 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased activity of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein modified form]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA] |
CTD |
PMID:18604214 PMID:19130485 PMID:21832250 PMID:23430110 PMID:24149798 PMID:25288807 PMID:25448682 PMID:26431797 PMID:26586371 PMID:32721574 PMID:33524445 PMID:33929904 PMID:34212273 PMID:34217685 PMID:34405489 PMID:35131329 PMID:35962723 PMID:36002070 PMID:36577999 PMID:36847822 PMID:37001609 More...
|
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases expression multiple interactions |
ISO |
Adenosine Triphosphate results in increased expression of CASP3 Adenosine Triphosphate inhibits the reaction [chromium hexavalent ion results in increased activity of CASP3 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of CASP3] |
CTD |
PMID:19448140 PMID:24732427 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of CASP4 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased secretion of and results in increased activity of CASP4 protein] Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein] |
CTD |
PMID:24149798 PMID:25288807 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Cat |
catalase |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of CAT mRNA |
CTD |
PMID:22129738 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases secretion multiple interactions |
ISO |
Adenosine Triphosphate results in increased secretion of CCL3 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CCL3 protein] |
CTD |
PMID:26522449 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
3-((3-trifluoromethyl)phenyl)-5-((3-carboxyphenyl)methylene)-2-thioxo-4-thiazolidinone inhibits the reaction [Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides]]; [Phosphatidylinositol 4,5-Diphosphate co-treated with Adenosine Triphosphate] results in increased activity of CFTR protein; Adenosine Triphosphate affects the reaction [Curcumin results in increased activity of CFTR protein mutant form]; Adenosine Triphosphate binds to and results in increased activity of CFTR protein; Adenosine Triphosphate promotes the reaction [CFTR protein results in increased export of Chlorides] |
CTD |
PMID:14710196 PMID:15623556 PMID:17178710 PMID:20675434 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Chordc1 |
cysteine and histidine rich domain containing 1 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein] Adenosine Triphosphate binds to and affects the folding of CHORDC1 protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein] |
CTD |
PMID:23184943 |
|
NCBI chr 8:15,374,356...15,398,436
Ensembl chr 8:15,374,471...15,399,162
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA; [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 mRNA]; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of COL1A1 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 mRNA]; L 709049 inhibits the reaction [[[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of Biological Factors] which results in increased expression of COL1A1 protein] |
CTD |
PMID:32721574 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Comt |
catechol-O-methyltransferase |
multiple interactions |
ISO |
[Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:14975680 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
multiple interactions |
ISO |
[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate; Carnitine promotes the reaction [[Bezafibrate results in increased activity of CPT2 protein] which results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:21816645 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crkl |
CRK like proto-oncogene, adaptor protein |
multiple interactions |
ISO |
[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; [BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein; sorafenib inhibits the reaction [[ABL1 protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein]; sorafenib inhibits the reaction [[BCR protein mutant form co-treated with Adenosine Triphosphate] results in increased phosphorylation of CRKL protein] |
CTD |
PMID:19366808 |
|
NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
[CSF2 protein affects the susceptibility to stearic acid] which affects the abundance of Adenosine Triphosphate |
CTD |
PMID:32347412 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csnk2a1 |
casein kinase 2 alpha 1 |
multiple interactions affects binding |
ISO |
silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]] |
CTD |
PMID:21174434 |
|
NCBI chr 3:140,709,984...140,756,757
Ensembl chr 3:140,709,991...140,756,696
|
|
G |
Csnk2b |
casein kinase 2 beta |
multiple interactions affects binding |
ISO |
silmitasertib inhibits the reaction [Adenosine Triphosphate binds to [CSNK2A1 protein binds to CSNK2A1 protein binds to CSNK2B protein binds to CSNK2B protein]] |
CTD |
PMID:21174434 |
|
NCBI chr20:3,700,363...3,705,331
Ensembl chr20:3,698,733...3,707,133
|
|
G |
Cstb |
cystatin B |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP1 protein]; Adenosine Triphosphate promotes the reaction [[CSTB gene mutant form results in increased susceptibility to lipopolysaccharide, E coli O55-B5] which results in increased cleavage of CASP4 protein] |
CTD |
PMID:25288807 |
|
NCBI chr20:10,245,462...10,247,505
Ensembl chr20:10,245,462...10,247,526
|
|
G |
Ctsb |
cathepsin B |
increases activity multiple interactions |
ISO |
Adenosine Triphosphate results in increased activity of CTSB protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of CTSB protein] |
CTD |
PMID:26522449 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases secretion multiple interactions |
ISO |
Adenosine Triphosphate results in increased secretion of CXCL2 protein azetidine inhibits the reaction [Adenosine Triphosphate results in increased secretion of CXCL2 protein] |
CTD |
PMID:26522449 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Dmd |
dystrophin |
increases secretion multiple interactions |
ISO |
DMD gene mutant form results in increased secretion of Adenosine Triphosphate Nifedipine inhibits the reaction [DMD gene mutant form results in increased secretion of Adenosine Triphosphate] |
CTD |
PMID:24349043 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP1 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Cesium-137 results in increased expression of DUSP6 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in decreased expression of DUSP6 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of EGFR protein] |
CTD |
PMID:26104857 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression |
EXP |
Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of EGR1 mRNA] |
CTD |
PMID:10723097 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [Toluene 2,4-Diisocyanate results in increased expression of ENPP2 protein] |
CTD |
PMID:26072274 |
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Enpp7 |
ectonucleotide pyrophosphatase/phosphodiesterase 7 |
decreases activity |
ISO |
Adenosine Triphosphate results in decreased activity of ENPP7 protein |
CTD |
PMID:12885774 |
|
NCBI chr10:104,242,169...104,247,185
Ensembl chr10:104,242,223...104,246,589
|
|
G |
Ercc6 |
ERCC excision repair 6, chromatin remodeling factor |
decreases abundance multiple interactions |
ISO |
ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate nicotinamide-beta-riboside inhibits the reaction [ERCC6 gene mutant form results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:25440059 |
|
NCBI chr16:7,764,983...7,835,587
Ensembl chr16:7,765,013...7,835,587
|
|
G |
F2 |
coagulation factor II, thrombin |
multiple interactions increases transport increases abundance increases secretion |
ISO |
2,4,3',5'-tetramethoxystilbene inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; [RWJ-56110 co-treated with 2,4,3',5'-tetramethoxystilbene] inhibits the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; calmidazolium affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Fendiline affects the reaction [F2 protein results in increased secretion of Adenosine Triphosphate]; Quercetin inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate]; Resveratrol inhibits the reaction [F2 protein results in increased abundance of Adenosine Triphosphate] F2 protein results in increased transport of Adenosine Triphosphate STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate] |
CTD |
PMID:2030746 PMID:15342215 PMID:30696774 PMID:35288162 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions decreases abundance |
ISO |
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; Protein Kinase Inhibitors inhibits the reaction [FASN protein results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:26670611 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fbp1 |
fructose-bisphosphatase 1 |
multiple interactions |
ISO |
[Enzyme Inhibitors results in decreased activity of FBP1 protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:31974165 |
|
NCBI chr17:2,207,271...2,230,076
Ensembl chr17:2,208,031...2,230,071
|
|
G |
Fbxo3 |
F-box protein 3 |
multiple interactions |
EXP |
FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein] |
CTD |
PMID:35962723 |
|
NCBI chr 3:90,417,262...90,449,557
Ensembl chr 3:90,417,297...90,449,557
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
EXP ISO |
Adenosine Triphosphate results in increased expression of FOS mRNA ALPL gene mutant form promotes the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] [Phenylephrine co-treated with Adenosine Triphosphate] results in increased expression of FOS mRNA; Glucose affects the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Iodoacetates inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Potassium Cyanide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA]; Sodium Azide inhibits the reaction [Adenosine Triphosphate results in increased expression of FOS mRNA] |
CTD |
PMID:10723097 PMID:19463813 PMID:27466191 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fscn1 |
fascin actin-bundling protein 1 |
increases expression multiple interactions |
ISO |
Adenosine Triphosphate results in increased expression of FSCN1 mRNA Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of FSCN1 mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [[GAPDH protein co-treated with NAD co-treated with Glyceraldehyde 3-Phosphate co-treated with Glutathione] results in increased reduction of sodium arsenite analog] |
CTD |
PMID:15788719 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions increases secretion |
ISO EXP |
oxophenylarsine inhibits the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; Phosphatidylinositol 4,5-Diphosphate affects the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein] NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]] |
CTD |
PMID:12471042 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases export |
ISO |
GJA1 protein mutant form results in increased export of Adenosine Triphosphate; GJA1 protein results in increased export of Adenosine Triphosphate |
CTD |
PMID:17687502 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO EXP |
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein] [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of GSDMD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased cleavage of GSDMD protein] |
CTD |
PMID:33851234 PMID:34212273 PMID:34217685 PMID:35962723 PMID:36577999 PMID:37001609 More...
|
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
[GSTP1 protein co-treated with Glutathione] inhibits the reaction [[Adenosine Triphosphate results in increased metabolism of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] which results in increased abundance of 2-amino-1-methyl-6-phenolimidazo(4,5-b)pyridine-DNA adduct]; [GSTP1 protein co-treated with Glutathione] inhibits the reaction [Adenosine Triphosphate results in increased activity of 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine] |
CTD |
PMID:11196146 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form]] |
CTD |
PMID:32941855 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hck |
HCK proto-oncogene, Src family tyrosine kinase |
multiple interactions affects binding |
ISO |
[Curcumin binds to 4-bis(2-chloroethyl)aminobenzaldehyde] inhibits the reaction [HCK protein binds to Adenosine Triphosphate] |
CTD |
PMID:33617879 |
|
NCBI chr 3:141,571,587...141,614,696
Ensembl chr 3:141,571,587...141,614,693
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [protoporphyrin IX results in decreased activity of HIF1A protein] |
CTD |
PMID:23624237 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk1 |
hexokinase 1 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased activity of CASP1 protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of GSDMD protein]]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of HK1 protein] |
CTD |
PMID:37001609 |
|
NCBI chr20:30,230,488...30,332,099
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hk2 |
hexokinase 2 |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of HK2 protein |
CTD |
PMID:36577999 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmgb1 |
high mobility group box 1 |
affects chemical synthesis multiple interactions |
ISO |
HMGB1 protein affects the chemical synthesis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; Adenosine Triphosphate promotes the reaction [fullerene C60 results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [graphene oxide results in increased secretion of HMGB1 protein]; Adenosine Triphosphate promotes the reaction [Nanotubes, Carbon results in increased secretion of HMGB1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased cleavage of CASP1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of CASP1 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein] |
CTD |
PMID:21641551 PMID:31504961 PMID:34405489 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of HMOX1 protein] |
CTD |
PMID:34217685 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 mRNA]; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of HSPA5 protein] |
CTD |
PMID:24149798 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
affects chemical synthesis |
ISO |
HSPB1 protein affects the chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:21641551 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
multiple interactions increases expression |
EXP |
bisindolylmaleimide I inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; chelerythrine inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; Neomycin inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; resveratrol inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein]; tricyclodecane-9-yl-xanthogenate inhibits the reaction [Adenosine Triphosphate results in increased expression of HSPD1 protein] |
CTD |
PMID:16178011 |
|
NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Fructose results in increased expression of ICAM1 protein] |
CTD |
PMID:18508964 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone] |
CTD |
PMID:14623498 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B protein] |
CTD |
PMID:17707769 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il18 |
interleukin 18 |
multiple interactions increases secretion |
ISO EXP |
[Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL18 protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein] Adenosine Triphosphate results in increased secretion of IL18 protein 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL18 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL18 protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL18 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL18 mRNA] |
CTD |
PMID:17404311 PMID:24149798 PMID:26431797 PMID:27311643 PMID:31993881 PMID:33579316 PMID:33851234 PMID:34212273 PMID:34405489 PMID:35962723 PMID:36577999 PMID:36847822 More...
|
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein]]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1A protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1A protein] |
CTD |
PMID:26068648 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases secretion decreases abundance |
EXP ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; Enzyme Inhibitors inhibits the reaction [IL1B protein results in decreased abundance of Adenosine Triphosphate]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]] Adenosine Triphosphate results in increased secretion of IL1B protein (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; (N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) inhibits the reaction [Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of and results in increased secretion of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased activity of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Acetylcysteine inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Arsenic Trioxide inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Chlorquinaldol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; diphenyleneiodonium inhibits the reaction [Adenosine Triphosphate results in increased secretion of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of and affects the cleavage of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; Okadaic Acid inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of IL1B mRNA]; zinc chloride inhibits the reaction [N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]] 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [Adenosine Triphosphate co-treated with K-12 lipopolysaccharide] results in increased secretion of IL1B protein modified form; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein; [Disulfiram co-treated with Adenosine Triphosphate] inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased cleavage of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; [Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein; Adenosine Triphosphate promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Adenosine Triphosphate promotes the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein; Apigenin inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; flavone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; HK1 protein affects the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; HK1 protein affects the reaction [hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of IL1B protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL1B protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of IL1B protein]; L 709049 inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; MitoTEMPO inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of IL1B mRNA]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of and results in increased secretion of IL1B protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA]; Resveratrol promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; tyrosyl-valyl-alanyl-aspartic acid fluoromethyl ketone analog inhibits the reaction [Adenosine Triphosphate results in increased cleavage of and results in increased secretion of IL1B protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B mRNA] |
CTD |
PMID:10365824 PMID:14623498 PMID:17404311 PMID:18604214 PMID:19130485 PMID:22221676 PMID:23430110 PMID:24149798 PMID:24158569 PMID:24685903 PMID:26068648 PMID:26086368 PMID:26431797 PMID:26586371 PMID:26819091 PMID:26968431 PMID:27311643 PMID:29960001 PMID:31993881 PMID:32721574 PMID:33050067 PMID:33524445 PMID:33579316 PMID:33851234 PMID:33929904 PMID:34212273 PMID:34217685 PMID:34405489 PMID:35962723 PMID:36002070 PMID:36577999 PMID:36847822 PMID:37001609 PMID:37544346 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO EXP |
[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of IL6 protein]; NF157 compound inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; Suramin inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein] Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; resveratrol inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]] [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of IL6 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of IL6 protein]; MRS 2211 inhibits the reaction [Adenosine Triphosphate results in increased expression of IL6 protein] |
CTD |
PMID:17707769 PMID:24793913 PMID:24849676 PMID:25348860 PMID:26104857 PMID:26522449 PMID:33851234 PMID:37001609 PMID:37544346 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions increases secretion |
ISO EXP |
Adenosine Triphosphate inhibits the reaction [Glucose results in increased secretion of INS1 protein] Adenosine Triphosphate results in increased secretion of INS1 protein [[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate; IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]; Quercetin inhibits the reaction [IL1B protein inhibits the reaction [Adenosine Triphosphate results in increased secretion of INS1 protein]]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein] |
CTD |
PMID:10535451 PMID:10780946 PMID:16366736 PMID:22221676 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[ammonium ferrous sulfate results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; [chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate; INS protein inhibits the reaction [Acetaminophen results in decreased abundance of Adenosine Triphosphate]; Mannose inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate]; Phloretin inhibits the reaction [[chromic chloride results in increased activity of INS protein modified form] which results in increased secretion of Adenosine Triphosphate] |
CTD |
PMID:17965850 PMID:26739624 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Irf2 |
interferon regulatory factor 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA; Hirudins inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IRF2 mRNA] |
CTD |
PMID:34212273 |
|
NCBI chr16:45,439,215...45,550,054
Ensembl chr16:45,439,225...45,550,024
|
|
G |
Itgb1bp2 |
integrin subunit beta 1 binding protein 2 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to CHORDC1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to ITGB1BP2 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to HSP90AA1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr X:66,572,537...66,577,174
Ensembl chr X:66,572,537...66,577,174
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of JUN protein] |
CTD |
PMID:24149798 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnd2 |
potassium voltage-gated channel subfamily D member 2 |
multiple interactions increases abundance |
ISO |
[[FAM66C mRNA binds to and results in decreased expression of MIR23 mRNA] which results in increased expression of KCND2 protein] which results in increased abundance of Adenosine Triphosphate; [[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate KCND2 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:34418280 |
|
NCBI chr 4:49,775,812...50,277,746
Ensembl chr 4:49,776,246...50,277,728
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Adenosine Triphosphate deficiency results in decreased activity of KCNH2 protein |
CTD |
PMID:12531891 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnj11 |
potassium inwardly-rectifying channel, subfamily J, member 11 |
multiple interactions decreases response to substance |
ISO |
Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]; Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]; Creatine metabolite inhibits the reaction [Adenosine Monophosphate inhibits the reaction [Adenosine Triphosphate results in decreased activity of [KCNJ11 protein binds to ABCC9 protein]]] KCNJ11 protein mutant form results in decreased susceptibility to Adenosine Triphosphate |
CTD |
PMID:11390963 PMID:28842488 |
|
NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082
|
|
G |
Kcnj15 |
potassium inwardly-rectifying channel, subfamily J, member 15 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of KCNJ15 protein |
CTD |
PMID:15328350 |
|
NCBI chr11:34,577,397...34,621,725
Ensembl chr11:34,577,363...34,621,952
|
|
G |
Kcnj8 |
potassium inwardly-rectifying channel, subfamily J, member 8 |
multiple interactions decreases response to substance |
EXP |
Adenosine Triphosphate results in decreased activity of [KCNJ8 protein binds to ABCC9 protein] KCNJ8 protein mutant form results in decreased susceptibility to Adenosine Triphosphate |
CTD |
PMID:28842488 |
|
NCBI chr 4:175,508,908...175,515,829
Ensembl chr 4:175,508,912...175,515,603
|
|
G |
Khk |
ketohexokinase |
multiple interactions |
ISO |
KHK protein promotes the reaction [Fructose results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:19158351 |
|
NCBI chr 6:25,445,298...25,455,834
Ensembl chr 6:25,445,300...25,455,717
|
|
G |
Kif5a |
kinesin family member 5A |
multiple interactions increases hydrolysis |
ISO |
Adenosine Triphosphate inhibits the reaction [zinc chloride results in decreased activity of KIF5A protein]; Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]; Egtazic Acid inhibits the reaction [Cadmium Chloride inhibits the reaction [KIF5A protein results in increased hydrolysis of Adenosine Triphosphate]] |
CTD |
PMID:24239783 PMID:28122263 |
|
NCBI chr 7:63,051,894...63,089,024
Ensembl chr 7:63,049,424...63,092,858
|
|
G |
Lep |
leptin |
multiple interactions |
EXP |
[[Glucose co-treated with INS1 protein] results in increased abundance of Adenosine Triphosphate] which results in increased secretion of LEP protein; [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] which results in decreased secretion of LEP protein |
CTD |
PMID:10780946 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipe |
lipase E, hormone sensitive type |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of LIPE protein |
CTD |
PMID:7155675 |
|
NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
|
|
G |
Lpl |
lipoprotein lipase |
affects response to substance |
ISO |
LPL protein affects the susceptibility to Adenosine Triphosphate |
CTD |
PMID:11786490 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
affects binding |
ISO |
Adenosine Triphosphate binds to MAP2K1 protein |
CTD |
PMID:17693661 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK1 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK1 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK1 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12513686 PMID:15034929 PMID:21503959 PMID:24300283 PMID:26104857 PMID:26522449 PMID:30502331 PMID:32941855 PMID:34405489 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; [Alcohols co-treated with Adenosine Triphosphate] results in increased activity of MAPK3 protein; Alcohols inhibits the reaction [Adenosine Triphosphate results in increased activity of MAPK3 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased phosphorylation of MAPK3 protein]]; sodium arsenite promotes the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased phosphorylation of MAPK3 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12513686 PMID:15034929 PMID:21503959 PMID:24300283 PMID:26104857 PMID:26522449 PMID:30502331 PMID:32941855 PMID:34405489 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
[annonacin results in decreased abundance of Adenosine Triphosphate] which affects the localization of MAPT protein |
CTD |
PMID:17634376 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Metrnl |
meteorin-like, glial cell differentiation regulator |
multiple interactions |
ISO |
METRNL protein inhibits the reaction [Dietary Fats results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:30213948 |
|
NCBI chr10:106,963,880...106,977,875
Ensembl chr10:106,963,880...106,977,869
|
|
G |
Mfn2 |
mitofusin 2 |
decreases response to substance multiple interactions increases chemical synthesis |
ISO EXP |
MFN2 results in decreased susceptibility to Adenosine Triphosphate deficiency MFN2 protein inhibits the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate] MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate] MFN2 protein results in increased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:22292091 PMID:24898700 PMID:25416777 |
|
NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342
|
|
G |
Mir219a1 |
microRNA 219a-1 |
multiple interactions |
EXP |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of MIR219A1 mRNA; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of CASP1 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of GSDMD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL18 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein] |
CTD |
PMID:35962723 |
|
NCBI chr20:4,829,687...4,829,796
Ensembl chr20:4,829,687...4,829,796
|
|
G |
Mir23b |
microRNA 23b |
multiple interactions decreases abundance |
ISO |
[[MIR23B mRNA binds to KCND2 3' UTR] which results in decreased expression of KCND2 protein] which results in decreased abundance of Adenosine Triphosphate MIR23B mRNA results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:34418280 |
|
NCBI chr17:1,813,667...1,813,763
Ensembl chr17:1,813,667...1,813,763
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP2 mRNA] |
CTD |
PMID:36847822 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases activity increases secretion |
EXP ISO |
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; SB 3CT compound inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein]; wortmannin inhibits the reaction [Adenosine Triphosphate results in increased activity of MMP9 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of MMP9 mRNA] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of MMP9 protein] Adenosine Triphosphate results in increased secretion of MMP9 protein |
CTD |
PMID:20195827 PMID:26522449 PMID:36847822 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mt-atp6 |
mitochondrially encoded ATP synthase membrane subunit 6 |
affects abundance |
EXP |
ATP6 protein affects the abundance of Adenosine Triphosphate |
CTD |
PMID:18273840 |
|
NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599 NCBI chr MT:7,919...8,599
Ensembl chr MT:7,919...8,599
|
|
G |
Mt-co3 |
mitochondrially encoded cytochrome c oxidase III |
increases abundance |
ISO |
COX3 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:17428446 |
|
NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382 NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382
|
|
G |
Mvd |
mevalonate diphosphate decarboxylase |
increases hydrolysis |
ISO |
MVD protein results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:9392419 |
|
NCBI chr19:50,496,366...50,506,429
Ensembl chr19:50,496,367...50,507,971
|
|
G |
Mvk |
mevalonate kinase |
increases hydrolysis multiple interactions |
ISO |
MVK protein results in increased hydrolysis of Adenosine Triphosphate 3,3-dimethylallyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; dolichol monophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; Farnesol inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; farnesyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranyl diphosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; geranylgeranyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate]; isopentenyl pyrophosphate inhibits the reaction [MVK protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:9392419 |
|
NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of MYD88 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of MYD88 protein] |
CTD |
PMID:34405489 PMID:37544346 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myh7 |
myosin heavy chain 7 |
increases abundance |
ISO |
MYH7 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:29741611 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Nadsyn1 |
NAD synthetase 1 |
multiple interactions |
ISO |
[Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased activity of NADSYN1 protein; [NADSYN1 protein co-treated with Ammonium Chloride co-treated with nicotinic acid adenine dinucleotide co-treated with Adenosine Triphosphate] results in increased chemical synthesis of NAD |
CTD |
PMID:12547821 |
|
NCBI chr 1:198,981,559...199,009,853
Ensembl chr 1:198,981,604...199,009,869
|
|
G |
Ncs1 |
neuronal calcium sensor 1 |
multiple interactions increases response to substance |
EXP |
NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]; oxophenylarsine inhibits the reaction [NCS1 protein promotes the reaction [Adenosine Triphosphate results in increased secretion of GH1 protein]] NCS1 protein results in increased susceptibility to Adenosine Triphosphate |
CTD |
PMID:12471042 |
|
NCBI chr 3:14,523,220...14,568,829
Ensembl chr 3:14,523,220...14,568,829
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
affects localization multiple interactions |
EXP ISO |
Adenosine Triphosphate affects the localization of NFATC1 protein azetidine analog inhibits the reaction [Adenosine Triphosphate affects the localization of NFATC1 protein] |
CTD |
PMID:21464294 PMID:26522449 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfatc3 |
nuclear factor of activated T-cells 3 |
affects localization |
EXP |
Adenosine Triphosphate affects the localization of NFATC3 protein |
CTD |
PMID:21464294 |
|
NCBI chr19:33,960,643...34,035,150
Ensembl chr19:33,960,852...34,035,150
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein; Luteolin promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] affects the localization of NFE2L2 protein] |
CTD |
PMID:34217685 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP ISO |
Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]] [Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of NFKBIA protein] |
CTD |
PMID:21464294 PMID:24149798 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
[NGF protein co-treated with Adenosine Triphosphate] results in increased uptake of Calcium |
CTD |
PMID:1374475 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nlrp1a |
NLR family, pyrin domain containing 1A |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with resveratrol] results in increased expression of NLRP1 mRNA |
CTD |
PMID:24149798 |
|
NCBI chr10:55,778,560...55,833,639
Ensembl chr10:55,778,560...55,825,180
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of NLRP3 protein] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NLRP3 protein; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased activity of NLRP3 protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate co-treated with Resveratrol] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 mRNA; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein; Acetylcysteine inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; KN 62 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of NLRP3 protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NLRP3 protein] |
CTD |
PMID:18604214 PMID:23430110 PMID:24149798 PMID:26086368 PMID:26586371 PMID:32721574 PMID:33524445 PMID:34217685 PMID:34405489 PMID:35131329 PMID:35962723 PMID:36847822 PMID:37001609 PMID:37544346 More...
|
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nolc1 |
nucleolar and coiled-body phosphoprotein 1 |
multiple interactions |
ISO |
Adenosine Triphosphate affects the reaction [Doxorubicin binds to NOLC1 protein] |
CTD |
PMID:17129415 |
|
NCBI chr 1:244,921,275...244,932,089
Ensembl chr 1:244,921,377...244,932,088
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; ubiquinone-O inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of NOS2 protein] azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein] [Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [Adenosine Triphosphate results in increased expression of NOS2 protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased abundance of Nitric Oxide] |
CTD |
PMID:21464294 PMID:26522449 PMID:36847822 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
Adenosine Triphosphate affects the reaction [Alcohols affects the phosphorylation of NOS3 protein]; Adenosine Triphosphate inhibits the reaction [Alcohols results in decreased expression of NOS3 protein] |
CTD |
PMID:24300283 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Npy |
neuropeptide Y |
affects response to substance |
ISO |
NPY protein affects the susceptibility to Adenosine Triphosphate |
CTD |
PMID:15003356 |
|
NCBI chr 4:78,881,294...78,888,495
Ensembl chr 4:78,881,264...78,888,495
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
increases expression |
EXP |
Adenosine Triphosphate results in increased expression of NR4A1 mRNA |
CTD |
PMID:10723097 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Oas1a |
2'-5' oligoadenylate synthetase 1A |
multiple interactions |
ISO |
[OAS1 protein results in increased metabolism of Adenosine Triphosphate] which results in increased chemical synthesis of 2',5'-oligoadenylate |
CTD |
PMID:15732009 |
|
NCBI chr12:35,669,798...35,680,505
Ensembl chr12:35,669,801...35,680,517
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions increases secretion |
EXP |
Adenosine Triphosphate promotes the reaction [Phenylephrine results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Phenylephrine co-treated with Adenosine Triphosphate] results in increased secretion of OXT protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased secretion of OXT protein] |
CTD |
PMID:11102496 |
|
NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
multiple interactions affects binding |
EXP |
geldanamycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; herbimycin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1]; monorden promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX1] ATP binds to P2rx1 protein |
CTD RGD |
PMID:11930156 PMID:12237343 |
RGD:727431 |
NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623
|
|
G |
P2rx2 |
purinergic receptor P2X 2 |
multiple interactions affects activity increases activity affects response to substance |
EXP ISO |
1-amino-4-(3-(4,6-dichloro(1,3,5)triazine-2-ylamino)phenylamino)-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Acetylcysteine inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Acetylcysteine inhibits the reaction [Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Cadmium Chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cobaltous chloride affects the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Copper promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; cupric chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Dithiothreitol inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercuric Chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; methyl methanethiosulfonate inhibits the reaction [Hydrogen Peroxide promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; methyl methanethiosulfonate inhibits the reaction [Mercury promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]]; myxothiazol promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; nickel chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; palladium chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Rotenone promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; zinc chloride promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX2 protein] ATP affects activity of rat P2x2 receptor in transfected glial cells P2RX2 protein affects the susceptibility to Adenosine Triphosphate |
CTD RGD |
PMID:15081800 PMID:16190872 PMID:19793987 PMID:21207957 PMID:16388598 |
RGD:1642662 |
NCBI chr12:46,338,979...46,342,891
Ensembl chr12:46,339,549...46,342,891
|
|
G |
P2rx3 |
purinergic receptor P2X 3 |
multiple interactions increases activity affects activity |
EXP |
Eugenol inhibits the reaction [P2RX3 protein affects the activity of Adenosine Triphosphate] Adenosine Triphosphate results in increased activity of P2RX3 protein |
CTD |
PMID:19967073 PMID:27481062 |
|
NCBI chr 3:70,080,850...70,124,664
Ensembl chr 3:70,080,851...70,125,178
|
|
G |
P2rx4 |
purinergic receptor P2X 4 |
multiple interactions increases activity |
EXP ISO |
[Cadmium co-treated with Zinc] promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [Mercury co-treated with Copper] inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cadmium promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Cobalt promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Copper inhibits the reaction [Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]]; Mercury inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Zinc promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro(3,2-e)-1,4-diazepin-2-one inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; [ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 mRNA; [Resveratrol co-treated with Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]; Ivermectin promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein] |
CTD |
PMID:10737610 PMID:15629187 PMID:19793987 PMID:21638035 PMID:24149798 PMID:27481062 PMID:30545933 More...
|
|
NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253
|
|
G |
P2rx5 |
purinergic receptor P2X 5 |
affects transport |
EXP |
ATP affects transport ion flux of P2rx5 receptor |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:57,777,737...57,789,426
Ensembl chr10:57,777,819...57,789,423
|
|
G |
P2rx7 |
purinergic receptor P2X 7 |
multiple interactions increases response to substance increases expression decreases response to substance increases activity |
ISO EXP |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA; [Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein; Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein; AZ 11645373 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; calmidazolium inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; KN 62 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein]; P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased transport of Barium]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 mRNA]; Resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of P2RX7 protein]; ZINC58368839 inhibits the reaction [Adenosine Triphosphate binds to and results in increased activity of P2RX7 protein] P2RX7 protein results in increased susceptibility to Adenosine Triphosphate Adenosine Triphosphate results in increased expression of P2RX7 protein P2RX7 gene mutant form results in decreased susceptibility to Adenosine Triphosphate 3-(5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl)methylpyridine inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased expression of P2RX7 protein]; coomassie Brilliant Blue inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate results in increased activity of P2RX7 protein] |
CTD |
PMID:11003599 PMID:17728465 PMID:19023039 PMID:21638035 PMID:23565201 PMID:24101734 PMID:24149798 PMID:26522449 PMID:27466191 PMID:27481062 PMID:30545933 PMID:31263019 PMID:31504961 More...
|
|
NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619
|
|
G |
P2ry1 |
purinergic receptor P2Y1 |
multiple interactions affects activity |
ISO EXP |
[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate inhibits the reaction [P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY1 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY1 protein] which results in increased abundance of Calcium] [N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate binds to and results in decreased activity of P2RY1 protein] inhibits the reaction [Adenosine Triphosphate results in increased uptake of Calcium] Adenosine Triphosphate affects the activity of P2RY1 protein |
CTD |
PMID:12694404 PMID:15243297 PMID:16973929 PMID:22129738 |
|
NCBI chr 2:145,241,975...145,248,186
Ensembl chr 2:145,241,849...145,248,457
|
|
G |
P2ry13 |
purinergic receptor P2Y13 |
multiple interactions |
ISO |
MRS 2211 inhibits the reaction [P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY13 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide] |
CTD |
PMID:22129738 |
|
NCBI chr 2:143,470,437...143,476,360
Ensembl chr 2:143,470,425...143,473,434
|
|
G |
P2ry2 |
purinergic receptor P2Y2 |
multiple interactions affects activity increases activity |
ISO EXP |
[Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Calcium [Adenosine Triphosphate results in increased activity of P2RY2 protein] which results in increased uptake of Calcium Adenosine Triphosphate affects the activity of P2RY2 protein |
CTD |
PMID:11527950 PMID:15243297 PMID:17003265 |
|
NCBI chr 1:155,352,050...155,367,423
Ensembl chr 1:155,351,165...155,367,632
|
|
G |
P2ry4 |
pyrimidinergic receptor P2Y4 |
multiple interactions |
ISO |
[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium; Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein; Trichloroethylene inhibits the reaction [[Adenosine Triphosphate binds to and results in increased activity of P2RY4 protein] which results in increased abundance of Calcium] |
CTD |
PMID:12694404 |
|
NCBI chr X:65,681,680...65,717,404
Ensembl chr X:65,683,232...65,721,748
|
|
G |
P2ry6 |
pyrimidinergic receptor P2Y6 |
multiple interactions |
ISO |
N,N''-1,4-butanediylbis(N'-(3-isothiocyanatophenyl))thiourea inhibits the reaction [P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide]]; P2RY6 protein promotes the reaction [Adenosine Triphosphate results in decreased susceptibility to Hydrogen Peroxide] |
CTD |
PMID:22129738 |
|
NCBI chr 1:155,295,110...155,330,610
Ensembl chr 1:155,295,111...155,330,808
|
|
G |
Panx1 |
Pannexin 1 |
decreases activity multiple interactions increases export |
ISO |
Adenosine Triphosphate results in decreased activity of PANX1 protein Carbenoxolone inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate]; Probenecid inhibits the reaction [PANX1 protein results in increased export of Adenosine Triphosphate] |
CTD |
PMID:19023039 PMID:19213873 |
|
NCBI chr 8:11,851,176...11,889,774
Ensembl chr 8:11,850,730...11,889,774
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases expression |
ISO |
PARP1 mutant form inhibits the reaction [Cadmium results in decreased abundance of Adenosine Triphosphate] PARP1 protein affects the reaction [pyrithione zinc results in decreased abundance of Adenosine Triphosphate]; PARP1 protein affects the reaction [Zinc results in decreased abundance of Adenosine Triphosphate] Adenosine Triphosphate results in increased expression of PARP1 protein |
CTD |
PMID:17728843 PMID:19809895 PMID:21767558 PMID:22253048 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdk1 |
pyruvate dehydrogenase kinase 1 |
multiple interactions affects response to substance |
ISO |
[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium; Adenosine Triphosphate promotes the reaction [PDK1 protein affects the abundance of Calcium]; tubacin affects the reaction [[PDK1 protein affects the susceptibility to Adenosine Triphosphate] which affects the abundance of Calcium] |
CTD |
PMID:28887310 |
|
NCBI chr 3:56,705,824...56,733,040
Ensembl chr 3:56,705,871...56,733,038
|
|
G |
Pfkm |
phosphofructokinase, muscle |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [resveratrol results in decreased activity of PFKM protein] |
CTD |
PMID:23454376 |
|
NCBI chr 7:129,221,679...129,259,192
Ensembl chr 7:129,221,653...129,259,192
|
|
G |
Pgp |
phosphoglycolate phosphatase |
decreases phosphorylation |
ISO |
PGP protein results in decreased phosphorylation of Adenosine Triphosphate |
CTD |
PMID:24338473 |
|
NCBI chr10:13,495,232...13,497,858
Ensembl chr10:13,494,291...13,497,858
|
|
G |
Pik3ca |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha |
multiple interactions affects binding |
ISO |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [Adenosine Triphosphate binds to PIK3CA protein]; Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]] |
CTD |
PMID:17550345 PMID:18754654 |
|
NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [resveratrol results in decreased activity of [PIK3R1 protein binds to PIK3CA protein]] |
CTD |
PMID:17550345 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pla2g4a |
phospholipase A2 group IVA |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of PLA2G4A protein |
CTD |
PMID:10535451 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Plau |
plasminogen activator, urokinase |
increases secretion |
ISO |
Adenosine Triphosphate results in increased secretion of PLAU protein |
CTD |
PMID:20177776 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plpp3 |
phospholipid phosphatase 3 |
decreases chemical synthesis |
ISO |
PLPP3 gene mutant form results in decreased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:28982073 |
|
NCBI chr 5:119,927,085...120,002,206
Ensembl chr 5:119,927,085...120,002,205
|
|
G |
Pml |
PML nuclear body scaffold |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PML protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [PML protein binds to CASP1 protein]; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PML protein; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to CASP1 protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased abundance of Reactive Oxygen Species]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; PML protein promotes the reaction [[resiquimod co-treated with Adenosine Triphosphate] results in increased expression of IL1B protein] |
CTD |
PMID:23430110 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Pmvk |
phosphomevalonate kinase |
increases hydrolysis |
ISO |
PMVK protein results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:9392419 |
|
NCBI chr 2:174,876,586...174,886,365
Ensembl chr 2:174,876,657...174,886,364
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Fenofibrate results in increased activity of PPARA protein] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:19593819 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions decreases abundance |
ISO |
FASN protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]]; rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]] PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate; PPARG protein results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:26670611 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp5c |
protein phosphatase 5, catalytic subunit |
multiple interactions |
ISO |
Adenosine Triphosphate binds to and affects the folding of PPP5C protein; Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to PPP5C protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to PPP5C protein] |
CTD |
PMID:23184943 |
|
NCBI chr 1:77,690,203...77,714,507
Ensembl chr 1:77,690,208...77,714,456
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression |
EXP |
Adenosine Triphosphate results in increased expression of PRDX2 protein modified form |
CTD |
PMID:16178011 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:31974165 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
multiple interactions |
ISO |
[[PRKAA1 gene co-treated with PRKAA2 gene] affects the susceptibility to Metformin] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Dihydroxyacetone co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate; [[PRKAA1 gene mutant form co-treated with PRKAA2 gene mutant form] affects the susceptibility to [Glucose co-treated with S 4048]] which results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:31974165 |
|
NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin |
CTD |
PMID:16087181 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein; resveratrol inhibits the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein] |
CTD |
PMID:24149798 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO EXP |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; Resveratrol inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in decreased expression of PYCARD mRNA] [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; FBXO3 protein inhibits the reaction [MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]]; FBXO3 protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; MIR219A1 mRNA inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to CASP1 protein]]; lonidamine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] promotes the reaction [PYCARD protein binds to PYCARD protein]]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased expression of PYCARD protein]; PML protein promotes the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] promotes the reaction [NLRP3 protein binds to PYCARD protein]]; PYCARD gene mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of G(M3) Ganglioside]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased cleavage of CASP1 protein]; PYCARD protein affects the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of and results in increased cleavage of IL1B protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of PYCARD protein] |
CTD |
PMID:18604214 PMID:23430110 PMID:24149798 PMID:24475307 PMID:32721574 PMID:34405489 PMID:35962723 PMID:36577999 More...
|
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Ralbp1 |
ralA binding protein 1 |
multiple interactions |
ISO |
[[Adenosine Triphosphate co-treated with PRKCA protein] results in increased phosphorylation of RALBP1 protein] which results in increased transport of Doxorubicin; Adenosine Triphosphate promotes the reaction [RALBP1 protein affects the transport of Leukotriene C4] |
CTD |
PMID:15386349 PMID:16087181 |
|
NCBI chr 9:105,456,425...105,493,235
Ensembl chr 9:105,456,425...105,492,707
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]; Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to ARRB2 protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NFKBIA protein]]; ARRB2 affects the reaction [Adenosine Triphosphate promotes the reaction [RELA protein binds to NOS2 protein]]; Cyclosporine inhibits the reaction [[Adenosine Triphosphate results in increased expression of NOS2 protein] promotes the reaction [NOS2 protein binds to RELA protein]] [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein; [Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein; [Carbonyl Cyanide m-Chlorophenyl Hydrazone co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein; [mitochondrial uncoupler BAM15 co-treated with Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in decreased expression of RELA protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased phosphorylation of RELA protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased phosphorylation of RELA protein]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of and results in increased phosphorylation of RELA protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased phosphorylation of RELA protein] [Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein; Luteolin inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased phosphorylation of and affects the localization of RELA protein]; NOS2 protein affects the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein]; Resveratrol promotes the reaction [[Adenosine Triphosphate co-treated with Lipopolysaccharides] affects the localization of RELA protein]; S-Nitrosoglutathione promotes the reaction [Adenosine Triphosphate results in increased metabolism of RELA protein] |
CTD |
PMID:21464294 PMID:24149798 PMID:33524445 PMID:34217685 PMID:34405489 PMID:37544346 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhof |
ras homolog family member F, filopodia associated |
multiple interactions increases expression |
ISO |
Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of RHOF mRNA] |
CTD |
PMID:29733962 |
|
NCBI chr12:33,422,375...33,446,689
Ensembl chr12:33,431,280...33,446,703
|
|
G |
S100a10 |
S100 calcium binding protein A10 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of S100A10 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of S100A11 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
multiple interactions increases expression |
ISO |
Adenosine Triphosphate results in increased expression of and results in increased secretion of S100A4 protein; Niclosamide inhibits the reaction [Adenosine Triphosphate results in increased expression of S100A4 protein] Adenosine Triphosphate results in increased expression of S100A4 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of S100A6 mRNA |
CTD |
PMID:29733962 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
Sell |
selectin L |
multiple interactions |
ISO |
P2RX7 protein affects the reaction [Adenosine Triphosphate results in increased secretion of SELL protein] |
CTD |
PMID:11003599 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Sftpa1 |
surfactant protein A1 |
multiple interactions |
ISO |
[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]; Ozone inhibits the reaction [[SFTPA1 protein polymorphism binds to SFTPA2 protein polymorphism] inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]]; Ozone inhibits the reaction [SFTPA1 protein polymorphism inhibits the reaction [Adenosine Triphosphate results in increased secretion of Phosphatidylcholines]] |
CTD |
PMID:15065867 |
|
NCBI chr16:17,008,180...17,011,686
Ensembl chr16:17,008,180...17,011,685
|
|
G |
Sftpb |
surfactant protein B |
increases secretion multiple interactions |
ISO EXP |
Adenosine Triphosphate results in increased secretion of SFTPB protein Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPB protein] |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr 4:104,359,303...104,368,439
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sftpc |
surfactant protein C |
increases secretion multiple interactions |
EXP ISO |
Adenosine Triphosphate results in increased secretion of SFTPC protein Ro 31-8220 inhibits the reaction [Adenosine Triphosphate results in increased secretion of SFTPC protein] |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr15:45,596,565...45,599,615
Ensembl chr15:45,596,574...45,610,777
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP ISO |
[SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate]; SIRT1 protein promotes the reaction [[Glucose results in increased abundance of Adenosine Triphosphate] which results in increased expression of INS1 protein]; SIRT1 protein promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate] [STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein |
CTD |
PMID:16366736 PMID:34216621 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions |
ISO |
SIRT3 protein inhibits the reaction [Metformin results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:23166782 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc25a14 |
solute carrier family 25 member 14 |
decreases chemical synthesis |
ISO |
SLC25A14 protein results in decreased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:20600837 |
|
NCBI chr X:127,807,630...127,845,823
Ensembl chr X:127,807,449...127,845,823
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases stability |
ISO |
Adenosine Triphosphate results in decreased stability of SLC2A1 protein |
CTD |
PMID:11420438 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
increases abundance |
ISO |
SLC2A4 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:34904774 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions |
ISO |
[SLC46A1 protein results in increased susceptibility to N-((5-((2-amino-4-oxo-4,7-dihydro-3H-pyrrolo(2,3-d)pyrimidin-6-yl)propyl)thiophen-2-yl)carbonyl)glutamic acid] which results in decreased chemical synthesis of Adenosine Triphosphate |
CTD |
PMID:21879757 |
|
NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein] |
CTD |
PMID:16439463 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Snca |
synuclein alpha |
multiple interactions decreases abundance |
ISO |
GW8510 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate]; SB 216763 inhibits the reaction [SNCA protein results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:24989254 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
EXP ISO |
Adenosine Triphosphate results in increased expression of SOD1 protein |
CTD |
PMID:16178011 PMID:22129738 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
affects chemical synthesis decreases abundance multiple interactions |
ISO |
SOD2 protein affects the chemical synthesis of Adenosine Triphosphate SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate MK-886 promotes the reaction [SOD2 gene mutant form results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:20638473 PMID:25362851 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srr |
serine racemase |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [Edetic Acid inhibits the reaction [SRR protein results in increased abundance of D-Aspartic Acid]]; Adenosine Triphosphate promotes the reaction [SRR protein results in increased abundance of D-Aspartic Acid] |
CTD |
PMID:27387750 |
|
NCBI chr10:59,769,563...59,786,688
Ensembl chr10:59,769,571...59,787,011
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
[STK11 protein co-treated with Adenosine Triphosphate] results in increased activity of and results in increased phosphorylation of SIRT1 protein |
CTD |
PMID:34216621 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Stxbp2 |
syntaxin binding protein 2 |
multiple interactions |
ISO |
STXBP2 protein affects the reaction [F2 protein results in increased transport of Adenosine Triphosphate] |
CTD |
PMID:30696774 |
|
NCBI chr12:1,689,364...1,701,145
Ensembl chr12:1,689,410...1,700,458
|
|
G |
Sugt1 |
SGT1 homolog, MIS12 kinetochore complex assembly cochaperone |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [CHORDC1 protein binds to SUGT1 protein]; Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]; Calcium promotes the reaction [Adenosine Triphosphate promotes the reaction [ITGB1BP2 protein binds to SUGT1 protein]] |
CTD |
PMID:23184943 |
|
NCBI chr15:54,991,419...55,032,244
Ensembl chr15:54,990,672...55,069,150
|
|
G |
Syn2 |
synapsin II |
multiple interactions |
ISO |
SYN2 mutant form inhibits the reaction [Adenosine Triphosphate results in increased abundance of Calcium] |
CTD |
PMID:18701217 |
|
NCBI chr 4:148,178,846...148,347,010
Ensembl chr 4:148,186,270...148,344,192
|
|
G |
Tac1 |
tachykinin, precursor 1 |
increases secretion multiple interactions |
EXP |
Adenosine Triphosphate results in increased secretion of TAC1 protein Iloprost promotes the reaction [Adenosine Triphosphate results in increased secretion of TAC1 protein] |
CTD |
PMID:16039053 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Taldo1 |
transaldolase 1 |
increases abundance |
ISO |
TALDO1 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:19436114 |
|
NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974
|
|
G |
Tas2r145 |
taste receptor, type 2, member 145 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of TAS2R131 protein |
CTD |
PMID:29347925 |
|
NCBI chr 4:166,138,007...166,138,957
Ensembl chr 4:166,138,007...166,138,957
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Dimethyl Sulfoxide co-treated with TGFB1 protein] results in decreased abundance of Adenosine Triphosphate |
CTD |
PMID:35366062 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timm17a |
translocase of inner mitochondrial membrane 17A |
multiple interactions decreases expression |
ISO |
1,10-phenanthroline inhibits the reaction [Adenosine Triphosphate results in decreased expression of TIMM17A protein] |
CTD |
PMID:24315374 |
|
NCBI chr13:46,731,117...46,742,604
Ensembl chr13:46,730,660...46,742,655
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases secretion multiple interactions |
ISO |
Adenosine Triphosphate results in decreased secretion of TIMP1 protein azetidine analog inhibits the reaction [Adenosine Triphosphate results in decreased secretion of TIMP1 protein] |
CTD |
PMID:26522449 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA; [Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TLR4 protein]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 mRNA]; sodium houttuyfonate inhibits the reaction [[Adenosine Triphosphate co-treated with HMGB1 protein] results in increased expression of TLR4 protein] |
CTD |
PMID:34405489 PMID:37544346 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases chemical synthesis |
ISO EXP |
[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased expression of TNF protein; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Chlorides]; Adenosine Triphosphate deficiency inhibits the reaction [TNF protein results in increased transport of Potassium]; Adenosine Triphosphate promotes the reaction [[TNF protein co-treated with IFNG protein co-treated with IL1B protein] results in increased abundance of Dinoprostone]; azetidine analog inhibits the reaction [Adenosine Triphosphate results in increased secretion of TNF protein]; Carbonyl Cyanide m-Chlorophenyl Hydrazone inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased expression of TNF mRNA]; fuzheng huayu inhibits the reaction [[lipopolysaccharide, E coli O55-B5 co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; gypenoside LXXV inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; mitochondrial uncoupler BAM15 inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA]; Niclosamide inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of TNF mRNA] TNF protein promotes the reaction [[Oxygen deficiency co-treated with Blood Glucose deficiency] results in decreased chemical synthesis of Adenosine Triphosphate] TNF protein results in decreased chemical synthesis of Adenosine Triphosphate [Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein; [Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate; [Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein; Adenosine Triphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Disulfiram inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; hydroxysafflor yellow A inhibits the reaction [[Adenosine Triphosphate co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased secretion of TNF protein]; MFN2 protein inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Rosiglitazone inhibits the reaction [TNF protein results in decreased chemical synthesis of Adenosine Triphosphate]; Vitamin K 3 promotes the reaction [[Asbestos, Amosite co-treated with TNF protein] results in increased metabolism of Adenosine Triphosphate] |
CTD |
PMID:8817062 PMID:10783394 PMID:14623498 PMID:17707769 PMID:23430110 PMID:24898700 PMID:26522449 PMID:33050067 PMID:33524445 PMID:33851234 PMID:36577999 PMID:37001609 PMID:37544346 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
increases abundance |
ISO |
TNFSF11 protein results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:26287518 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Top2a |
DNA topoisomerase II alpha |
multiple interactions increases hydrolysis |
ISO |
Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; copper-thiosemicarbazone complex analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Dithiothreitol inhibits the reaction [Cannabidiol metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]]; Emodin inhibits the reaction [TOP2A results in increased hydrolysis of Adenosine Triphosphate]; Etoposide metabolite inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate]; Thiosemicarbazones analog inhibits the reaction [TOP2A protein results in increased hydrolysis of Adenosine Triphosphate] TOP2A protein results in increased hydrolysis of Adenosine Triphosphate; TOP2A results in increased hydrolysis of Adenosine Triphosphate |
CTD |
PMID:20855424 PMID:26982206 PMID:27533850 PMID:29272108 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Top2b |
DNA topoisomerase II beta |
increases hydrolysis multiple interactions |
ISO |
TOP2B protein results in increased hydrolysis of Adenosine Triphosphate cannabidiol hydroxyquinone inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate]; Cannabidiol metabolite inhibits the reaction [TOP2B protein results in increased hydrolysis of Adenosine Triphosphate] |
CTD |
PMID:29272108 |
|
NCBI chr15:9,051,340...9,111,721
Ensembl chr15:9,051,341...9,112,085
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases abundance |
ISO |
TP53 protein inhibits the reaction [Deoxyglucose results in decreased abundance of Adenosine Triphosphate] TP53 gene mutant form results in increased abundance of Adenosine Triphosphate |
CTD |
PMID:21042727 PMID:33070465 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]; AZ10606120 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]]; U 0126 inhibits the reaction [Adenosine Triphosphate promotes the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein]] |
CTD |
PMID:32941855 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Trpc3 |
transient receptor potential cation channel, subfamily C, member 3 |
multiple interactions increases activity |
ISO |
ethyl-1-(4-(2*3*3-trichloroacrylamide)phenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate inhibits the reaction [Adenosine Triphosphate results in increased activity of TRPC3 protein] |
CTD |
PMID:19289841 |
|
NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:119,481,400...119,558,855
|
|
G |
Trpc5 |
transient receptor potential cation channel, subfamily C, member 5 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of TRPC5 protein |
CTD |
PMID:19289841 |
|
NCBI chr X:107,946,163...108,230,991
Ensembl chr X:107,939,131...108,230,991
|
|
G |
Trpc6 |
transient receptor potential cation channel, subfamily C, member 6 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of TRPC6 protein |
CTD |
PMID:19289841 |
|
NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:5,758,935...5,828,092
|
|
G |
Trpc7 |
transient receptor potential cation channel, subfamily C, member 7 |
increases activity |
ISO |
Adenosine Triphosphate results in increased activity of TRPC7 protein |
CTD |
PMID:19289841 |
|
NCBI chr17:7,708,911...7,833,435
Ensembl chr17:7,709,583...7,833,435
|
|
G |
Trpm4 |
transient receptor potential cation channel, subfamily M, member 4 |
decreases activity |
ISO EXP |
Adenosine Triphosphate results in decreased activity of TRPM4 protein |
CTD |
PMID:16966582 PMID:17188667 |
|
NCBI chr 1:95,781,805...95,812,095
Ensembl chr 1:95,782,000...95,812,532
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
[Capsaicin binds to and affects the activity of TRPV1 protein] which results in increased secretion of Adenosine Triphosphate |
CTD |
PMID:19860742 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [TSHB protein results in increased expression of SLC5A5 protein] |
CTD |
PMID:16439463 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
Adenosine Triphosphate results in increased expression of TXN protein |
CTD |
PMID:22129738 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnip |
thioredoxin interacting protein |
increases activity |
EXP |
Adenosine Triphosphate results in increased activity of TXNIP mRNA |
CTD |
PMID:21832250 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions decreases abundance |
EXP ISO |
Adenosine Triphosphate inhibits the reaction [UCP1 protein results in increased transport of Protons] UCP1 results in decreased abundance of Adenosine Triphosphate UCP1 protein promotes the reaction [PPARG protein mutant form results in decreased abundance of Adenosine Triphosphate]; UCP1 protein promotes the reaction [rosiglitazone promotes the reaction [PPARG protein results in decreased abundance of Adenosine Triphosphate]] |
CTD |
PMID:12734183 PMID:26670611 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Ucp2 |
uncoupling protein 2 |
multiple interactions |
ISO EXP |
Adenosine Triphosphate inhibits the reaction [UCP2 protein results in increased transport of Protons] [SIRT1 protein results in decreased expression of UCP2 mRNA] promotes the reaction [Glucose results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:12734183 PMID:16366736 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ucp3 |
uncoupling protein 3 |
multiple interactions |
ISO |
Adenosine Triphosphate inhibits the reaction [UCP3 protein results in increased transport of Protons] |
CTD |
PMID:12734183 |
|
NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions |
ISO |
VDAC1 mutant form inhibits the reaction [chromium hexavalent ion results in decreased abundance of Adenosine Triphosphate] |
CTD |
PMID:22858589 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
multiple interactions increases abundance decreases abundance |
ISO |
Acetylcysteine inhibits the reaction [XRCC1 gene mutant form results in decreased abundance of Adenosine Triphosphate]; Acetylcysteine promotes the reaction [XRCC1 protein results in increased abundance of Adenosine Triphosphate] |
CTD |
PMID:30998386 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
butyryl-coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions |
ISO |
cangrelor results in decreased expression of and results in decreased activity of F3 protein; Indomethacin promotes the reaction [cangrelor results in decreased expression of and results in decreased activity of F3 protein] |
CTD |
PMID:20200314 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Uridine Diphosphate results in increased activity of GPR17 protein] |
CTD |
PMID:18974869 |
|
NCBI chr18:23,576,232...23,583,153
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Itga2b |
integrin subunit alpha 2b |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of [ITGA2B protein binds to ITGB3 protein]]] |
CTD |
PMID:18404433 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
P2ry12 |
purinergic receptor P2Y12 |
multiple interactions decreases activity affects response to substance |
ISO |
[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased abundance of phosphatidylinositol 3,4,5-triphosphate; [cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein cangrelor results in decreased activity of P2RY12 protein P2RY12 gene polymorphism affects the susceptibility to cangrelor |
CTD |
PMID:12606772 PMID:20126830 PMID:22273509 |
|
NCBI chr 2:143,481,468...143,523,340
Ensembl chr 2:143,481,430...143,523,361
|
|
G |
Pf4 |
platelet factor 4 |
multiple interactions |
ISO |
cangrelor inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased secretion of PF4 protein] |
CTD |
PMID:22273509 |
|
NCBI chr14:17,298,304...17,299,220
Ensembl chr14:17,298,308...17,299,365
|
|
G |
Selp |
selectin P |
multiple interactions |
ISO |
cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]; N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate promotes the reaction [cangrelor inhibits the reaction [Adenosine Diphosphate analog results in increased expression of SELP protein]] |
CTD |
PMID:18404433 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Syk |
spleen associated tyrosine kinase |
multiple interactions |
ISO |
[cangrelor binds to and results in decreased activity of P2RY12 protein] which results in decreased phosphorylation of SYK protein |
CTD |
PMID:12606772 |
|
NCBI chr17:12,604,615...12,678,437
Ensembl chr17:12,604,619...12,661,410
|
|
|
G |
Adcy5 |
adenylate cyclase 5 |
increases response to substance multiple interactions |
ISO |
ADCY5 protein results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine ADCY5 protein results in increased susceptibility to [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with Quinpirole] |
CTD |
PMID:12223546 |
|
NCBI chr11:65,471,612...65,618,877
Ensembl chr11:65,471,612...65,618,974
|
|
G |
Adora2a |
adenosine A2a receptor |
increases response to substance multiple interactions |
ISO EXP |
ADORA2A protein results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of ADORA2A protein]; 8-(3-chlorostyryl)caffeine inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A mRNA]]; 8-(3-chlorostyryl)caffeine inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of ADORA2A protein]]; PRKCZ protein affects the reaction [[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein] which results in decreased expression of VEGFA mRNA] 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of ADORA2A mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of ADORA2A protein] |
CTD |
PMID:11172060 PMID:12590138 PMID:15452191 PMID:19749167 PMID:19966059 PMID:26367767 PMID:27289578 PMID:30555576 More...
|
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of BDNF mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of BDNF protein] |
CTD |
PMID:35917217 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of BECN1 protein] |
CTD |
PMID:30555576 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
increases expression multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of BMAL1 mRNA [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in increased expression of BMAL1 mRNA |
CTD |
PMID:22923002 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]] |
CTD |
PMID:30555576 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Clock |
clock circadian regulator |
increases expression |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of CLOCK mRNA |
CTD |
PMID:22923002 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of COL3A1 protein CTNNB1 protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of COL3A1 protein] |
CTD |
PMID:27595240 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of CREB1 mRNA] |
CTD |
PMID:35917217 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Ctnnb1 |
catenin beta 1 |
affects localization multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine affects the localization of CTNNB1 protein modified form 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of and affects the phosphorylation of CTNNB1 protein; CTNNB1 protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of COL3A1 protein] |
CTD |
PMID:27595240 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of CYP27A1 protein] |
CTD |
PMID:19035488 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions increases response to substance decreases response to substance |
ISO |
12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [EPHX2 gene results in decreased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]; 14,15-eicosa-5-enoic acid inhibits the reaction [EPHX2 gene mutant form results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]; 4-(4-(3-adamantan-1-ylureido)cyclohexyloxy)benzoic acid inhibits the reaction [EPHX2 gene results in decreased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine]; T 0070907 inhibits the reaction [EPHX2 gene mutant form results in increased susceptibility to 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine] |
CTD |
PMID:23152114 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of FOS mRNA] |
CTD |
PMID:15452191 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of HMGCR mRNA] |
CTD |
PMID:30825513 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of HMGCS1 mRNA] |
CTD |
PMID:30825513 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [TNF protein results in increased expression of IL10 mRNA] |
CTD |
PMID:22923002 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in decreased expression of IL12A mRNA |
CTD |
PMID:22923002 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of LEP mRNA] |
CTD |
PMID:26367767 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein] |
CTD |
PMID:30555576 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
decreases activity |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased activity of MMP14 protein |
CTD |
PMID:16783407 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased activity of MMP2 protein |
CTD |
PMID:16783407 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity decreases expression |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased activity of MMP9 protein 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of MMP9 mRNA |
CTD |
PMID:16783407 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions |
EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; Caffeine analog inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]] |
CTD |
PMID:15452191 PMID:19966059 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
increases expression |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of NR1D1 mRNA |
CTD |
PMID:22923002 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions increases expression |
EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of NTRK2 mRNA] 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of NTRK2 mRNA |
CTD |
PMID:35917217 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Per2 |
period circadian regulator 2 |
decreases expression |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of PER2 mRNA |
CTD |
PMID:22923002 |
|
NCBI chr 9:92,007,289...92,049,551
Ensembl chr 9:92,007,296...92,049,459
|
|
G |
Prkce |
protein kinase C, epsilon |
multiple interactions |
EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine affects the localization of and results in increased activity of PRKCE protein |
CTD |
PMID:12590138 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions |
EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine affects the localization of and results in increased activity of PRKCZ protein; PRKCZ protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of VEGFA mRNA]; PRKCZ protein affects the reaction [[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein] which results in decreased expression of VEGFA mRNA] |
CTD |
PMID:12590138 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Ren |
renin |
multiple interactions increases expression |
EXP |
Atenolol inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of REN protein] |
CTD |
PMID:9300315 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rgs2 |
regulator of G-protein signaling 2 |
multiple interactions |
EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of RGS2 mRNA] |
CTD |
PMID:15452191 |
|
NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in decreased expression of SIRT1 mRNA] |
CTD |
PMID:30825513 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt3 |
sirtuin 3 |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in decreased expression of SIRT3 protein]] |
CTD |
PMID:30555576 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc9a1 |
solute carrier family 9 member A1 |
multiple interactions |
EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Phenylephrine results in increased expression of SLC9A1 protein] |
CTD |
PMID:15452191 |
|
NCBI chr 5:145,576,341...145,629,630
Ensembl chr 5:145,576,334...145,629,624
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
EXP |
8-(4-methoxyphenyl)-4-oxo-4,6,7,8-tetrahydroimidazo(2,1-c)(1,2,4)triazine-3-carbohydrazide inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of SMAD3 protein] |
CTD |
PMID:22063920 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of SOCS3 mRNA]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [Oxygen deficiency results in increased expression of SOCS3 protein] |
CTD |
PMID:27289578 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine results in increased expression of SREBF2 mRNA] |
CTD |
PMID:30825513 |
|
NCBI chr 7:113,663,202...113,720,850
Ensembl chr 7:113,663,202...113,720,848
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine promotes the reaction [TNF protein results in increased expression of IL10 mRNA]; [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in decreased expression of IL12A mRNA; [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine co-treated with TNF protein] results in increased expression of BMAL1 mRNA |
CTD |
PMID:21538184 PMID:22923002 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]] |
CTD |
PMID:30555576 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases secretion decreases expression multiple interactions |
ISO EXP |
2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased secretion of VEGFA protein 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of VEGFA mRNA 2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine inhibits the reaction [cobaltous chloride results in increased expression of VEGFA mRNA]; PRKCZ protein affects the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in decreased expression of VEGFA mRNA]; PRKCZ protein affects the reaction [[2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine binds to and results in increased activity of ADORA2A protein] which results in decreased expression of VEGFA mRNA] |
CTD |
PMID:12590138 PMID:20067761 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Acot8 |
acyl-CoA thioesterase 8 |
affects hydrolysis |
ISO |
ACOT8 protein affects the hydrolysis of Coenzyme A analog |
CTD |
PMID:16141203 |
|
NCBI chr 3:153,531,192...153,542,851
Ensembl chr 3:153,531,193...153,542,851
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
Coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
|
G |
Cd38 |
CD38 molecule |
decreases abundance |
ISO |
CD38 gene mutant form results in decreased abundance of Cyclic ADP-Ribose |
CTD |
PMID:23343681 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Homer1 |
homer scaffold protein 1 |
multiple interactions |
EXP |
HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]] |
CTD |
PMID:12887973 |
|
NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785
|
|
G |
Ryr2 |
ryanodine receptor 2 |
multiple interactions |
EXP |
HOMER1 protein alternative form inhibits the reaction [Cyclic ADP-Ribose promotes the reaction [RYR2 protein results in increased secretion of Calcium]] |
CTD |
PMID:12887973 |
|
NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142
|
|
|
G |
Taldo1 |
transaldolase 1 |
increases abundance |
ISO |
TALDO1 gene mutant form results in increased abundance of ribose-5-phosphate |
CTD |
PMID:19436114 |
|
NCBI chr 1:196,493,634...196,503,965
Ensembl chr 1:196,493,589...196,503,974
|
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
multiple interactions |
ISO |
[decanoyl-coenzyme A co-treated with NADP] binds to HSDL2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
multiple interactions |
ISO |
[decanoyl-coenzyme A co-treated with NADP] binds to PECR protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
|
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
affects hydrolysis |
ISO |
ACOT4 protein affects the hydrolysis of glutaryl-coenzyme A |
CTD |
PMID:16141203 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
G |
Acot8 |
acyl-CoA thioesterase 8 |
affects hydrolysis |
ISO |
ACOT8 protein affects the hydrolysis of glutaryl-coenzyme A |
CTD |
PMID:16141203 |
|
NCBI chr 3:153,531,192...153,542,851
Ensembl chr 3:153,531,193...153,542,851
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
Guanosine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein] |
CTD |
PMID:25174304 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
affects binding multiple interactions |
ISO |
Guanosine analog binds to EIF4E protein Guanosine analog inhibits the reaction [7-methylguanosine 5'-diphosphate analog binds to EIF4E protein]; Guanosine analog inhibits the reaction [RNA Caps binds to EIF4E protein] |
CTD |
PMID:27592390 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions |
ISO |
[Guanosine co-treated with Ketamine] results in increased activity of GLUL protein |
CTD |
PMID:36878458 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Guanosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Impdh2 |
inosine monophosphate dehydrogenase 2 |
decreases expression |
EXP |
Guanosine results in decreased expression of IMPDH2 mRNA |
CTD |
PMID:11145582 |
|
NCBI chr 8:109,256,705...109,261,365
Ensembl chr 8:109,256,728...109,261,359
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
Guanosine inhibits the reaction [tiazofurin results in decreased expression of KRAS] |
CTD |
PMID:9381980 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Guanosine results in increased phosphorylation of and results in increased activity of MAPK1 protein |
CTD |
PMID:18456249 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Guanosine results in increased phosphorylation of and results in increased activity of MAPK3 protein |
CTD |
PMID:18456249 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
Guanosine inhibits the reaction [tiazofurin results in decreased expression of MYC] |
CTD |
PMID:9381980 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Slc1a2 |
solute carrier family 1 member 2 |
multiple interactions |
ISO |
[Guanosine co-treated with Ketamine] results in increased expression of SLC1A2 protein |
CTD |
PMID:36878458 |
|
NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
multiple interactions |
ISO EXP |
Guanosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] |
CTD |
PMID:9353301 PMID:11085929 |
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
G |
Slc29a2 |
solute carrier family 29 member 2 |
multiple interactions |
ISO |
Guanosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine] |
CTD |
PMID:11085929 |
|
NCBI chr 1:202,327,641...202,335,185
Ensembl chr 1:202,327,354...202,335,171
|
|
G |
Slc29a3 |
solute carrier family 29 member 3 |
affects transport |
ISO |
SLC29A3 protein affects the transport of Guanosine |
CTD |
PMID:19164483 |
|
NCBI chr20:28,645,265...28,685,388
Ensembl chr20:28,647,391...28,685,388
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Guanosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
G |
Upp1 |
uridine phosphorylase 1 |
increases metabolic processing |
ISO |
UPP1 protein results in increased metabolism of Guanosine |
CTD |
PMID:15772079 |
|
NCBI chr14:83,809,495...83,829,299
Ensembl chr14:83,809,960...83,829,462
|
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
multiple interactions |
ISO |
[hexanoyl-coenzyme A co-treated with NADP] binds to PECR protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
|
|
|
G |
Ada |
adenosine deaminase |
decreases abundance increases abundance |
ISO |
ADA alternative form results in decreased abundance of Inosine ADA protein results in increased abundance of Inosine |
CTD |
PMID:16221767 |
|
NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Inosine results in increased expression of FASLG protein |
CTD |
PMID:16419169 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
Inosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of H2AX protein modified form] |
CTD |
PMID:32941855 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Slc29a1 |
solute carrier family 29 member 1 |
multiple interactions |
ISO EXP |
Inosine inhibits the reaction [SLC29A1 protein results in increased uptake of Uridine] |
CTD |
PMID:9353301 PMID:11085929 |
|
NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203
|
|
G |
Slc29a2 |
solute carrier family 29 member 2 |
multiple interactions |
ISO |
Inosine inhibits the reaction [SLC29A2 protein results in increased uptake of Uridine] |
CTD |
PMID:11085929 |
|
NCBI chr 1:202,327,641...202,335,185
Ensembl chr 1:202,327,354...202,335,171
|
|
G |
Tp53bp1 |
tumor protein p53 binding protein 1 |
multiple interactions |
ISO |
Inosine inhibits the reaction [Cesium-137 results in increased expression of and affects the localization of TP53BP1 protein] |
CTD |
PMID:32941855 |
|
NCBI chr 3:108,166,574...108,270,229
Ensembl chr 3:108,169,980...108,269,822
|
|
|
G |
Kat2b |
lysine acetyltransferase 2B |
affects binding |
ISO |
isobutyryl-coenzyme A binds to KAT2B protein |
CTD |
PMID:28077572 |
|
NCBI chr 9:6,562,525...6,667,064
Ensembl chr 9:6,562,288...6,667,064
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
lauroyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Hsdl2 |
hydroxysteroid dehydrogenase like 2 |
multiple interactions |
ISO |
[lauroyl-coenzyme A co-treated with NADP] binds to HSDL2 protein |
CTD |
PMID:25526675 |
|
NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839
|
|
G |
Pecr |
peroxisomal trans-2-enoyl-CoA reductase |
multiple interactions |
ISO |
[lauroyl-coenzyme A co-treated with NADP] binds to PECR protein |
CTD |
PMID:25526675 |
|
NCBI chr 9:73,897,877...73,926,511
Ensembl chr 9:73,897,880...73,926,511
|
|
|
G |
Mlycd |
malonyl-CoA decarboxylase |
multiple interactions |
ISO |
PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] |
CTD |
PMID:14641110 |
|
NCBI chr19:47,447,931...47,463,794
Ensembl chr19:47,447,970...47,463,793
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
PPARA protein promotes the reaction [MLYCD protein results in decreased abundance of Malonyl Coenzyme A] |
CTD |
PMID:14641110 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Echs1 |
enoyl-CoA hydratase, short chain 1 |
increases abundance |
ISO |
ECHS1 gene mutant form results in increased abundance of methacrylyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884
|
|
G |
Hibch |
3-hydroxyisobutyryl-CoA hydrolase |
increases abundance |
ISO |
HIBCH gene mutant form results in increased abundance of methacrylyl-coenzyme A |
CTD |
PMID:25125611 |
|
NCBI chr 9:48,590,097...48,669,896
Ensembl chr 9:48,590,099...48,669,824
|
|
|
G |
Dbi |
diazepam binding inhibitor |
affects binding |
ISO |
S-tetradecanoyl-coenzyme A binds to DBI protein |
CTD |
PMID:17044054 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
S-tetradecanoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
S-tetradecanoyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
decreases expression multiple interactions |
ISO |
N(6),N(6)-dimethyladenosine results in decreased expression of ADAM17 protein N(6),N(6)-dimethyladenosine inhibits the reaction [Cycloheximide results in decreased stability of ADAM17 protein] |
CTD |
PMID:36558177 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Bsg |
basigin (Ok blood group) |
decreases expression |
ISO |
N(6),N(6)-dimethyladenosine results in decreased expression of BSG protein |
CTD |
PMID:36574092 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
|
G |
Adora2b |
adenosine A2B receptor |
affects response to substance |
ISO |
ADORA2B protein affects the susceptibility to Adenosine-5'-(N-ethylcarboxamide) |
CTD |
PMID:16920807 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Adora3 |
adenosine A3 receptor |
affects binding |
ISO |
Adenosine-5'-(N-ethylcarboxamide) binds to ADORA3 protein |
CTD |
PMID:21186795 |
|
NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357
|
|
G |
Casp1 |
caspase 1 |
increases activity |
EXP |
Adenosine-5'-(N-ethylcarboxamide) results in increased activity of CASP1 mRNA; Adenosine-5'-(N-ethylcarboxamide) results in increased activity of CASP1 protein |
CTD |
PMID:21832250 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases secretion |
ISO |
Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of CCL2 protein |
CTD |
PMID:17696452 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases response to substance |
ISO |
EPHX2 gene mutant form results in increased susceptibility to Adenosine-5'-(N-ethylcarboxamide) |
CTD |
PMID:23152114 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Il13 |
interleukin 13 |
increases secretion |
ISO |
Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of IL13 protein |
CTD |
PMID:17696452 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Sftpb |
surfactant protein B |
increases secretion multiple interactions |
EXP ISO |
Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPB protein Ro 31-8220 inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPB protein] |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr 4:104,359,303...104,368,439
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sftpc |
surfactant protein C |
increases secretion multiple interactions |
ISO EXP |
Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPC protein Ro 31-8220 inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) results in increased secretion of SFTPC protein] |
CTD |
PMID:11704537 PMID:14565945 |
|
NCBI chr15:45,596,565...45,599,615
Ensembl chr15:45,596,574...45,610,777
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
5-amino-7-(2-phenylethyl)-2-(2-furyl)pyrazolo(4,3-e)-1,2,4-triazolo(1,5-c)pyrimidine inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; ZM 241385 inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]] |
CTD |
PMID:21538184 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
increases expression |
EXP |
Adenosine-5'-(N-ethylcarboxamide) results in increased expression of TNFSF11 mRNA; Adenosine-5'-(N-ethylcarboxamide) results in increased expression of TNFSF11 protein |
CTD |
PMID:29649498 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Txnip |
thioredoxin interacting protein |
increases activity |
EXP |
Adenosine-5'-(N-ethylcarboxamide) results in increased activity of TXNIP mRNA |
CTD |
PMID:21832250 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA mRNA]; Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA protein]; N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA mRNA]]; N-(4-cyanophenyl)-2-(4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-phenoxy)acetamide inhibits the reaction [Adenosine-5'-(N-ethylcarboxamide) inhibits the reaction [Cyclosporine results in decreased expression of VEGFA protein]] |
CTD |
PMID:26311998 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
oleoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
oleoyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
oleoyl-coenzyme A binds to and results in increased activity of PPARG protein |
CTD |
PMID:11139385 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
EXP |
diadenosine tetraphosphate inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein] |
CTD |
PMID:19442829 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Nudt2 |
nudix hydrolase 2 |
increases hydrolysis |
ISO |
NUDT2 protein results in increased hydrolysis of diadenosine tetraphosphate |
CTD |
PMID:20533549 |
|
NCBI chr 5:56,628,265...56,643,104
Ensembl chr 5:56,628,265...56,643,104
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
diadenosine tetraphosphate inhibits the reaction [Methamphetamine results in decreased expression of TH protein] |
CTD |
PMID:19442829 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
|
G |
Cftr |
CF transmembrane conductance regulator |
multiple interactions |
ISO |
P(1),P(5)-di(adenosine-5'-)pentaphosphate inhibits the reaction [Adenosine Diphosphate binds to and results in decreased activity of CFTR protein] |
CTD |
PMID:15684079 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Nudt11 |
nudix hydrolase 11 |
multiple interactions increases metabolic processing |
ISO |
[NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of adenosine 5'-tetraphosphate; [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate; manganese chloride promotes the reaction [NUDT11 protein results in increased metabolism of P(1),P(5)-di(adenosine-5'-)pentaphosphate] |
CTD |
PMID:12121577 |
|
NCBI chr X:16,326,775...16,333,396
Ensembl chr X:16,326,598...16,333,145
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
P(1),P(5)-di(adenosine-5'-)pentaphosphate analog inhibits the reaction [[Nitrites co-treated with Oxygen deficiency] results in increased expression of SIRT1 mRNA] |
CTD |
PMID:22892143 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
|
G |
Nudt11 |
nudix hydrolase 11 |
multiple interactions increases metabolic processing |
ISO |
[NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of adenosine 5'-pentaphosphate; [NUDT11 protein results in increased metabolism of diadenosine 5',5''''-P1,P6-hexaphosphate] which results in increased chemical synthesis of Adenosine Monophosphate |
CTD |
PMID:12121577 |
|
NCBI chr X:16,326,775...16,333,396
Ensembl chr X:16,326,598...16,333,145
|
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
increases metabolic processing multiple interactions |
ISO |
ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A [ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide; benz(a)anthracene promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Dehydroepiandrosterone promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide]; Tetrachlorodibenzodioxin promotes the reaction [[ACOX1 protein results in increased metabolism of Palmitoyl Coenzyme A] which results in increased chemical synthesis of Hydrogen Peroxide] |
CTD |
PMID:10497882 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis |
EXP |
CES1 protein results in increased hydrolysis of Palmitoyl Coenzyme A |
CTD |
PMID:8611161 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
valproyl-coenzyme A inhibits the reaction [CPT1A protein results in increased metabolism of Palmitoyl Coenzyme A] |
CTD |
PMID:19854160 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Dgat1 |
diacylglycerol O-acyltransferase 1 |
multiple interactions |
ISO |
DGAT1 protein results in increased metabolism of [Palmitoyl Coenzyme A co-treated with Vitamin A] |
CTD |
PMID:16214399 |
|
NCBI chr 7:108,223,860...108,235,413
Ensembl chr 7:108,218,524...108,234,299
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
Palmitoyl Coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
decreases expression |
ISO |
Palmitoyl Coenzyme A results in decreased expression of HNF4A mRNA; Palmitoyl Coenzyme A results in decreased expression of HNF4A protein |
CTD |
PMID:17992261 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Palmitoyl Coenzyme A binds to and results in increased activity of PPARA protein Acetylglucosamine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atorvastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Atropine inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Budesonide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Fenofibrate promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gamma-Aminobutyric Acid inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; gedunin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]; Pravastatin promotes the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Saccharin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; salicylamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolazoline inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]; Tolmetin inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] |
CTD |
PMID:11139385 PMID:18812576 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
Palmitoyl Coenzyme A binds to and results in increased activity of PPARG protein |
CTD |
PMID:11139385 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Shbg |
sex hormone binding globulin |
decreases expression |
ISO |
Palmitoyl Coenzyme A results in decreased expression of SHBG mRNA; Palmitoyl Coenzyme A results in decreased expression of SHBG protein |
CTD |
PMID:17992261 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
stearoyl-coenzyme A binds to and results in decreased activity of GSTA1 protein |
CTD |
PMID:10542059 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
stearoyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
stearoyl-coenzyme A binds to and results in increased activity of PPARG protein |
CTD |
PMID:11139385 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Acot4 |
acyl-CoA thioesterase 4 |
affects hydrolysis |
ISO |
ACOT4 protein affects the hydrolysis of succinyl-coenzyme A |
CTD |
PMID:16141203 |
|
NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917
|
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions decreases expression |
ISO |
Guanosine inhibits the reaction [tiazofurin results in decreased expression of KRAS] |
CTD |
PMID:9381980 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression multiple interactions |
ISO |
tiazofurin results in decreased expression of MYC Guanosine inhibits the reaction [tiazofurin results in decreased expression of MYC] |
CTD |
PMID:9381980 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
|
G |
P2rx1 |
purinergic receptor P2X 1 |
affects binding |
EXP |
TNP-ATP binds to P2rx1 protein |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:57,618,586...57,633,648
Ensembl chr10:57,618,586...57,633,623
|
|
G |
P2rx2 |
purinergic receptor P2X 2 |
multiple interactions |
EXP |
TNP-ATP binds to P2rx2 protein; TNP-ATP inhibits the reaction [ATP binds to P2rx2 protein] in transfected glial cells |
RGD |
PMID:16388598 |
RGD:1642662 |
NCBI chr12:46,338,979...46,342,891
Ensembl chr12:46,339,549...46,342,891
|
|
G |
P2rx5 |
purinergic receptor P2X 5 |
affects transport |
EXP |
TNP-ATP affects transport ion flux of P2rx5 receptor |
RGD |
PMID:12237343 |
RGD:727431 |
NCBI chr10:57,777,737...57,789,426
Ensembl chr10:57,777,819...57,789,423
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
xanthosine inhibits the reaction [Palmitates results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:36627075 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
EXP |
xanthosine inhibits the reaction [Palmitates results in decreased phosphorylation of FOXO1 protein] |
CTD |
PMID:36627075 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
EXP |
xanthosine inhibits the reaction [Palmitates results in increased expression of G6PC1 protein] |
CTD |
PMID:36627075 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
xanthosine inhibits the reaction [Palmitates results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:36627075 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gys1 |
glycogen synthase 1 |
multiple interactions |
EXP |
xanthosine inhibits the reaction [Palmitates results in increased phosphorylation of GYS1 protein] |
CTD |
PMID:36627075 |
|
NCBI chr 1:95,915,443...95,935,292
Ensembl chr 1:95,915,443...95,935,292
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
multiple interactions |
EXP |
xanthosine inhibits the reaction [Palmitates results in increased expression of PCK2 protein] |
CTD |
PMID:36627075 |
|
NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283
|
|